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Résumé 
Le méthotrexate (MTX), un agent anti-cancéreux fréquemment utilisé en 
chimiothérapie, requiert généralement un suivi thérapeutique de la médication (Therapeutic 
Drug Monitoring, TDM) pour surveiller son niveau sanguin chez le patient afin de maximiser 
son efficacité tout en limitant ses effets secondaires. Malgré la fenêtre thérapeutique étroite 
entre l’efficacité et la toxicité, le MTX reste, à ce jour, un des agents anti-cancéreux les plus 
utilisés au monde. Les techniques analytiques existantes pour le TDM du MTX sont 
coûteuses, requièrent temps et efforts, sans nécessairement fournir promptement les résultats 
dans le délai requis. Afin d’accélérer le processus de dosage du MTX en TDM, une stratégie a 
été proposée basée sur un essai compétitif caractérisé principalement par le couplage 
plasmonique d’une surface métallique et de nanoparticules d’or. Plus précisément, l’essai 
quantitatif exploite la réaction de compétition entre le MTX et une nanoparticule d’or 
fonctionnalisée avec l’acide folique (FA-AuNP) ayant une affinité pour un récepteur 
moléculaire, la réductase humaine de dihydrofolate (hDHFR), une enzyme associée aux 
maladies prolifératives. Le MTX libre mixé avec les FA-AuNP, entre en compétition pour les 
sites de liaison de hDHFR immobilisés sur une surface active en SPR ou libres en solution. 
Par la suite, les FA-AuNP liées au hDHFR fournissent une amplification du signal qui est 
inversement proportionnelle à la concentration de MTX.  
La résonance des plasmons de surface (SPR) est généralement utilisée comme une 
technique spectroscopique pour l’interrogation des interactions biomoléculaires. Les 
instruments SPR commerciaux sont généralement retrouvés dans les grands laboratoires 
d’analyse. Ils sont également encombrants, coûteux et manquent de sélectivité dans les 
analyses en matrice complexe. De plus, ceux-ci n’ont pas encore démontré de l’adaptabilité en 
milieu clinique. Par ailleurs, les analyses SPR des petites molécules comme les médicaments 
n’ont pas été explorés de manière intensive dû au défi posé par le manque de la sensibilité de 
la technique pour cette classe de molécules. Les développements récents en science des 
matériaux et chimie de surfaces exploitant l’intégration des nanoparticules d’or pour 
l’amplification de la réponse SPR et la chimie de surface peptidique ont démontré le potentiel 
de franchir les limites posées par le manque de sensibilité et l’adsorption non-spécifique pour 
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les analyses directes dans les milieux biologiques. Ces nouveaux concepts de la technologie 
SPR seront incorporés à un système SPR miniaturisé et compact pour exécuter des analyses 
rapides, fiables et sensibles pour le suivi du niveau du MTX dans le sérum de patients durant 
les traitements de chimiothérapie. L’objectif de cette thèse est d’explorer différentes stratégies 
pour améliorer l’analyse des médicaments dans les milieux complexes par les biocapteurs SPR 
et de mettre en perspective le potentiel des biocapteurs SPR comme un outil utile pour le TDM 
dans le laboratoire clinique ou au chevet du patient. 
Pour atteindre ces objectifs, un essai compétitif colorimétrique basé sur la résonance 
des plasmons de surface localisée (LSPR) pour le MTX fut établi avec des nanoparticules d’or 
marquées avec du FA. Ensuite, cet essai compétitif colorimétrique en solution fut adapté à une 
plateforme SPR. Pour les deux essais développés, la sensibilité, sélectivité, limite de détection, 
l’optimisation de la gamme dynamique et l’analyse du MTX dans les milieux complexes ont 
été inspectés. De plus, le prototype de la plateforme SPR miniaturisée fut validé par sa 
performance équivalente aux systèmes SPR existants ainsi que son utilité pour analyser les 
échantillons cliniques des patients sous chimiothérapie du MTX. Les concentrations de MTX 
obtenues par le prototype furent comparées avec des techniques standards, soit un essai 
immunologique basé sur la polarisation en fluorescence (FPIA) et la chromatographie liquide 
couplée avec de la spectrométrie de masse en tandem (LC-MS/MS) pour valider l’utilité du 
prototype comme un outil clinique pour les tests rapides de quantification du MTX. En dernier 
lieu, le déploiement du prototype à un laboratoire de biochimie dans un hôpital démontre 
l’énorme potentiel des biocapteurs SPR pour utilisation en milieux clinique. 
 
Mots-clés : Résonance des plasmons de surface, SPR, LSPR, nanoparticule d’or, couplage 
plasmonique, méthotrexate,  réductase humaine de dihydrofolate, suivi thérapeutique de la 
médication, analyse des médicaments anti-cancéreux, biocapteurs.  
 iii 
Abstract 
Methotrexate (MTX) cancer therapy requires therapeutic drug monitoring (TDM) for 
following its levels in a patient during the course of treatment in order to maximize efficacy 
while minimizing side effects. Despite its narrow therapeutic window, MTX remains until this 
date, one of the most employed chemotherapy agents. Existing TDM analytical techniques for 
MTX are costly, time-consuming and labor intensive which are not suitable to promptly 
generate results within the therapy timeframe. To provide rapid MTX quantification for TDM, 
a strategy is proposed based on a competitive assay featuring gold nanoparticles and surface 
plasmonic coupling. More specifically, the inhibition of MTX with its molecular receptor, 
human dihydrofolate reductase (hDHFR), an enzyme associated with proliferative diseases, is 
explored. Free MTX mixed with folic acid-functionalized gold nanoparticles (FA-AuNP) are 
in competition for hDHFR binding sites immobilized on a SPR active surface or free in 
solution. FA-AuNP binding to hDHFR provides signal amplification which is inversely 
proportional to the concentration of MTX. 
Surface plasmon resonance (SPR) is commonly used as a spectroscopic technique for 
the interrogation of biomolecular interactions. Current commercial SPR instruments are 
laboratory-based, bulky, expensive, lack sensitivity in complex matrix and have not shown 
adaptability in clinical settings. In addition, SPR analysis of small molecules such as drugs has 
not been extensively explored due to lack of sensitivity. The recent advances in materials 
science and surface chemistry exploiting gold nanoparticle integration for SPR response 
enhancement and peptide surface chemistry have shown potential in overcoming the poor 
sensitivity and surface-fouling limitations for crude biofluids analysis. These novel concepts 
of SPR technology are incorporated with a miniaturized fully integrated SPR prototype to 
conduct fast, reliable and sensitive analysis to monitor MTX levels of a patient undergoing 
chemotherapy. The objective of the thesis is to explore different strategies in improving drug 
analysis in a complex matrix using SPR biosensors and to put in perspective of the potential of 
SPR biosensors as a useful TDM tool in clinical laboratories or at a point-of-care situation.   
To achieve these objectives, a colorimetric solution-based MTX competitive assay is 
first established with FA-AuNP. Then, the solution-based MTX competitive assay is translated 
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onto a SPR platform. For both developed assays, sensitivity, selectivity, detection limit, 
dynamic range optimization as well as analysis of methotrexate in complex matrix are 
inspected. Furthermore, the SPR prototype is validated by its equivalent performance to 
existing SPR systems and by its utility in executing MTX analysis in actual serum samples 
from patients undergoing chemotherapy. The concentrations of MTX obtained by SPR 
biosensing are compared to standard techniques: fluorescence polarization immunoassay 
(FPIA) and liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) in 
order to confirm the feasibility of SPR biosensors as a useful clinical tool for performing rapid 
MTX concentration evaluation. Finally, the successful deployment of the prototype to a 
hospital laboratory demonstrates enormous prospective of SPR biosensors in clinical use.  
 
Keywords: SPR, LSPR, gold nanoparticles, methotrexate, human dihydrofolate reductase, 
therapeutic drug monitoring, small molecule detection, plasmonic coupling, biosensors, point-
of-care device. 
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Chapter 1 Introduction 
This thesis entails the application of surface plasmon resonance (SPR) biosensors in 
therapeutic drug monitoring (TDM) of methotrexate as a potential point-of-care (POC) device. 
It presents one of the first applications of SPR-based biosensors for the analysis of real clinical 
samples of patients undergoing chemotherapy and it explores the challenges associated with 
SPR biosensors in TDM. The technology presented in this thesis could be one of the exclusive 
examples of POC diagnostics using SPR biosensors. 
POC tests have been approved for its vital roles in reducing illness aggravation and 
mortality in clinical settings 
1
. The applications of POC devices extend from near-patient 
assessment in the hospital, clinical or at the doctor’s office to therapy or disease management 
at home or remote places. Ideally, a POC device can easily analyze an unprocessed specimen 
with basic manipulation to obtain a readable signal for interpretation. Easy preparation and 
simple manipulation and handling are important prerequisites so that presence of skilled staff 
is not necessary. The response of the test is ready for interpretation within a short period of 
time desirably, within minutes. The interpretation of the response should be as simple as 
viewing a color change or digital response that is relevant and indicative of the user’s 
condition. The device may be composed of low-cost components such as chips and cartridges 
that preferably are disposable. In this way, not only on-site diagnosis is achieved but the costs 
for expensive reagents for in-laboratory assays as well as training expenses for qualified 
personnel are reduced 
2
. It is important to note that POC devices are emerging not only in the 
clinical healthcare setting but also in the field of environmental, food industries as well as 
security and defense.  
With miniaturization of technologies such as microfluidics and optimized material 
manufacturing processes, the cost of fabricating POC devices becomes increasingly 
competitive to the cost of tests using benchtop instruments. With considerations of expensive 
reagents and instruments, paid laboratory staff, instrumental maintenance and repair as well as 
exhaustive facility usage, the cost of one single laboratory test is indeed quite expensive. In 
addition, sample mishandling or misinterpretation and instrumental malfunction or failure may 
lead to further increase in costs which are hurtful to public health care.  
 2 
One of the major benefits of POC devices is the reduction of time and facilitation of 
diagnostics on-site without the time spent for multiple hospital or clinical visits. For instance, 
a doctor suspects a patient is afflicted by a disease which requires a blood test to take action 
for the treatment. Currently, in the best scenario, during the visit to the doctor, a sample is 
collected from the patient and sent to the laboratory. However, most of the time, the patient 
may need to relocate to a second healthcare facility for sample collection. Then the sample is 
sent to a laboratory, and the results are usually expected after two weeks for regular in vitro 
diagnostic tests. With POC devices, time is tremendously reduced between sample collection 
and test results since the samples do not need to be sent to the laboratory and the results do not 
require extra time to be transferred back to the doctors. The results are given back on-site 
without a long waiting period. The diagnosis can be made by the doctor, with help from the 
nurse or care-giver and even the patient him/herself very rapidly 
3
. Furthermore, there is an 
increasing trend of patient compliance while employing POC tests. More self-awareness is 
induced in the patient while managing their own condition or therapy due to the self-
administration feature of the POC tests 
4. Studies have shown significant changes in patients’ 
behaviors in terms of adherence to treatment regimens, which in turn improve clinical results 
5,6
.  In theory, POC testings can improve patient clinical outcomes and benefit to the 
healthcare system in reducing medical costs and dissipating hospital or clinic overcrowding 
situation. However, there are still many practical challenges associated with the new concept 
in terms of accuracy of testings (sensitivity, false positives and false negatives
 7
, result 
misinterpretations 
3
, single-use chip or cartridge performance deviation 
8
).   
As a part of the flourishing biosensor market, it is estimated that new market entry 
POC diagnostics will demonstrate a remarkable growth in revenue. The billion dollar business 
is expected to grow more than double in 2016 from $6.72 billion in 2009 
9
. The glucose and 
the pregnancy POCs test are the best known ones. The increasing number of diabetic patients 
worldwide made the glucose POCs tests a major success in the biosensor market. It has been 
reported that the glucose sensor test strips for home use are manufactured on a scale 
approaching 10
10 
per year. The current state-of-the-art glucometer relies on a catalytic 
electrochemical current with a 5 second detection time using as little as 300 nL of samples. 
Many factors affect the evaluation of device performance such as individual training, sample 
 3 
collection, characteristics of the blood just to name a few 
3
. So far for tight glycemic control, 
the glucometer may not attain the expected performance 
10
. Only 4 out of 27 glucose 
monitoring systems achieved results that are 75% or better. This implies the extent of the 
results to fall within the specific requirement of ± 5 mg/dL for glucose concentration ˂ 75 
mg/dL 
10,11
. It was also reported by Freckmann et al. that for conventional glucose monitoring, 
about 3 out of 5 for a total of 27 systems were able to meet the performance requirements of 
achieving 95% of a reference measurement which falls within ± 15 mg/dL and ± 20 mg/dL for 
glucose concentrations of ˂ 75 mg/dL and > 75 mg/dL respectively 7. The pregnancy test 
depends on a lateral-flow assay. In this assay, a fluid migrates to a label capable of capturing 
the analyte of interest for visible signal generation. The lateral-flow assay has been employed 
for an exploding array of tests such as infectious diseases, drug of abuse screening as well as 
biomarkers heart attack, stroke, and thrombosis 
12
. The POC concept of self-testing allows 
personalized care and renders the user more self-conscious about his/her own condition. 
With the success of glucose and pregnancy POC tests and the outgrowth of new 
sensing technologies, multiple step benchtop analyses are being replaced by simpler portable 
lab-on-a-chip devices for instantaneous readout 
13
.  Amongst the wide range of available 
biosensing techniques, SPR biosensors have matured into the standard device beneficial for 
bio-analytical sciences which shows great potential for POC instrumentation development. 
Such optical detection technique is highly sensitive, low in cost in terms of instrumental and 
material fabrication, robust and versatile with fluidic integrations. The following sections 
discuss the physics behind the SPR phenomenon which consist of the basics of its biosensing 
capability as well as the current state and challenges of SPR biosensor development in terms 
of applications and instrumentation. As a sub-category of SPR, localized SPR (LSPR) 
phenomenon occurring on noble metal nanoparticles smaller than the wavelength of light is 
also discussed in addition to a review of applications and limitations based on LSPR 
biosensing. Furthermore, since the intended application of the developed biosensors targets 
mainly therapeutic drug monitoring of methotrexate, an overview of the concept of TDM is 
undertaken to provide insights on the integration of SPR biosensors for this specific purpose.  
 4 
1.1 Surface plasmon resonance 
Although contemporary applications employing SPR have blossomed over the past 
decades, the history of the discovery of the phenomenon began as early as the beginning of 
last century. At that time, Wood reported that when polarized light is directed onto a metal 
diffraction grating, anomalous reflective patterns were observed 
14
. A few years later, Lord 
Rayleigh attempted to formulate a theory behind the phenomenon 
15
. It was not until 1968 that 
the phenomenon was fully understood by Otto
 16
 with parallel supporting evidences reported 
by Kretschmann and Raether of surface plasmon excitation via attenuated total reflection 
17
.  
1.1.1 Theory of surface plasmon resonance 
Surface plasmon polariton (SPP) designates an electromagnetic excitation of electrons 
in the conduction band of a noble metal which propagates along the metal-dielectric interface. 
The magnitude of this electromagnetic field decays exponentially into each medium with 
increasing distance from the interface 
18
. In a way, the SPP is considered as a surface 
electromagnetic wave with confined electromagnetic field near the vicinity of the interface. 
This results in an enhancement of localized electromagnetic field near the surface that 
attributes surface plasmon sensitivity to minute changes in dielectric constant of the medium 
at the vicinity of the sensor.  At a specific incident wavelength of light or angle, resonance of 
SPP and light leads to absorption of light.  In order to successfully excite SPP, a few criteria 
need to be met: 1) the dielectric constant of the plasmonic substrate must have a negative real 
and small imaginary component. 2) The wavevector of p-polarized incident light (TM, 
transverse magnetic) must be equal to the wavevector of surface plasmons to attain resonance 
(kspp = kph). 
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where kspp is the surface plasmon polariton wavevector and kph is the wavevector of the light,  
is the angular frequency of the light,  is the wavelength of light, m is the dielectric constant 
of the metal film (a function of), d () is the dielectric constant of the surrounding media 
which is related to refractive index by εd = ηd² and c is the speed of light.  
 The resonance conditions are never met with direct excitation of SPP of a thin metallic 
film since the wavevector of light is always smaller than the wavevector of the surface 
plasmons kspp > kph. Consequently, by employing grating or prism coupling, the surface 
plasmon can be excited by decreasing kspp or increasing kph illustrated in figure 1.1 
19
. In the 
case of Kretschmann configuration, the wavevector of the light is augmented by  or D 
undergoing a total internal reflection in a prism for excitation of surface plasmons of a thin 
metallic film. An evanescent field penetrated to the interface metal-dielectric medium is 
formed by light impinging at the interface of prism-metal. At this point, p-polarized light (TM 
polarized) having its electric field oscillating perpendicular to the interface excites TM 
polarized surface plasmon at the interface of the metallic film and the dielectric. Surface 
plasmon excitation is made possible when kph,x equals to kspp.  
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The governing equations show that the wavevector of the light is dependent on the wavelength 
(λ) or the angle of incidence () of the light beam. Note that kph,x is the wavevector of light 
when propagating along the x-axis. This has given rise to two major configurations in 
interrogating SPR: scanning angle or wavelength-modulated SPR. As mentioned above,  εd = 
ηd² , as refractive index near the vicinity of the sensor surface (metallic thin film) changes, the 
light wavevector also changes in order to remain in resonance and excite surface plasmons. 
Modulation of incident wavelength or angle compensates for light wavevector changes. SPR is 
thus capable of measuring small refractive index changes near the sensor surface.  
 6 
 
Figure 1.1 Matching of the light wavevector with the surface plasmon wavevector for the 
excitation of surface plasmons using prism or grating coupling. kx on the x-axis is the 
wavevector of light when propagating along the x-axis (kph, x).  Illustration adapted from 
Couture, M. et al. 
19
. 
 
1.1.2 Principle of SPR biosensors 
The characteristic of SPR for its sensitivity to refractive index changes in the medium 
at the proximity of the sensor surface makes it a quasi-universal detector 
20
. Change in the 
refractive index (RI) induced by the bulk or near the surface promotes change in the plasmonic 
wavelength or angle in parallel. Consequently, SPR is highly sensitive for interrogating 
surface related processes such as adsorption, desorption and binding interaction. The first 
application of SPR was demonstrated from monitoring biomolecular interactions 
21
.  
The SPR biosensor is constructed by first immobilizing a receptor specific for a 
biomolecule of interest on the surface of a plasmonic substrate illustrated in figure 1.2. When 
the biomolecules bind to receptors immobilized on the surface, a change in the dielectric layer 
directly above the metallic film induces changes in refractive index. The dynamic change in RI 
near the surface is monitored in real-time with the concomitant change in SPR signal. The 
minimum wavelength or angle (λmin or θmin) of the SPR signal is derived using mathematical 
models. The evolution of λmin or θmin with respect to time measures and quantifies RI changes 
at the sensor surface.  In this way, the sensor is sensitive to biological events occurring at the 
 7 
surface that can be monitored in real-time. The real-time data acquisition possibility using 
SPR sensors provides valuable biomolecular interaction information such as thermodynamics, 
binding kinetics as well concentration of the analyte solely from the sensorgram generated. 
The following equations are used to model the pseudo first order kinetics for a binding 
interaction monitored with SPR sensors using wavelength interrogation.  
5)                    (   ) 
 
6)                      
 
7)         At thermodynamic equilibrium           (   )      
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where a is the binding partners’ association reaction rate, d is the binding partners’ 
dissociation reaction rate, C is the concentration of the analyte,   is the surface coverage of 
the analyte on the receptor, Keq is the thermodynamic equilibrium constant for binding (Keq = 
kd/ka), ΔSPR is the shift of the SPR wavelength for a given concentration of analyte and ΔSPR, 
sat is the shift of the SPR signal for a saturating concentration of analyte.  
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Figure 1.2 Schematic illustration of SPR biosensing. The analyte interacts with bound 
receptors on a plasmonic substrate inducing refractive index changes near the surface. 
 
1.1.3 Surface plasmon resonance biosensor applications
1 
 
The growth of SPR in the bio-analytical field has gained significant impact over the 
past few years. Even since SPR has been proven to be a dominant tool for biomolecular 
interactions characterization in real-time, progress exploring the possibilities of SPR for bio-
analysis has persisted. With label-free, sensitive and real-time data acquisition, biosensing of 
different classes of biomolecules were assayed. The diversity of large biomolecules spans 
from proteins, peptides, DNA, RNA as well as microorganisms which can be presented as 
potential disease biomarkers of clinical interest. In addition, small molecules such as drugs 
and hormones are more challenging for SPR biosensors; sensitivity is low for small molecules 
with molecular weight under 1000 Daltons since low molecular weight molecules cannot 
induce a large change of refractive index near the sensor surface. However, modified detection 
schemes can lead to more successful analytical assays. In recent years, SPR and LSPR 
biosensors have been developed in parallel. Both sensing schemes rely on biomolecular 
                                                 
1
 This section was published in Couture M, Zhao SS, Masson JF, Modern surface plasmon 
resonance for bioanalytics and biophysics, Phys Chem Chem Phys, 2013, 15 (27), 11190 - 
11216 - Reproduced by permission of the PCCP Owner Societies 
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interactions. As a bio-recognition receptor is fixed onto the sensor surface, the action of the 
analyte binding specifically to the receptors induces a change of refractive index close to the 
sensor surface. The change of refractive index can be correlated to concentration of analyte 
binding at the surface, which has been exploited for various analytical detection schemes.  
1.1.3.1 Surface plasmon resonance biosensors 
One of the most prominent research areas focuses on developing SPR biosensors for 
the rapid analysis of biomarkers for early disease detection 
22
.  Ideally, in the future, patients 
suspected of having a disease can have their blood tested at the doctor’s office and will 
acknowledge their test results desirably within a single visit. Such anticipation may become a 
reality considering progress made with miniaturization of the SPR instrumentation as potential 
point-of-care clinical platform. There have been a great number of biomarkers previously 
identified by molecular biology that have been well studied at the cellular level on how their 
presence or absence may be indicative of a disease state. However, there is not enough 
emphasis put into the research and development of rapid and cost-effective diagnostic tools for 
detecting these biomarkers. The existing analytical techniques such as ELISA can be time- and 
reagent-consuming. Therefore, it is important to explore development of diagnostic tools with 
reliable robustness, rapidity and cost effectiveness towards more efficient personalized 
medicine. 
There are examples of studies of SPR sensing for diagnostic purposes, which have 
been reported for biomarkers and pathogen detection as well as some drug and hormone 
analysis with reasonably low limit of detection (LOD). For instance, prostate specific antigen 
23
, carbohydrate antigen 
24
, protein vascular endothelial growth factor 
25
, interleukin-8 
26
 are 
some of the target cancer markers for which SPR biosensing has been validated. SPR 
biosensors were also used to detect several pathogen-specific antibodies such as hepatitis 
viruses 
27
, herpes simplex virus type 1 and type 2 
28
 to name a few. LODs in the low 
nanomolar and picomolar range were reported in buffer solutions or in diluted serum for these 
disease-related biomarkers and pathogen-specific antibodies 
22
.  
SPR biosensors were also developed for the analysis of metabolites of doping 
substances such as morphine-3-glucuronide 
29
. In addition, hormones such as estradiol 
30
 and 
 10 
progesterone 
31
 and neurotransmitter, dopamine detection
 32
 were also achieved by SPR 
biosensing. It is important to note that there are two other detection schemes that are 
commonly employed: sandwich 
33,34
 and competitive assay 
35
 for SPR assay sensitivity 
enhancement illustrated in figure 1.3. Competitive assay format is preferred for small 
molecules to enhance the SPR signal indirectly with an amplification element such as protein, 
latex nanoparticles (NP) or metallic NP attached to a competitor of the analyte to compete for 
a constant number of receptors on the surface.  
Homola’s review 22 has reported that SPR biosensors which have been developed for 
medical diagnostics purposes were able to reach LODs ˂ 1-100 ng/mL for the detection of 
cancer markers and antibodies but most of the experiments were assayed in buffers rather than 
in clinical samples. Although increasingly more studies are moving from analysis in simple 
buffers to more representative biological fluids, clinical biological sample analysis remains a 
main challenge for SPR biosensors. A great variety of biomolecules is found in biological 
matrices in high concentrations which could compete nonspecifically with the analyte of 
interest to interfere with the specific interaction on the SPR surface. As a result, the sensor 
performance (sensitivity and LOD) is affected. In the literature, studies that have tested their 
system in biological matrix rely on drastic sample dilution. However, the very few who have 
succeeded in SPR analysis in complex matrix have employed original antifouling surface 
chemistry for conditioning the sensor surface to prevent nonspecific adsorption. Some of the 
examples of surface coatings include polymers (poly(carboxybetaine acrylamide)) 
36
 and 
peptides 
37
 which at the same time serve for anchoring the receptor and reduce fouling protein 
adsorption. In terms of sensitivity enhancement in crude matrix, metallic nanoparticles, with 
ease of synthesis and high dielectric constant, can couple with SPR for signal amplification. 
NP offer the advantage of increasing the signal for a constant noise (background level), which 
improves the signal to noise ratio 
38
. In other cases, novel plasmonic materials with increased 
bulk sensitivity can offer substrates with greater sensitivity for biosensing. It has been reported 
that the use of innovative plasmonic materials achieved a significant enhancement of up to 7-
fold in sensitivity 
39,40
. Ultralow detection limits was also possible in the femtomolar range 
41
. 
The SPR biosensors should be designed to suit the specific target analyte in terms of 
sensitivity and LOD requirements in real biological samples.   
 11 
Some of the examples of SPR analysis in real biological fluid matrix are discussed 
below. For instance, a membrane-based sensitive SPR study with embedded cell receptor for 
the capture of bacterial Cholera toxin was conducted with a gold nanoparticle (AuNP) 
sandwich assay in combination with atom transfer radical polymerization in 50% serum 
42
. 
Carcinoembryonic antigens were determined in 50% diluted human blood plasma as low as 
0.1 ng/mL in a sandwich assay using nanoparticle amplification 
43
. The interaction of human 
chorionic gonadotropin and its antibody was examined in 50% blood plasma using SPR 
biosensor in conjugation with a dispersionless microfluidic cell. Fast response time and high 
sensitivity were obtained  
44
.  It is interesting to highlight that many of the studies have relied 
on commercial SPR instruments. The current state of commercial SPR instruments is robust 
enough to provide a suitable platform for method development for specific bio-analytical 
targets. Nonetheless, these instruments are not suitable for clinical settings due to their 
bulkiness. It is important to stress that there is a lack of availability of analytical platform 
based on SPR in real clinical settings. So far, all studies have been conducted and developed 
on commercial or in-laboratory instruments. There is a need for translating laboratory-
developed SPR assays for biological samples into a point-of-care, rapid analytical platform 
useful in clinical settings.  
 12 
 
Figure 1.3 SPR detection schemes of reflectance-based a) direct b) sandwich c) competitive 
assays. Sensing schemes of colloidal NP-based LSPR assays with e) surface binding and f) 
aggregation wavelength shifts and g) patterned NP substrate LSPR assays with surface binding 
wavelength shift. The resonance wavelength or angle on the d) reflectance and the h) 
transmission spectra is monitored in real-time due to biomolecular interactions. i) Sensorgram 
derived from the binding shift with respect to time. 
 
1.2.1 SPR Instrumentation
2
 
Commercialization of SPR instruments has blossomed over the past two decades. 
Enormous progress has been made in establishing a variety of SPR instruments from high- 
performance laboratory SPR instrument to user-friendly portable miniature SPR devices and 
                                                 
2
 This section was published in Couture M, Zhao SS, Masson JF, Modern surface plasmon 
resonance for bioanalytics and biophysics, Phys Chem Chem Phys, 2013, 15 (27), 11190 - 
11216 - Reproduced by permission of the PCCP Owner Societies 
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high-throughput SPR imaging systems. Different instruments can be suited and marketed for 
specific applications. Current state and future direction of development for laboratory and 
portable/handheld SPR platform are discussed.  
1.2.1.1 Laboratory SPR 
The first SPR instrument commercialized was a benchtop analytical instrument 
launched in the early 1990s by Biacore, a Swedish company later acquired by GE Healthcare 
in 2006. The Biacore technology is the market leader in producing SPR products which allow 
high-throughput label-free protein interaction analysis in real time
 45,46
. Most of the Biacore 
instruments as well as some other manufacturers such as Reichert technologies 
47
, Xantec 
bioanalytics GmBH 
48
, Sensiq 
49
, Sensia 
50
 and KMAC  
51
 rely on fixed angle Kretschmann 
configuration. In addition, Biosensing Instruments 
52
 and Bionavis 
53
 use scanning optics with 
the same optical configuration. High angular resolution is achieved with the Biosensing 
Instrument series where the position of the SPR angular minimum is scanned and measured. 
This provides greater resolution of the SPR measurement at the expense of long analysis time. 
Bionavis has combined fixed angle and focused beam SPR to attain a wide angular range of 40 
degrees. Examples of laboratory SPR systems are shown in figure 1.4. Until this day, the 
benchtop SPR instrument with the best performance on the market can achieve a resolution of 
2 x 10
-7 
RIU 
54
. Most of the instruments are equipped with at least dual channels where one 
serves as the reference channel to correct for background signal. The surface plasmons can be 
excited at multiple areas on the sensor surface with appropriate optical settings, defining the 
sensing spots. The demand for high-throughput analysis led to the development of 
multichannel SPR sensors which further evolved into SPR imaging sensing platforms 
55,56
. 
 
A 
few of the companies offer the possibility of adapting different flow cells rendering the system 
versatile for coupling to other analytical techniques such as electrochemistry, fluorescence, 
photochemistry and matrix-assisted laser desorption ionization mass spectrometry (MALDI-
MS) 
46,49,50,57
. Throughout the years, commercialized SPR have evolved into robust and high 
performance laboratory instrumentation. The systems are built to reduce the operator’s input, 
greatly simplifying the use of SPR instruments. Readily available sensor chips with suitable 
surface chemistry are inserted into a cavity where, during operation, the plasmonic sensor chip 
is interrogated. Then, automation of the system allows the user to program for automatic 
 14 
instrumental control of injection valves and syringe pump during autonomous runs. 
Sophisticated temperature regulation and noise compensation parts are integrated for optimal 
signal to noise ratio. Well-established data treatment algorithms contribute to user-friendly 
data analysis programs which allow for fast results interpretation 
58
. 
So far, high-throughput SPR imaging systems, where up to thousands of analyses are 
simultaneously conducted on a single chip, have taken over high-performance automated SPR 
systems with fewer sensing areas. The direction of development for high-performance SPR 
systems foresees an emergence of SPR hyphenated techniques. By coupling SPR to other 
analytical spectroscopic techniques such as Raman, infrared, fluorescence or mass 
spectrometry, specificity and sensitivity can be improved. By adding an orthogonal detection 
technique, the possibility of analyzing the interacting species increases the information space 
about the binding system, with the consequence of diminishing false positives in the process 
40
. Predictions are that hybrid SPR systems will gain popularity for sensor development, but 
functional optical design and appropriate interfaces need to be optimized for further advances.  
 
 
Figure 1.4 Images of a) Schematic representation of the Biacore biosensor. Reprinted with 
permission from J. Amino Acids, 2012, 2012, 816032. DOI: 10.1155/2012/816032. b) Biacore 
T100 (GE Life Sciences). c) BI SPR 1000 (Biosensing instrument). d) SensiQ® (Nomadic 
Inc.) and e) SPR Navi 200 (Bionavis). Reproduced with permission from BioNavis. b), c) and 
d) are reproduced from ref. 59 
59
 with permission from The Royal Society of Chemistry.  
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1.2.1.2 Portable/handheld SPR devices 
Several companies are interested in producing compact, low-cost and portable SPR 
systems for applications that extend beyond the laboratory and conventional molecular 
interaction analysis. For instance, the portable system can be brought to the field for rapid 
analysis of water and soil contamination or for fast clinical diagnostics in emergency 
situations. Currently, portable SPR systems have sizes no larger than a lunch box and weigh 
no more than 5 kg. All optical components and electronic parts are integrated into a single 
module; only the area on the prism for chip insertion is exposed. Then, a microfluidics flow 
cell can be manually placed on top of the chip for liquid handling. Manual injection or a 
syringe pump can be used for sample delivery. The flow cell and tubing are normally robust 
enough to withstand rugged injection and prevent leaks in remote situations. Ideally, a 
disposable fluidic cell would be more adaptable to portable systems  
60
. Reference channels 
are now common and facilitate the compensation of temperature drift 
61
. SPR micro (KMAC) 
51
, SPIRIT (Seattle sensing systems) 
62
, Smart SPR SS-1001 (Mebius advance technology) 
63
  
and Biosuplar 6 (Analytical μ-systems/Mivitec) 64 all have designs of dual or multiple 
channels for referencing or multiplex analysis. In the case of SPIRIT, 4 channels are available 
for multiplex analysis in triplicate. Fixed angle Kretschmann configuration remains the most 
popular optical set-up in several of the mentioned devices for optimized resolution and design 
simplicity. Data acquisition and analysis program are simplified but sufficiently reliable for 
fast results 
65
. Finally, portability implies that the system can be operated on battery for a 
reasonably long period of time on the field. One of the pioneers in portable SPR devices, 
Texas Instruments Inc. was the first to develop SPREETA, a small and inexpensive sensor of 
1.5 cm x 0.7 cm x 3 cm. Such an instrument integrates all the SPR optical components into a 
molded and compact device 
62
. The sensing surface is replaceable and the device only weighs 
7g 
66,67
. Examples of portable/handheld SPR devices are shown in figure 1.5. Contrary to 
reusable sensor chips employed for laboratory-based SPR system, disposable sensor chips are 
more suited for portable SPR devices since the cost of production is decreased and time for 
regenerating the sensor surface for subsequent analyses is saved.  
Contemporary miniature instruments have RI resolution of 10
-6 
RIU in comparison to 
10
-7 
RIU of high-performance laboratory SPR systems 
62
. Improving the resolution and 
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sensitivity of portable SPR devices is one of the main challenges. As miniaturization and 
portability compromise the analytical performance, solutions such as assay development with 
the addition of a label or incorporation of novel plasmonic substrates 
68
 for sensitivity 
enhancement can be envisaged 
69
. Secondly, the next big challenge for portable SPR will be 
the achievement of analysis in real sample matrix. At the present, some manufacturers have 
tested their devices in analyzing environmental pollutants and water quality in remote areas 
63
 
but none have demonstrated examples of biomedical diagnostics in clinical settings. Direct 
analysis in crude biological fluids may further pose problems to the analytical performance of 
portable system. Development should focus on assembly of a highly specific recognition 
element, efficient anti-fouling surface chemistry and enhanced plasmonic materials for 
tackling real biological sample analysis. Portable SPR holds great promises in future clinical 
diagnostics and will continue to be the rising star in point-of-care biosensing devices 
technologies. 
 
Figure 1.5 Images of a) Schematic representation of SPREETA sensors. Reprinted with 
permission from Biosens. Bioelectron. 2007, 22, 1908. Copyright © 2007, Elsevier. b) 
SPREETA (Texas Instruments). Reproduced with permission by Nomadic Inc. c) Biosuplar 2 
(Analytical μ-systems). Reproduced from ref. 59 59 with permission from The Royal Society 
of Chemistry and d) SPIRIT (Seattle sensing systems). Reprinted with permission from 
Biosens. Bioelectron. 2007, 22, 2268. Copyright © 2007, Elsevier.  
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1.2 Localized surface plasmon resonance 
The fascinating optical properties of noble metal nanoparticles in generating spectra of 
bright colors have attracted considerable interest since the Roman age. Notably, they were 
used as decorative pigments in stained glass and artwork for their interchanging features with 
light 
70. It wasn’t until 1857 that Faraday elucidated the size dependence of particles on the 
variety of resulting coloration 
71
. Mie and Gans refined the theoretical aspects of the 
phenomenon at a later stage in the 1900s. Since then, the applications of the noble metal 
nanoparticles have exploded in many different fields remarkably ranging from nanomedicine, 
photonics and sensing technologies 
72,73
.   
1.2.1 Theory of localized surface plasmon resonance 
For nanoparticles with dimensions much smaller than the wavelength of the light, 
direct visible light excitation is possible. The interaction of light with the nanoparticles results 
in extinction which is a sum of absorption and scattering of light by the nanomaterials. Usually 
extinction of smaller nanoparticles is predominated by absorption due to surface plasmon 
resonance 
74
. SPR absorption results from the resonance of a collective oscillation of free 
electrons from the conduction band with the electromagnetic field of the irradiated light. More 
specifically, when a nanoparticle is subjected to an electromagnetic field, the electrons of the 
conduction band on the nanoparticle oscillate in resonance with the electromagnetic field of 
the light. This creates a positive and negative charge density separation from the nuclei given 
rise to a dipole 
75
. The energy of the incident electromagnetic (EM) wave is absorbed at 
specific wavelengths oscillating at the same frequencies as the electron dipole on the 
nanoparticle. As the oscillating electrons are confined at the nanoparticle surface, the term 
localized surface plasmon resonance (LSPR) is often used. 
In 1908, Gustav Mie was able to solve Maxwell’s equations using a quasi-static 
approximation. This implied that the nanoparticle subject to a field is spatially constant with a 
time dependent phase 
74,76
. Therefore the extinction spectrum of a metallic sphere can be 
defined as followed: 
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where E() is the extinction at a specific wavelength, r and i are respectively the real and 
imaginary part of the metal dielectric constant, εd is the dielectric constant of the surrounding 
environment. N refers to the number of particles, a is the size,  is the form factor of the 
nanoparticle, usually 2 for spherical nanoparticles. It is important to note that ε = εr + i εi  is 
the complex dielectric constant of the metal. Mathematically, when the dielectric constant of 
the metal equals approximately -2 εd, resonance condition is satisfied and the EM field is 
enhanced in comparison with the initial field 
77
. This is the case for gold and silver metallic 
nanoparticles having their LSPR band in the visible spectrum. Therefore the LSPR spectrum is 
dependent on the factors mentioned in the equation above. NP is sensitive to small changes of 
refractive index due to the enhanced highly localized EM field induced by LSPR.   
 
Figure 1.6 Schematic illustration of LSPR biosensors. Receptors immobilized on the 
nanoparticle surface interact with the analyte of interest. The local dielectric environment is 
changed due to the binding event which results in coloration change of the colloidal solution. 
1.2.2 Principle of LSPR biosensors  
The strong local electric field enhancement at the NP surface renders the NP sensitive 
to changes in the local dielectric environment (refractive index) caused by surface events such 
as adsorption or desorption and binding or dissociation of molecules, that in turn, modulate RI 
changes in the local medium illustrated in figure 1.6. These processes occurring at the surface 
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of the metallic NP change the wavelength of the LSPR band maximum (λmax). In this way, a 
relationship is established between the spectral shift of λmax induced by analyte binding to NP 
surface receptor and the concentration of the analyte, which constitutes the basics of LSPR 
biosensing 
76,78
. The change of concentration dictates the change in surrounding RI (Δn). Δλmax 
can then be correlated with Δn described in equation 10). Furthermore, sensing by exploiting 
plasmon coupling is another popular scheme. Inter-nanoparticle associations due to 
biomolecular interactions induce a large spectral LSPR shift sensitive to biomolecule detection 
since the EM field is further enhanced with the close proximity NP associations.  
 
10)                 [     (
   
  
⁄ )] 
 
where m is the bulk refractive index surrounding the NP, also termed as the sensitivity of the 
NP, Δn is the change in refractive index, d is the effective thickness of the adsorbed layer and 
ld is the decay length of the EM field. Δλmax corresponds to the spectra shift of LSPR extinction 
spectrum. 
1.2.3 LSPR biosensors and applications
3
 
LSPR biosensors encompass two categories: colloidal NP in solution and patterned NP 
array substrates interrogated in transmission or reflection mode 
79
. The principle behind the 
sensing mechanism of LSPR based on colloidal NP can be divided into two main classes: NP 
aggregation and dielectric medium changes near the surface of the NP. Both LSPR from 
colloidal NP or NP on substrate have different sensitivity to varying shape, size, interparticle 
distance, dielectric material and the surrounding medium 
77,80
.  Interaction of biomolecules 
fixed onto the NP surface with analytes can induce physical changes of the stabilized NP or 
                                                 
3
 This section was published in Couture M, Zhao SS, Masson JF*, Modern surface plasmon 
resonance for bioanalytics and biophysics, Phys Chem Chem Phys, 2013, 15 (27), 11190 - 
11216 - Reproduced by permission of the PCCP Owner Societies 
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refractive index changes near the NP surface. Both result in a plasmonic shift of the LSPR 
band. 
NP aggregation sensing scheme was introduced in 1996 by Mirkin et al. where NP 
were coated with 2 different sets of non-complementary single stranded (ss) DNA. Following 
the addition of DNA in solution which is complementary to both ends of ssDNA on the NP, 
NP autoassemble together which display great color changes from red to purple 
81
. Single base 
mismatches as well as single nucleotide polymorphism 
82
 tests can be carried out using this 
methodology. Furthermore, this strategy has been utilized for detection of small 
concentrations of heavy metal ions as well. Chelating of metal ions induced aggregation of 
functionalized NP, which also induces distinguishable color change. Furthermore, other 
analytes such as streptavidin, homocysteine, anti-protein A, glucose 
83
 and histone modifying 
enzymes 
84
 have been detected using the same scheme 
85
. The second LSPR detection scheme 
relies on the transduction of refractive index sensing based on LSPR wavelength shift.  
In an analogous scheme to SPR, the change of refractive index near the surface of the 
colloidal or substrate sensor induces a shift in LSPR maximum which was indicative of a 
biomolecular interaction. In some early work, biotin-streptavidin and antibody-bovine/human 
serum albumin interactions were examined by using gold nanospheres 
86,87
. Recently, C-
reactive protein associated with cardiac diseases was quantified in blood serum collected from 
patients using surface-functionalized gold nanoparticles 
88
. Furthermore, nanorods with a 
sensitive longitudinal plasmonic band, attracted great attention for shift-based assays. Their 
biosensing capabilities were investigated with streptavidin-biotin interaction, giving a LOD of 
94 pM in buffer solution and 19 nM in serum samples 
89
. Detection of Escherichia coli and 
Salmonella typhimurium were performed simultaneously using amine-modified nanorods of 
different aspect ratios 
90
. Qualitative analysis of Hepatitis B surface antigen was performed in 
blood and serum media using nanorods 
91
.  
LSPR active patterned substrates were also examined 
76,78
. One of the most popular 
examples was a study conducted using a triangular array of Ag NPs for the investigation of the 
well-established biotin-streptavidin interactions with an LOD of 0.7 nM. Then it was used to 
monitor in real-time on the interaction of concanavalin A to the monosaccharide mannose that 
was functionalized onto the NP on the substrate 
92
. Gold nanorod substrates developed by 
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Hafner’s group were used to interrogate IgG and anti-IgG interactions and binding constants 
were comparable to existing values 
93
. An example illustrating the potential of LSPR 
substrates for biomedical screening is the detection of an Alzheimer’s disease biomarker using 
Ag triangular arrays in cerebrospinal fluids and human brain extracts 
94
. Lastly, low molecular 
weight analysis was demonstrated using LSPR matching to molecular resonance of the 
analytes 
95
.  
Despite the ease and low cost of fabrication, the analytical performance of LSPR 
remains an issue for analysis in biological samples. Nonspecific adsorption and high 
absorptivity of biological matrix proteins greatly reduce the sensitivity of the assay in real 
clinical sample analysis. Only a few NP-based diagnostic tools were tested using real clinical 
samples with sample pre-treatment  
96
. There is also a lack of suitable platform for increasing 
the throughput of LSPR analysis in clinical settings. Progress made so far in the area shows 
great potential of multiplexed sensing with LSPR-sensitive materials but attention should be 
paid on the reproducibility of batch-to-batch synthesis and of NP substrates from one sensing 
area to another. 
1.3 Therapeutic Drug Monitoring 
The biosensors presented in this thesis are developed for the application of TDM for an 
anti-neoplastic drug, methotrexate. This is one of the first reported studies of integrating 
biosensors based on SPR and LSPR in the field of TDM. Background information is provided 
in order to gain a better perception of the clinical utility of TDM and to highlight the need for 
improved analytical tools for this application. 
 TDM was first introduced into medical practice in the 1970s for assisting clinicians in 
monitoring anticonvulsant drugs for personalizing dosage regimen in avoiding adverse effects 
97
. TDM implies that the measurement of drug concentration is conducted in a biological 
matrix, most commonly in serum or plasma, accompanied by appropriate interpretation of the 
value in order to provide drug dosage or schedule adjustment and individualization for 
maximizing clinical outcomes and/or minimizing toxicity 
98
.   There are several criteria for a 
drug to be valuable with TDM practice. These are mentioned in table 1.1.  
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Table 1.1 Criteria of a drug requiring TDM. 
Narrow therapeutic window 
Clear relationship between concentration and pharmacological effects (therapeutic response or 
toxicity) 
Considerable pharmacokinetic variability from individuals 
Poor relationship between dosage and drug concentration in serum or plasma 
Toxicity results in severe consequences: hospitalization, organ damage, death 
Poorly defined therapeutic and toxicity levels based on clinical evidence 
 
TDM is especially beneficial in patient care in a way that the dosages can be adjusted with 
respect to the individual. Pharmacokinetics such as metabolism and excretion of drugs are 
highly dependent on the age, sex, disease state, environment causes, drug to drug interactions 
and physiological conditions of the patient 
97
. Furthermore, drug monitoring provides 
prevention of drug toxicity and manifestation of adverse effects. In some of the cases, drug 
non-response can be identified if the patient is a fast metabolizer of a particular drug. In 
addition, TDM can significantly reduce costs for unnecessary overdose and toxicity treatment 
as well as long hospital stays. The therapeutic ranges are established from the clinical 
observation of a small group of patients taking the drug. The lowest drug concentration limit 
(trough) is defined as 50% of the therapeutic response whereas the upper concentration limit 
(peak) is associated with toxicity 
99
. One dose does not fit all as patients can achieve 
therapeutic effects with concentrations below therapeutic range or reach toxicity within the 
therapeutic window 
100
. Essentially, the goal of TDM is to optimize drug dosages in order to 
maintain the patient’s drug concentrations within the proper therapeutic range defined 
according to the average response of a small group of patient. In some therapy, multiple doses 
are required to reach and maintain the drug level within the therapeutic range. In that case, 
frequent blood sampling of the patient under therapy for pinpointing the true peak and trough 
concentrations will contribute to optimized dosage adjustment.  
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The evolution of TDM techniques has permitted better patient care with more sensitive 
assays of fast turnaround time. Existing analytical techniques can readily provide drug level 
measurements required in TDM. However, the accuracy and precision of the analysis could 
vary greatly depending on the performance of the analytical platform 
97
.  The gold standard 
method referred to as the reference method, is until this day, liquid chromatography coupled 
with tandem mass spectrometry (LC-MS/MS). In general, this technique has high sensitivity 
and selectivity with low inaccuracies but often requires skilled operators. The samples may 
need to be treated before the analysis which becomes labor intensive and time consuming. On 
the other hand, drug analyses are conducted by routine methods, usually immunoassays. 
Currently, there are more than 25 immunoassays that are available for routine use in TDM 
101
. 
These analytical methods have the advantages of low cost, ease of use (most of the time with 
full automation), no pre-preparation, small sample volume and high throughput. However, 
they are known to be less specific due to metabolites interference which results in erroneous 
data with large imprecision. Nonetheless, the degree of uncertainty of the analytical method 
must not affect the clinical decision. Some of the commonly known immunoassays are 
radioimmunometric assay (RIA), fluorescence polarization immunoassay (FPIA), enzyme-
multiplied immunoassay technique (EMIT), chemiluminescent immunoassays (CLIA), 
enzyme-linked immunosorbent assay (ELISA) and enzyme immunoassay (EIA). It is 
important to stress that most of the TDM immunoassays target analytes of small molecular 
weight, such that competitive assay is the preferred format. The assay involves mostly a 
competition between the labels and the analyte of interest for a constant number of receptor 
molecules. The detection scheme varies with respect to the characteristics of the label 
employed. 
1.3.1 TDM of anti-neoplastic drugs  
Chemotherapy agents are narrow therapeutic window drugs that induce large 
pharmacokinetic variability amongst individuals during treatment. TDM has enormous 
potential in providing better patient therapy management. However, the utility of TDM for 
anticancer drugs is debated since a few limitations are presented. For instance, one of the main 
concerns is that the link between concentration and therapeutic effect cannot be established. 
Therefore, knowing the drug level cannot provide insights of the outcome. Furthermore, the 
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pharmacokinetics of antineoplastic drugs is often not well understood; the situation is more 
complex when the drug is administered with other drugs as a cocktail 
98
. Despite these 
limitations, TDM is beneficial if used for drugs with well-defined dose-dependent therapeutic 
responses. More specifically, TDM can improve efficacy, minimize toxicity, identify 
abnormal drug distribution and initiate rescue at the first sight of hepatic or renal dysfunction 
or adverse side effects. The practice of TDM allows the monitoring of the patient condition 
more closely during chemotherapy and quick remedial actions in case of toxicity.  
1.3.1.1 Methotrexate TDM 
Methotrexate (4-amino-10-methylpteroylglutamic acid) is an antifolate employed for 
treating a wide range of cancers. It is involved in maintenance therapy for acute lymphoblastic 
leukemia (ALL) and in high-dose treatment of prolonged intravenous infusion of ALL, 
lymphoma, choriocarcinoma, osteosarcoma, breast cancer, gastric, bladder  and head and neck 
cancer 
102
. For a long time, methotrexate is used in a combination regimen with 
cyclophosphamide and 5-fluorouracil (CMF treatment) for adjuvant breast cancer therapy and 
metastatic diseases. Furthermore, MTX has demonstrated efficacy in non-neoplastic 
conditions such as rheumatoid arthritis, psoriasis and transplant complications. Note that only 
low dose of MTX is required for non-neoplastic diseases.  
The mechanism of action of MTX is briefly described here. MTX, as a folate analogue, 
tightly inhibits the human dihydrofolate reductase (hDHFR) (EC 1.5.1.3) which is a 
ubiquitous cytosolic enzyme. hDHFR reduces its substrate, 5, 6-dihydrofolate (DHF), to 
5,6,7,8-tetrahydrofolate (THF) which is a major cofactor for the biosynthesis of purines and 
pyrimidines essential for proper replication of DNA and thus, cell division. In other words, 
MTX is able to ultimately terminate cancerous cell proliferation 
103
.  
It has been established that high-dose MTX treatment could lead to life-threatening 
toxicity that can be corroborated with serum concentrations. It has been reported that high-
dose MTX infusions are susceptible to result in toxicity cases such as myelosuppression and 
gastrointestinal mucositis. MTX clearance depends greatly on the proper renal function of the 
patient. The risk of potentially fatal toxicity associated with high-dose MTX increases with 
renal impairment where MTX has prolonged duration of exposure in the serum of the patient 
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104
. Because there is a defined relationship between the efficacy/toxicity and systemic drug 
expose, MTX is the perfect example of a drug that provides better therapy with TDM. Dose 
adjustment in MTX chemotherapy occurs routinely due to large variation in inter-individual 
pharmacokinetics where concentrations can vary over a 5-fold range from one patient to 
another using one single fixed dose 
105,106
. In order to decrease toxicity of the patient induced 
by MTX, folinic acid (leucovorin) rescue is undertaken by administering doses of folinic acid 
until serum MTX levels reach 0.2 μM. For adults, high-dose MTX treatments vary in dose and 
duration. But TDM of each patient is more or less practiced in a similar way, with the first 
measurements within 24h or a bit after 24h of MTX initiation. Then the drug level is 
monitored at least once daily. Leucovorin rescue is begun after 24-48h of MTX therapy until 
reaching the safety threshold. In infants, pharmacokinetic variability is generally even greater 
than with adults.  More frequent monitoring is required. Sometimes within 24h after MTX 
administration, up to 7 samples were collected at different time points 
107
.  
1.3.1.2 Existing techniques for TDM of MTX 
There are currently four companies which have submitted a 510 (k) premarket 
submission to the FDA for marketing approval of a medical device with integrated 
immunoassay for MTX analysis 
108
. In reality, the ACA Dupont MTX assay from E.I. Dupont 
de Nemours & CO. INC. has assumingly stopped production since the 1990s because of the 
inactivity of the company in marketing the assay and the TDx from Abbott has been 
discontinued since 2011 with no replacement. Unfortunately, the TDx is the current workhorse 
in clinical laboratories. The discontinuation of the instrument forces the clinical laboratories to 
look for alternatives. This leaves the market with the EMIT from Dade Behring and the most 
recently approved ARK MTX assay from Ark diagnostics. It has been reported that the EMIT 
MTX assay lacks precision especially in the lower concentration end of the calibration. For 
instance, the assay is not sensitive enough to analyse concentration near the safety threshold 
(0.05-0.2 μM) 109.  The Ark MTX assay has found 64-100% cross-reactivity with the 
metabolite, DAMPA. The assay is not compatible with therapy employing carboxypeptidase 
G2 rescue that induces fast metabolism of MTX to DAMPA
110
. Nonetheless, both enzyme 
immunoassays offer high sensitivity, ease of use and fast MTX analysis. Lastly, LC-MS/MS, 
as the reference method, is also used for MTX analyses 
111,112
. However, LC-MS/MS is not 
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suitable for clinical laboratories requiring fast turnaround time since this technique is more 
time-consuming and labor intensive. This explains the preference of clinical laboratories in 
employing routine immunoassays for MTX quantification.  
1.4  Scope and structure of the thesis 
The application of SPR biosensors for the analysis of small molecules such as drugs is 
less common than its use in protein interactions investigation and is still under development. It 
is as yet mainly reserved for drug-receptor interrogation in drug discovery employed by the 
pharmaceutical industry. It has not been popular for bio-analytical chemistry applications 
especially for drug analysis because of poor sensitivity and detection limit in complex matrix. 
In addition, current commercially available SPR systems are not suitable for drug analysis in 
clinical settings because of their bulkiness, high cost and lack of sensitivity in biological 
media. The aim of the thesis is to develop different strategies in improving drug analysis in a 
complex matrix using SPR biosensors and to prove the potential of a prototype SPR system as 
a reliable diagnostic tool in clinical settings with the example of TDM of methotrexate.   
First, Chapter 2 reports on the importance of choosing the proper surface chemistry for 
the SPR substrate. This is investigated by immobilization of active biological receptors and 
specific interaction with the analyte of interest. Chapter 3 explores the possibility of a 
competitive assay for MTX detection indirectly with labeled gold nanoparticles.  The labeled 
gold nanoparticles are in turn investigated for optimized ligand attachment as well as colloidal 
stability. The findings from chapters 2 and 3 are applied in the studies presented in the 
following chapters 4, 5 and 6 in which two established and optimized sensing schemes based 
on SPR and LSPR for MTX detection are discussed. Chapters 4, 5 and 6 detail sensitivity, 
selectivity, detection limit and dynamic range optimization to analysis of methotrexate in 
actual clinical samples with validation using two existing techniques, FPIA and LC-MS/MS. 
Finally, the performance of a high resolution fully integrated SPR system deployed at a 
hospital laboratory is summarized and discussed in more detail in chapter 6 to demonstrate the 
perspective of SPR biosensors as a point-of-care device for performing rapid MTX 
concentration testings for patients undergoing chemotherapy.   
  
 
Chapter 2 Direct detection of methotrexate using a surface 
plasmon resonance biosensor 
I was the sole contributor for the experimental part of the work discussed in this 
chapter. Jean-François and I were responsible for the experimental design. The SPR system 
was designed and built by Jean-François Masson and Olivier Bolduc. The purified hDHFR 
was provided by Natalia Timchenko from Joelle Pelletier’s laboratory. Jean-François Masson 
and Joelle Pelletier were involved in the edition of the chapter. 
Abstract  
A SPR biosensor was constructed using immobilized hDHFR for the direct analysis of 
MTX. The pre-activated self-assembled monolayer (SAM), N-hydroxysuccinimide ester of 
16-mercaptohexadecanoic acid (NHS-MHA), serving as a linker molecule for attaching 
hDHFR, was used primarily to coat the sensor surface. Its presence on the surface was 
confirmed using FTIR, contact angle measurements and SPR. Despite the popularity in use of 
NHS-MHA for linking biomolecules to the SPR substrate, it was not optimal for hDHFR 
immobilization. An N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide -N-
hydroxysuccinimide ester (EDC-NHS) on-chip activation method was then employed and 
achieved a surface coverage of 5.6 x 10
12 
units of hDHFR per cm
2
 which correlates with 
theoretical calculations. Finally, direct detection of varying MTX concentrations showed SPR 
response variation of 0.5 nm from 100 μM to 500 μM.   
2.1 Introduction 
SPR as a biosensing device provides useful information on biomolecular interactions 
such as affinity, specificity and inhibition from real-time kinetics measurement 
113
. For 
instance, one of the main applications involves the interrogation of small ligand-receptors 
interactions using SPR biosensors for high-throughput drug screening. Important information 
such as the equilibrium constant and IC50 values can be derived. Based on this information, the 
best and worst drug candidates from a series of structurally similar drug inhibitors could be 
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identified 
114
. It is important to highlight that most of the small ligands investigated by SPR 
are molecules of molecular weight of at least 10 kDa.  
The coupling of surface plasmon polaritons with p-polarized light at the interface of 
the plasmonic metallic substrate and a high refractive index medium generates an EM field 
penetrating into a second dielectric medium directly above the substrate surface. The EM field 
penetrates a distance of a few μm into the second dielectric medium in the case for continuous 
gold film substrate. The EM penetration distance varies depending on the physical features 
and nature of the plasmonic substrate. The intensity of the field is greatest near the substrate 
and decays exponentially the more the field penetrates into the second dielectric medium and 
away from the surface. The SPR sensor is therefore highly sensitive to refractive index 
changes at the surface, which allows simple, label-free analysis with which analytes in its 
complex matrix can be unambiguously detected in real time 
115
.  
Measurable signal in SPR studies relies on the change in refractive index generated by 
the adsorption of biomolecules of significant molecular weight onto the sensor surface. Small 
biomolecules or molecules of molecular weight of ˂ 1000 Daltons are usually problematic 
targets for SPR analysis because their presence near the plasmonic surface cannot induce a 
significant change in refractive index. Usually in order to obtain a detectable signal in SPR, 
important displacement of water molecules near the surface is needed. This is normally 
achieved with large biomolecule adsorption. Therefore, it poses as a challenge for small 
molecule detection by SPR. Consequently, previous studies on biomolecular interactions were 
mostly focused on high molecular weight biomolecules mainly involving antibody-antigen, 
protein-peptide, DNA-DNA and DNA-protein interactions. Due to its low molecular weight, 
small molecule detection is often limited and rendered difficult at low concentration which 
leads to weak or no SPR signal. Highlighting this drawback is important, as a wide range of 
small molecules such as drugs and metabolites constitute an important class of analytes in 
clinical diagnosis where SPR could be of great use. Thus, it is necessary to improve the SPR 
technique for molecular interaction studies of small molecules.    
Very few research studies have reported on direct analysis or quantification of low 
molecular weight synthesized drug molecules using SPR. One of the rare examples relied on 
receptor conformation induced by ligand binding leading to refractive index changes near the 
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sensor surface to modulate SPR signal 
116
. However, biomolecular receptors with drastic 
conformational changes upon drug binding are not common. There is practically no report on 
direct quantification of drugs in biological fluids based on SPR for clinical purposes. The limit 
of detection and sensitivity of an SPR developed assay are expected to vary depending on the 
nature of the buffer or matrix. Usually, competitive or displacement assays are preferred in the 
case of small molecule quantification.    
One of the most important aspects in building up a SPR biosensor relies on the 
efficiency of the receptor immobilization strategy. The SPR-active surface is modified with 
biomolecules that function as a receptor for capturing the analyte of interest. Not only does the 
receptor need to be strongly bound to the surface in order to prevent dissociation from the 
surface, but it also requires that the receptor retains its function and activity for further 
biosensing. This implies that the receptor needs to maintain proper orientation for analyte 
access for interaction. Appropriate surface chemistry is thus employed to achieve these goals. 
Amide formation promoted by EDC-NHS chemistry mediated by the carboxylic acid groups 
of the SAM and an amine on the receptor allows covalent linkage of the receptor to the 
surface. However, this surface chemistry is unspecific in terms of the point of anchor of the 
receptor so that the proper orientation of the receptor for binding may not be achieved. 
Nonetheless, it is one of the most popular strategies employed for the attachment of 
antibodies, antigens and enzymes onto sensor surfaces due to its robustness and simplicity.   
In this chapter, direct detection of methotrexate is attempted by immobilizing hDHFR 
directly to the SPR sensor (Figure 2.1). To attain this objective, the synthesis of a pre-activated 
SAM, NHS-MHA is described and its functionalization on the plasmonic substrate is 
characterized. The SAM functionalization is an important step in sensor surface preparation 
since it is the first step in conditioning the surface for receptor immobilization. Then SAM 
activation methods for covalent attachment of the enzyme receptor have been compared and 
optimized for achieving a maximum surface receptor density. Finally, the binding of MTX to 
surface-bound molecular receptor measured in real-time is evaluated.  
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Figure 2.1 Schematic illustration of MTX binding to surface-bound hDHFR.  
 
2.2 Experimental 
2.2.1 Synthesis of N-hydroxysuccinimide ester of 16-mercaptohexadecanoic acid 
(NHS-MHA)  
The synthesis of NHS-MHA was done by following a previously published method 
117
. 
Briefly, 1 g of MHA was dissolved in 20 mL dioxane (anhydrous, 99.8%, Sigma-Aldrich). 
Then 0.77 g N, N’-dicyclohexylcarbodiimide (99%, Sigma-Aldrich) and 0.4 g NHS (98%, 
Sigma-Aldrich) were added simultaneously to the MHA solution. The solution was then 
stirred for 4 hours until a white dicyclohexylurea precipitate was formed. The precipitate was 
filtered out and then the supernatant was evaporated at 70°C. The collected NHS-MHA was a 
waxy substance that was aliquoted into different vials and kept in a dessicator in the 
refrigerator.    
2.2.2 Preparation of NHS-MHA self-assembled monolayer (SAM) 
Gold-coated glass coverslips (BK7, 22x22 mm
2
, Fischer Scientific) were immersed 
into a solution of 5 mM of synthesized NHS-MHA dissolved in 10 mL of N,N-
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dimethylformamide (DMF, ≥99.8%, Fisher Scientific) for 16 h to form a well-organized SAM. 
The glass coverslips were coated with 1 nm chromium (Cr) and 45 nm gold (Au) (ESPI 
metals) by a Cressington 208HR sputter coater. The monolayer-covered gold sensor chips 
were then rinsed thoroughly with ethanol (EtOH, ≥99.5%, Fischer Scientific) and ultrapure 
water (18.2MΩ, EMD Millipore water purification system) before enzyme immobilization. 
2.2.3 Contact angle, FTIR and SPR characterization of NHS-MHA 
functionalization  
Functionalization of NHS-MHA onto the sensor surface can be confirmed by 
conventional spectroscopic and surface characterization methods. The advancing contact angle 
measurements were performed by using a contact angle instrument built in-house. More 
specifically, the contact angles were measured by depositing a droplet of 300 μL of Phosphate 
Buffer Saline (PBS, CellGro, Mediatech Inc) onto the sensor surface. An image of the side 
profile of the droplet deposited onto the sensor surface was taken by a camera. The sensor chip 
was placed onto a platform aligned with a camera for capturing the images before and after 
SAM surface formation. The images were then investigated for contact angles using the Image 
J program (NIH freeware -http://rsbweb.nih.gov/ij/).  
The Fourier Transform Infrared (FTIR) spectrum of the functionalized sensor was 
acquired using attenuated total reflection FTIR (Bruker optics) for verification of presence of 
NHS-MHA on the surface. The sensor chips were dried before acquisition of the FTIR 
spectrum. The FTIR measurements were taken at 4 cm
-1
 resolution with 1048 scans from 600 
to 4000 cm
-1
. 
A custom-built dove prism wavelength interrogation SPR system based on 
Krestchmann configuration was employed for monitoring the refractive index change on the 
sensor chip due to surface functionalization. The system is composed of several optical 
components mounted in a single axis alignment: visible light source, lenses, fiber optics, 
polarizer, dove prism, a spectrophotometer detector (Ocean Optics 4000, 550-850 nm) and a 
Teflon fluidic cell for solution delivery (Figure 2.2) 
118
. The sensor chip was adhered onto the 
prism using optical oil for refractive index matching. The Teflon fluidic cell was then pressed 
on the sensor chip. First the SPR signal of the sensor chip in PBS was allowed to stabilize for 
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5 minutes before taking an s-polarized light reference and then acquiring the SPR signal with 
p-polarized light. A minimum finding mathematical algorithm (Annex 5) was employed for 
extracting the wavelength minimum of the SPR reflectance spectrum. Identical measurements 
were done before and after NHS-MHA functionalization to measure surface coverage of the 
NHS-MHA monolayer. The shift which is the difference of wavelength minimum before and 
after functionalization was used to calculate the surface coverage using the following equation 
derived by Jung et al. 
119
:  
11)                         (       )    [
          
  (              )
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where the sensitivity ( ) of the SPR system was evaluated as 1765 nm/RI. The refractive 
index of PBS (    ) was determined to be 1.33476 RIU using a refractometer. The refractive 
index of the thiolated ligand SAM was evaluated as 1.45 RIU with a density (  ) of 0.9 g /cm3. 
The penetration depth of the plasmons (    ) for a gold film was approximated as 230 nm 
120
.  
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Figure 2.2 Schematic illustration and picture of the dove prism SPR system composed of: 1) 
light source, 2) lenses, 3) fiber optics, 4) polarizer, 5) dove prism, 6) gold sensor chip, 7) 
collector fiber optics and 8) spectrophotometer. 
2.2.4 Immobilization of hDHFR  
The hDHFR enzyme was expressed according to Volpato et al. 
121
. Similarly to a 
previous method for antibody immobilization, hDHFR was fixed onto the sensor surface by 
forming a covalent bond with a linker molecule, 16-MHA or NHS-MHA attached to the gold 
surface 
122
. Before the immobilization of hDHFR, the sensor chips were washed with ethanol 
and ultrapure water thoroughly to remove traces of DMF. Then a solution of 0.75 mL hDHFR 
diluted to 0.05 mg/mL using PBS was introduced onto the pre-activated NHS-MHA coated 
sensor surface (1.6 cm
2
) for receptor immobilization. The reaction took place in a temperature 
controlled chamber at 4°C overnight. The following day, the sensor surface was blocked for 
10 minutes by reacting with an aqueous solution of 1 M ethanolamine hydrochloride (≥98.0%, 
Sigma-Aldrich) adjusted to a pH of 8.5 with 10 M sodium hydroxide (NaOH, > 98%, Fluka) 
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to deactivate unreacted NHS-MHA linker molecules. Thereafter, the sensors with hDHFR 
were incubated in PBS at 4°C for 60 minutes before analysis. 
2.2.5 NHS-MHA SAM and hDHFR surface coverage quantification  
The surface coverage estimated from the change of SPR signal (ΔλSPR) induced by 
SAM formation or enzyme immobilization was calculated using a previously derived equation 
by Jung et al. 
119
 described in section 2.2.3. The calculated receptor surface coverage in ng / 
cm
2 can be converted to units of receptor per area using Avogadro’s number.   
2.2.6 Preparation of methotrexate solution 
Methotrexate hydrate (MTX, >98% HPLC, Sigma-Aldrich), was dissolved in 0.05M 
potassium hydroxide (KOH, pellets, ≥ 85.0%, Fischer Scientific) and quantified according to 
Volpato et al. 
121
. Then, the quantified MTX solution was diluted in PBS to 1 mM and 
aliquoted and stored at -20°C prior to use. Serial dilution was performed at room temperature 
to the desired concentration before analysis of MTX.  
2.2.7 MTX direct binding assay  
The stock solution of 1 mM MTX was then diluted in PBS to make solutions 
containing 100 nM, 100, 250 and 500 μM MTX.  As mentioned in section 2.2.3, a custom-
built dove prism SPR system was employed for the analysis. The sensor chip with 
immobilized hDHFR is first adhered to the prism using optical oil. Then a flow cell is pressed 
on top of the sensor chip for solution delivery. The reference was taken using s-polarized light 
and the signal was then acquired using p-polarized light. Each sensor surface was stabilized in 
PBS for 5 minutes; then PBS was replaced by a specific concentration of MTX in PBS for 20 
minutes followed by PBS rinsing for 5 minutes to wash away unbound analyte. By those 
means, different concentrations of MTX (100 nM and 100, 250 and 500 μM) were analyzed 
using a new sensor chip each time. Data were collected by a spectrophotometer and treated 
with Matlab software. A minimum finding mathematical algorithm (Annex 5) was employed 
to derive the wavelength minimum of the reflectance spectrum. A sensorgram of the evolution 
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of the wavelength minimum with respect to time is established for monitoring the extent of 
MTX binding to surface-bound hDHFR.  
2.3 Results and discussion 
2.3.1 Characterization of NHS-MHA surface functionalization 
The use of 16-mercaptohexadecanoic acid (16-MHA) is common in biosensor surface 
chemistry as it acts as a linker for attaching biomolecular receptors onto the surface 
117
. 16-
MHA is composed of 2 terminal functional groups: a thiol and a carboxylic acid. The thiol 
group is responsible for anchoring the molecule to the gold surface whereas the carboxylic 
acid is exposed for reaction. MHA is pre-activated by linking to NHS before surface 
functionalization on the sensor surface. The NHS-activated carboxylic acid is readily reactive 
to amine groups of biomolecules for amide bond formation. The presence of NHS-MHA 
molecules was verified with FTIR. The spectrum was taken from a dried sensor chip after 
NHS-MHA functionalization. The intense band around 1735-1750 cm
-1
 in figure 2.3 is 
indicative of presence of NHS-MHA on the surface due to the formation of an ester when 
NHS reacts with the carboxylic acid of MHA. The finding of this study is confirmed by 
similar observations in a previous study 
123
. 
 
Figure 2.3 FTIR spectrum of NHS-MHA coated on a gold film.  
 
 36 
Contact angle measurements are useful in monitoring interfacial surface changes based 
on surface hydrophobicity changes 
124
. Molecules linked to the sensor surface can modify the 
properties of the surface. By measuring the side profile of an aqueous solution droplet 
deposited on the sensor surface, the wettability of the surface can be associated with the 
aqueous droplet contact angle (Figure 2.4). At first, the droplet positioned on the gold-coated 
surface exhibited a contact angle of 65.2 ± 2.8°. After treating the surface with NHS-MHA, 
the contact angle has decreased to 46.5 ± 3.8° which is an indication of enhanced 
hydrophilicity of the surface. As shown in figure 2.4, there is a visual increase in wettability 
after NHS-MHA functionalization as the droplet looked more spread out. Normally, a Au 
metallic surface is more hydrophobic compared to a SAM-protected Au metallic surface 
124
. 
The exposed NHS protective group exhibits more hydrophilicity due to its polar carbonyl 
groups. The surface chemistry reaction changes the nature of the surface therein confirms the 
presence of the SAM.  
 
Figure 2.4 Contact angle of a PBS drop on a sensor chip left) before and right) after NHS-
MHA functionalization.               
 
In addition, refractive index changes induced by functionalization can be followed 
using SPR to measure the extent of the formation of the monolayer. Note that first, the SPR 
signal of the Au-coated film was measured in PBS. Then the film was rinsed before immersion 
into an NHS-MHA solution for SAM formation overnight. The next day, the modified gold 
film was rinsed with ethanol and ultrapure water before SPR measurement again in PBS. The 
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difference of λmin before and after functionalization is the shift of the SPR signal peak which 
corresponds to 5.9 ± 1.2 nm from 8 replicates. By using the equation derived by Jung et al. 
119
, 
there are nearly 2.0 x 10
14
 molecules of NHS-MHA / cm
2
 available on the surface. This is 
characteristic of a densely covered surface in accordance with previous observations using 
alkanethiol and peptide self-assembled monolayers 
122
. The densely NHS-MHA populated 
surface provides an anchor for enzyme immobilization. 
2.3.2 Optimization of hDHFR immobilization 
The pre-activated NHS-MHA fixed onto the sensor surface allows direct amide bond 
linkage with an amine on the receptors. Despite its success in immobilizing other biological 
receptors onto metallic surfaces, the strategy was not optimal for immobilizing the enzyme 
hDHFR as no signal was observed for 1 μM MTX binding (data not shown). Despite being a 
small molecule, MTX should nonetheless give a response for highly concentrated 1 μM 
solution. Hypotheses were proposed to explain this null result. Perhaps NHS-MHA was 
susceptible to degradation during storage. This is observed by a change of NHS-MHA 
appearance from waxy back to a grainier aspect, similar to the starting material MHA. In fact, 
NHS-MHA can be hydrolyzed and converted back to MHA with time.   
Due to the instability of the pre-activated NHS-MHA molecule, an alternative reaction 
was proposed. 16-MHA SAM was formed on the sensor surface overnight illustrated in figure 
2.5. The following day, room temperature reaction using EDC-NHS at slightly acidic pH (pH 
6) was undertaken to activate 16-MHA for 20 minutes. EDC reacts with the carboxyl group by 
forming an amine-reactive intermediate. The presence of NHS stabilizes the intermediate in 
water then converts it into an amine-reactive NHS ester intermediate for final amide bond 
formation 
125
. Subsequently, the hDHFR immobilization took place overnight at 4°C. To 
compare the two activation methods, the same amount of enzyme, 0.05 mg/mL was deposited 
on surfaces prepared with both activation methods. The results obtained in terms of SPR shift 
which corresponds to local refractive index changes due to enzyme immobilization has 
increased from 2.4 ± 0.8 nm using the pre-activated NHS-MHA method to 6.6 ± 1.7 nm using 
EDC-NHS on-chip surface activation. This corresponds to approximately an increase from 2 x 
10
12
 to 5.6 x 10
12 
units of hDHFR per cm
2
. Theoretically, 100% surface coverage of hDHFR is 
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calculated as 5.1 x 10
12
 units per cm
2
 assuming a diameter of 5 nm for the enzyme. As a result, 
the surface is well saturated with hDHFR using the on-chip activation with EDC-NHS. 
However, surface coverage does not reflect the fraction of active enzymes on the surface due 
to varying orientations the enzyme can take on the surface 
120
. An increase of 3-fold in number 
of surface-bound receptors generated with EDC-NHS on-chip surface activation relative to 
pre-activated NHS-MHA activation is ideal in maximizing the number of available receptors 
for analyte binding which may improve sensitivity.  
 
Figure 2.5 Schematic illustration of EDC-NHS activation for hDHFR immobilization. 
2.3.3 Investigation of MTX binding with surface bound hDHFR  
Direct detection of MTX was assayed by using the sensor chips prepared by activating 
16-MHA on-chip with EDC-NHS. After incubating the enzyme at 4°C for surface 
immobilization, the sensor chips were then blocked using ethanolamine and finally the signal 
was stabilized in PBS for 60 minutes before use. The presence of the enzyme on the surface 
was confirmed with a SPR shift from the signal before and after functionalization. The real-
time MTX binding to surface bound hDHFR was assessed from the kinetics shown from the 
derived sensorgram (Figure 2.5). The initial association of MTX molecules to surface-bound 
enzymes caused the SPR signal to displace until binding equilibrium was reached. This is 
shown by the later stabilization of the SPR signal after 20 minutes. The shape of the derived 
 39 
sensorgrams in figure 2.5 showed relatively fast association and attainment of equilibrium. 
This is justified by the inhibition constant of MTX for hDHFR (Ki = 34 pM) 
126
. The rapid 
increase in SPR signal at the initial association stage is usually indicative of a high affinity 
binding pair 
126. At concentrations of MTX in the μM range (100, 250 and 500 μM), SPR 
shifts were induced upon MTX binding. It is also expected that the SPR response induced with 
MTX concentrations ≥ 100 μM might have contribution of bulk refractive index changes due 
to high concentrations of the molecule in solution. As the MTX concentration decreases, the 
SPR binding shift diminishes. When the concentration of MTX decreases to 100 nM, only a 
slight difference of the SPR signal is observed compared to the background noise. Although 
the resolution of the SPR system is able to achieve 10
-6
 RIU with the dove prism SPR set-up 
118
, it may not suffice for direct small molecule detection. This assay confirms the difficulty of 
low concentration small molecule detection. Even if MTX binding may take place with the 
immobilized receptor, only a very high concentration could induce significant analytical 
signal. Note that detection of MTX concentration of 100 μM to 500 μM only generated a 
change in SPR response of about 0.5 nm. The sensitivity is low considering that even μM 
concentrations induced weak sensor responses. Nonetheless, direct detection of MTX was 
achieved. 
 
Figure 2.6 Direct binding assay of varying concentration of MTX in PBS within 20 minutes 
using SPR biosensors. 
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2.4 Conclusion  
In this chapter, surface chemistry has been explored for SPR sensor chip preparation 
for MTX binding. First, synthesis and characterization of NHS-MHA SAM formation on 
surface was confirmed by FTIR, SPR and contact angle measurements. The pre-activated 
NHS-MHA SAM was compared to EDC-NHS on-chip activation of 16-MHA for improved 
enzyme binding. For our assay, EDC-NHS activation allowed better immobilization of 
hDHFR. This was proven by an increase in surface coverage. Furthermore, the feasibility of 
the EDC-NHS surface chemistry for our assay is confirmed by successful MTX detection at 
μM concentrations. Clinically speaking, high μM in patients under MTX treatment are only 
observed at the beginning of drug infusion into the patient’s body. The ideal working range of 
the sensor should be between low nM to high μM concentrations. In that sense, the LOD of the 
assay must be improved to have real application value at this stage.  
 
 
 
 
  
 
Chapter 3 SPR competitive binding assay using free 
methotrexate and methotrexate-functionalized gold 
nanoparticles  
I was the sole contributor of the experimental part of the work discussed in this 
chapter. Jean-François and I were responsible for the experimental design. The SPR system 
was designed and built by Jean-François Masson and Olivier Bolduc. The purified hDHFR 
was provided by Natalia Timchenko from Joelle Pelletier’s laboratory. The specific activity 
tests were conducted by Natalia Timchenko and me. Jean-François Masson and Joelle Pelletier 
have edited the chapter. 
Abstract 
 
A competitive binding assay for the analysis of MTX was established using a SPR 
biosensor. MTX-labeled gold nanoparticles compete with free MTX for available hDHFR 
immobilized on the sensor surface. First, the gold nanoparticles were modified with 
covalently-bound MTX via cysteamine, a thiolated linker molecule. The colloidal stability 
during AuNP modification with cysteamine was investigated in terms of pH, ionic strength 
and initial ligand concentration. Subsequently, MTX was successful linked to cysteamine-
coated AuNP in water as confirmed using UV-Vis and FTIR. Finally, the MTX competitive 
assay was conducted. The results showed that the SPR response was modulated by increasing 
the concentrations of MTX. Furthermore, a competitive calibration curve for MTX was 
established with sensitivity in the pM range. However, the level of sensitivity and 
reproducibility were poor. Efforts were made to understand factors affecting these parameters 
for better sensor performance. 
3.1 Introduction 
Most of the research conducted on small molecule analysis using SPR has, to date, 
relied on labeled solution-based nanoparticles and assembled nanoparticle film 
31,127-129
 
130-132
 
for signal enhancement. Noble metallic nanoparticles exhibit localized SPR which entails a 
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collective oscillation of core free electrons of the nanoparticle in resonance with the 
electromagnetic field of the light. The resonance induces a localized electric field 
enhancement near the NP surface that is sensitive to small refractive index changes. 
Furthermore, the close proximity of the presence of AuNP near a SPR active surface allows 
resonance coupling between the surface and gold nanoparticles 
130
. Usually for small molecule 
detection, displacement or competitive assays are designed in a way that the bound small 
molecule is displaced by a labeled gold nanoparticle or the small molecule competes with the 
labeled gold nanoparticles for available sites on the surface. The analytical utility of these 
nanoparticles contributes extensively to amplify the SPR signal of small molecule interactions. 
As shown in the previous chapter, the direct detection approach of MTX using an 
hDHFR immobilized sensor attempted by SPR is limited by assay sensitivity for clinically 
relevant concentrations of MTX (from low nM to high μM). Consequently, for low 
concentration quantification, a competitive binding assay for MTX has been designed.  By 
functionalizing AuNP with MTX, specificity to hDHFR is imparted to the labeled entity. 
MTX competes with MTX-AuNP for available receptors on the surface. The binding of MTX-
AuNP to the surface is expected to generate a large SPR signal that is indirectly proportional 
to the concentration of MTX (Figure 3.1).  
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Figure 3.1 Schematic illustration of MTX and MTX-AuNP competitive binding for surface- 
bound hDHFR.    
 
 In this chapter, the success of MTX-coated AuNP synthesis is examined. Gold 
nanoparticles were chosen as the label because of their ease of synthesis and functionalization. 
The major challenge for surface modification on colloids is to ensure stability of the colloids. 
For instance, the suspension of individual AuNP in solution is kept by electrostatic repulsion 
between the NP. The repulsion between the NP can be easily disrupted by several factors 
which results in NP associations that are sometimes irreversible. The NP association leads to 
the formation of randomly sized aggregates. Consequently, polydispersed NP may induce 
variable SPR signal amplification when used in an assay.  Therefore, the stability of the MTX-
coated AuNP is particularly important for the SPR competitive assay.   
The MTX molecule is composed of a pteroyl ring on one end and glutamic acid on the 
other end (Figure 3.2). The two carboxylic acids are usually targeted for reaction activation. 
The pteroyl moiety is essential in molecular recognition for hDHFR. The active site of 
hDHFR is composed of amino acids that are specifically placed for interacting with the pteroyl 
ring 
133
.  It is important to keep the pteroyl ring intact even upon linkage of the MTX molecule 
to a NP.   
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Figure 3.2 Chemical structure of methotrexate. The pteroyl ring (left end) contributes to 
hDHFR binding. 
 
The proposed strategy is to employ EDC-NHS chemistry for amide bond formation to 
attach MTX to AuNP. Carboxylic acids on MTX are first activated then reacted with 
cysteamine-conjugated NP. In this work, re-establishment of NP stability after cysteamine 
functionalization is attempted. Different parameters such as concentration of ligands, pH and 
ionic strength are investigated for stability control. Then, the success of MTX linkage to 
AuNP was confirmed using UV-Vis and FTIR. Finally, the synthesized MTX-AuNPs were 
incorporated in a competitive assay with free MTX for indirect determination of MTX 
concentrations. Furthermore, activity of the immobilized hDHFR and the long-term stability 
of MTX-AuNP were examined in view to gain insights in improving the competitive binding 
assay.   
 
3.2 Experimental 
3.2.1 Synthesis and characterization of AuNP 
AuNP were synthesized by reducing chloroauric acid to neutral gold by sodium citrate. 
50 mL of 1 mM of gold trichloride trihydrate (Sigma-Aldrich, ≥ 99.9%) and 2 mL of 2% w/v 
sodium citrate dihydrate (Fischer Scientific, ≥98%) were mixed under boiling conditions to 
form gold nanoparticles stabilized with citrate. Each batch of synthesized AuNP was 
examined with Transmission Electron Microscopy (TEM, JEOL-TEM-1200-EX, Tokyo, 
Japan) where a drop of colloidal solution was dried on a copper mesh grip coated with 
amorphous carbon film (Electron microscopy Sciences). UV-Vis characterization was 
performed according to Haiss et al. 
134
. The synthesized NP was diluted in ultrapure water and 
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absorption spectra were taken for concentration and size approximation using Varian Cary 
UV-Vis spectrophotometer scanning in the wavelength range from 400-800 nm. A ratio 
between the absorbance at the wavelength with maximum intensity (λmax) and at 450 nm (λ450) 
was used for normalization. Then the ratio value was compared to a table 
134
 to estimate NP 
size. The concentration was then calculated based on tabulated values of the extinction 
coefficient ε at λ450 corresponding to a specific size of NP. 
3.2.2 Synthesis of MTX-conjugated AuNP 
The covalent attachment of MTX was done by preparing first, 1 mM MTX in DMSO 
mixed with an aqueous solution of 20 mM EDC and 5 mM NHS for 20 minutes. In parallel, 
150 µL of 15 μM aqueous cysteamine solution was reacted with the gold colloidal solution to 
yield cysteamine functionalized nanoparticles (CysNP) with stirring in water. Furthermore, the 
CysNP were centrifuged and resuspended in water twice for rinsing. Stability of the CysNP 
was optimized by changing pH, ionic strength and added cysteamine concentration before 
MTX attachment. Cysteamine was functionalized onto AuNP in different conditions for 20 
minutes then the solution was analyzed using UV-Vis from 400 – 800 nm. Once the stability 
of CysNP was optimized, EDC-NHS-activated MTX was added to the CysNP for MTX-NP 
attachment (MTX-AuNP). Constant stirring (120 rpm) was necessary during the solution-
based synthesis of MTX-AuNP overnight. The resulting MTX-AuNP were then centrifuged 
for 25 min at 10 000 rpm then rinsed with purified water twice for rinsing. The prepared 
MTX-AuNP were kept in ultrapure water at 4°C.   
3.2.3 Characterization of MTX-AuNP  
Absorption spectra were taken before and after each step of AuNP functionalization 
using a Cary 100 Bio UV/Vis spectrophotometer (Varian Canada, Inc., Montréal, QC) for a 
qualitative test in a 1 cm path length cell. Thereafter, mid-IR spectra were acquired for 
confirmation of sequential functionalization of AuNP by using FTIR-Reflectance Absorption 
Spectroscopy (Bruker optics). Samples were prepared by drying gold colloidal solution onto 
different gold coated coverslips. The NP were rinsed two times with centrifugation and 
 46 
resuspension in ultrapure water before drying. The reference MTX sample was prepared by 
evaporation of a MTX solution in DMSO on a gold film.  
3.2.4 Immobilization of hDHFR and TEM-1-β-lactamase antibody 
The glass coverslips were coated with 1 nm Cr and 45 nm Au (ESPI metals) using a 
Cressington 208HR sputter coater. The gold sensor chips were immersed into a solution of 5 
mM 16-mercaptohexadecanoic acid (16 MHA) in DMF overnight. The hDHFR enzyme was 
prepared according to Volpato et al. 
121
. hDHFR was fixed onto the sensor surface by forming 
a covalent bond with a linker molecule attached to the gold surface via EDC-NHS on-chip 
activation. Briefly, free carboxylic acid on 16-MHA was activated by reacting with an 
aqueous solution of 20 mM N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide (EDC, Fluka, 
purity. 97%) and 5 mM N-hydroxysuccinimide (NHS, Sigma-Aldrich, purity > 98%) for 20 
minutes. Then, dilution of the enzyme solution in PBS was performed to obtain a 
concentration of 40 µg/mL for overnight reaction with activated 16-MHA-covered sensor 
surface at 4°C. The following day, the same procedure was followed for stabilization of 
hDHFR before analysis (section 2.2.4). Furthermore, control sample coverslips were also 
prepared in an identical way by immobilizing TEM-1-β-lactamase antibody (QED Bioscience, 
Inc.) instead of hDHFR for nonspecific interaction investigation.  
3.2.5 Free MTX and MTX labeled AuNP competitive binding assay  
The same custom built dove prism SPR system described in chapter 2 was used. The 
hDHFR-immobilized sensor chip was adhered on the top of the prism using optical oil for 
refractive index matching.  Again, a reference was taken with s-polarized light and the signal, 
with p-polarized light. In this assay format, the real-time kinetic data for each MTX 
concentration binding was acquired for 55 minutes. First, each sensor was stabilized with PBS 
for 5 minutes then replaced by a specific concentration of MTX in PBS solution for 20 
minutes followed by 5 minutes PBS rinsing. Thereafter, a saturating concentration of MTX-
AuNP solution (1 nM) in PBS was injected for 20 minutes to occupy the free binding sites 
following by 5 minutes final PBS rinsing. Overall, different concentrations (10
-13
 – 10-5 M) of 
MTX were assayed using a new sensor chip each time. Data were collected using a 
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spectrophotometer and treated with Matlab software. A minimum finding mathematical 
algorithm (Annex 5) was employed to derive the wavelength minimum of the SPR reflectance 
spectrum. A sensorgram of the evolution of the wavelength minimum with respect to time was 
established for monitoring MTX binding to surface-bound hDHFR. The binding shift signal 
given by MTX-AuNP was plotted against the logarithm of MTX concentration to derive a 
competitive binding curve.  
3.2.6 Activity test of immobilized hDHFR 
The preparation of the hDHFR sensor surface was carried out as described in section 
3.2.4 using the immobilization reaction at 4°C overnight with sensor chip stabilization the next 
day. The SPR sensor chip with covalently bound hDHFR was inserted into a UV/Vis cuvette 
for real-time enzyme activity interrogation after stabilization, similar to a method developed 
by Xu et al.
135
. The sensor chip was inserted sideway into the cuvette in parallel with the 
optical path in order to expose the immobilized enzyme for activity measurements. The SPR 
sensors were immersed in a reaction solution of 100 μM NADPH (nicotinamide adenine 
dinucleotide phosphate, cofactor) and 100 μM dihydrofolate (DHF, substrate) in PBS, pH 7.4, 
for 1 h. The activity of the enzyme was measured by following the change in absorption 
intensity at λ = 340 nm due to consumption of the cofactor and substrate. hDHFR free in 
solution was also tested for activity. A negative control, consisting of a solely 16-MHA-
functionalized SPR sensor, was rinsed with buffer and inserted into the cuvette. Absorption 
spectra were recorded with a Cary 100 Bio UV/Vis spectrophotometer.  
3.3 Results and discussion 
3.3.1 Characterization of synthesized AuNP: size and concentration 
The physical appearance of synthesized AuNP was characterized microscopically by 
TEM.  Figure 3.3 displays relatively monodispersed AuNP with an average diameter of 13 ± 3 
nm calculated from 25 nanoparticles by using Image J software. The organic self-assembled 
layer around the AuNP could be imaged, but high carbon background signal due to the sample 
grid hinders a clear identification of SAM-coated NP.  
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AuNP exhibit localized surface plasmon resonance in the visible light region. Haiss et 
al. 
134
 ave found good agreement between the mean free path corrected Mie theoretical 
calculations and experimental data for spherical AuNP of size 5-100 nm in aqueous solution 
using UV-visible spectroscopy. Based on the individual optical properties of NP of different 
size, the relationship between the extinction efficiency and the NP diameter was established 
and allowed the determination of the nanoparticles’ concentration 134. Basically, NP diameter 
and concentration can be directly derived from UV-Vis spectra using simplified equations. 
Using their established method, batches of synthesized NP were analyzed using UV-Vis. For 
different synthesis of spherical AuNP of a diameter of approximately 13 nm, the concentration 
has been estimated to be around 2 x 10
-9 
M in water. The knowledge of size and approximate 
concentration is important in contributing to the reproducibility of the SPR analysis.  As 
AuNP from different syntheses may be used for the SPR analysis, an easy method to evaluate 
the size and concentration of a batch helps in standardizing and reducing variability in the SPR 
response induced by NP.  
 
Figure 3.3 TEM images of citrate-stabilized AuNP of diameter 13 ± 3 nm. 
3.3.2 Stability of cysteamine-functionalized AuNP 
Functionalization imparts specificity to NP which can be employed as amplification 
elements for SPR analysis. The modified drug molecule, MTX with activated free carboxylic 
acids, forms an amide bond with attached amine linkers, cysteamine on the AuNP.  
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Citrate reduced AuNP are negatively charged due to adsorption of negatively charged 
citrate, hydroxide and chloride 
136
. These adsorbed molecules and ions are responsible for the 
high negative zeta potential of AuNP. Thus, individual AuNP are dispersed in aqueous 
solution due to charge repulsion.  Disrupting the electrostatic repulsion between the colloids 
could cause irreversible aggregations which diminishes available surface area for sequential 
surface modification in addition to a decrease of individual NPs in solution 
137
. The presence 
of randomly sized aggregates as amplification elements will cause SPR signals to vary greatly. 
This is explained by the fact that nanoparticle aggregates behave as larger nanoparticles which 
generate greater SPR signal than individual colloids. A distribution of field enhancement 
caused by plasmonic coupling with NP aggregates of different sizes will affect the sensitivity 
and limit of detection of the assay.  
Thiolated molecules have been extensively used in AuNP surface modification 
136
. The 
thiol group in one end showed high affinity for gold through the formation of a strong S-Au 
bond. The opposite end exposed to the environment, is a functional terminal group for 
stabilization of the NP and alternatively, acts as a reaction site for further surface 
modifications. It is important to know that citrate, hydroxide and chloride adsorbed on the 
AuNP are displaced by adsorbed thiols with the exchange of hydrogen elimination in SAM 
formation 
136
.  In this case, cysteamine was chosen as the linker ligand where its ionizable 
amine functional group is exposed to form an amide bond with carboxylic acids on MTX. The 
stability of cysteamine-linked NP is important in a way that monodispersed colloids will allow 
better access of surface reaction with MTX onward. Many factors influence colloidal stability, 
especially for ionizable functional groups 
138
. Due to the presence of amines, the 
functionalization process strongly depends on the pH and ionic strength of the solution. In 
addition, the initial ligand concentration is also an important factor as demonstrated below.  
3.3.2.1 Influence of pH  
The stability of the colloidal dispersion can be assessed from their extinction spectra 
changes using UV-Vis spectrophotometer. The initial conditions of cysteamine 
functionalization are not favorable in colloidal stability. Visual inspection of 5 mM 
cysteamine addition into 1 nM AuNP showed a rapid change in color from red to violet or 
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blue. The UV-Vis spectra are characterized with a broad band ˃ 600 nm and a small or no 
peak ˂ 600 nm. These observations are characteristic of NP flocculations in solution scanned 
by UV-visible spectrophotometry 
137
. There are two basic means in stabilizing colloids. One 
implies electrostatic stabilization and the other is steric stabilization achieved by the 
coordination of sterically bulky organic molecules acting as protective layer 
139
. In this work, 
electrostatic stabilization has been favored. Normally, at low ionic strength, citrate-reduced 
AuNP are stable in a wide pH interval between 3 to 12. This could be explained by the fact 
that the pKa values of the citrate acidic groups are 3.28, 4.76 and 6.4 
140
. For cysteamine-
functionalized AuNP, the pH of the reaction solution is important in a way that the amine 
groups could be charged to maintain electrostatic repulsion between the NPs 
141
. The 
cysteamine chemisorption reaction was carried out at pH around 5-6 which ensures that the 
amine groups are ionized and provide surface charges to the colloids since the pKa of the 
amines is around 8.35 
142
. At acidic conditions, cysteamine functionalized NP are charged and 
in principle, are expected to stabilize NP. However, in solutions of a wide range of pH from 2 
to 11, the extinction spectra of CysNP all showed a major peak between 650-800 nm (Figure 
3.4). As specified earlier, peak appearance in the longer wavelength region in solutions of pH 
2-11 is characteristic of NP flocculates.  It is suspected that electrostatic attraction between the 
amines of cysteamine and carboxylic acids groups of citrates on adjacent NP may occur which 
results in intertwined networks of flocculates 
143
. Consequently, pH adjustment did not 
improve the stability of the NP in this case. 
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Figure 3.4 Absorption spectra of AuNP and cysteamine-functionalized AuNP in different pH 
conditions. 
3.3.2.2 Influence of ionic strength 
The ionic strength of the solution can be adjusted to provide a suitable environment for 
colloidal stability. The ionic strength is dictated by the presence of positively and negatively 
charged ions at different concentrations. The free charged ions contribute in forming the 
electric double layer around the NP.   As previously demonstrated in section 3.3.2.1, adjusting 
pH conditions did not improve the stability of cysteamine-functionalized NP. Flocculates were 
formed due to electrostatic attraction between amines of cysteamine and carboxylic acids 
groups of citrates on adjacent NP.  By increasing the ionic strength, presence of free ions is 
expected to screen the electrostatic attraction between the pair 
143,144
. The peak maximum of 
the plasmonic band is monitored since peak displacement towards a shorter wavelength is 
indicative of NP dispersion. The combination of 1 mM cysteamine and 0.5 mM NaCl provides 
increased stability of the colloidal solution as shown by the hypsochromic displacement of the 
plasmon band from 760 nm to 667 nm (Figure 3.5). Adding millimolar concentration of NaCl 
to cysteamine-functionalized NP prepared using both concentrations (1 and 5 mM) only 
further shifted the plasmonic band to longer wavelength. This could be due again to the 
disruption of electrostatic forces between the NP with abundant presence of sodium and 
chloride ions that result in Van der Waals interaction. Further decrease of NaCl concentration 
did not further displace the band to a shorter wavelength. Adjusting the ionic strength shows 
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perspective in improving NP stability. However, the surface ligand concentration needs to be 
optimized.  
 
.  
Figure 3.5 λmax of 1 and 5 mM cysteamine-functionalized AuNP in different NaCl 
concentrations. 
3.3.2.3 Influence of initial ligand concentration 
The initial concentration of the ligand added to the NP for functionalization cannot 
reflect the surface density of ligands attached onto each single NP’s surface. However, it is 
still an important factor which could influence the stability of the colloids. 5 mM cysteamine 
was chosen as the initial concentration for functionalization since usually an excess number of 
the ligand is needed to saturate the high surface area of AuNP. However, at high ligand 
concentration, the surface charges established by citrate are disrupted in water probably due to 
electrostatic attraction between the ligand (cysteamine) and exposed capping agent (citrate) of 
neighboring NPs in the close proximity of one another. Therefore, the initial concentration of 
cysteamine was readjusted and investigated. As the concentration of added cysteamine 
decreases, the shoulder in the longer wavelength region disappears. With 15 μM cysteamine, a 
sharp peak around λ=520 nm is a good indication of stable monodispersed functionalized NP 
(Figure 3.6). This is in concordance with previous findings on stability control using initial 
ligand’s concentrations 144. At high ligand concentration, the surface charges established by 
citrate are disrupted in water due to potential electrostatic attraction between the ligand and 
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capping agent on close proximity NPs. It is believed that at lower ligand concentration, the 
entire surface of the NP has not been completely replaced and remaining citric acid still 
contributes to dispersing the NP.  
 
Figure 3.6 Absorption spectra of cysteamine-functionalized AuNP using different initial 
concentrations of cysteamine. The spectra were corrected with background subtraction. 
3.3.3 MTX functionalization using EDC-NHS chemistry: UV-Vis, FTIR 
After finding the optimal conditions for ensuring stable cysteamine NP 
functionalization, covalent attachment of MTX followed. Flocculation was observed from the 
broadening and reduction of intensity of the peak at 520 nm after addition of cysteamine to 
AuNP in water. This was expected because the amine groups become protonated at pH 7. This 
may induce electrostatic interaction between carboxylic acid and amine groups between the 
NP to form flocculation. MTX was activated separately using EDC-NHS. Upon addition of 
activated MTX, the peak lost its sharpness and another broad band appeared from 600-800 
nm. After 12 h, the synthesized MTX-coated NP showed a sharp peak slightly shifted to 
longer wavelength than the bare AuNP. Figure 3.7 demonstrates that in water, the absorption 
maximum shifted from 523 nm for bare AuNP to 525 nm with MTX surface modification. 
Shifting of λmax to longer wavelength is a good confirmation of surface modification since 
adsorption of MTX to the NP surface causes an increase in mass near the surface which in turn 
changes in the dielectric constant of the surrounding environment of the NP  
145
.  
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Figure 3.7 Absorption spectra of sequential steps of MTX functionalization onto AuNP. 
 
Successful conjugation of MTX with AuNP was further confirmed by FTIR-
reflectance absorption spectroscopy qualitative analysis in figure 3.8 where overlapping mid-
IR spectra of AuNP, CysNP, MTX-AuNP and MTX were compared. For citrate-reduced 
AuNP, a strong characteristic peak at 1616 cm
-1
 appears due to the carboxylic acids of citrate. 
The spectrum for CysNP indicates the presence of primary amine groups in the 2800-3000 cm
-
1
 region. Furthermore, a shoulder around 1629 cm
-1
 and 1601 cm
-1
 in the MTX-AuNP 
spectrum indicates appearance of amide bonds. Nevertheless, an intrinsic amide bond is found 
in the structure of the drug molecule. Consequently, the spectrum of MTX-AuNP was 
compared with the reference MTX molecule. Characteristic IR absorption bands lie around 
1642 cm
-1
 and 1607cm
-1
 for MTX intrinsic amide bond 
146.  The peaks’ intensity for the amide 
bond on MTX-AuNP at 1629 and 1602 cm
-1
 is much more intense than the peaks’ intensity on 
MTX’s spectrum suggesting that MTX is covalently linked onto the AuNP. This is due to the 
increase in MTX molecules concentrated on individual NP surface.  
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Figure 3.8 FTIR-RAS analysis of functionalized gold nanoparticles deposited on gold chips in 
comparison to MTX molecule.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
3.3.4 SPR displacement assay of free MTX and MTX-AuNP with surface- 
bound enzyme 
To circumvent the sensitivity issue of direct analysis of small molecules using SPR, a 
competitive displacement assay with MTX-coated gold nanoparticles was employed for MTX 
analysis. A real-time SPR monitoring sensorgram of binding events occurring at the sensor 
surface is shown in Figure 3.9. The MTX-AuNP solution is injected following the MTX 
solution injection. No binding response was noticeable for direct detection of 10 fM MTX.  
On the other hand, a significant SPR shift due to MTX-AuNP binding was observed. This 
particular test has shown that MTX-AuNP occupied available surface-bound enzyme sites 
which generate a SPR shift that can be correlated to the concentration of MTX injected at the 
beginning. 
Thus, a competitive binding curve was established, using the response generated by 
MTX-AuNP in dependence to logarithmic of MTX concentration as depicted in Figure 3.10. 
The plotted curve shows 3 distinctive regions. At sub-picomolar concentrations of MTX, high 
response of MTX-AuNP is observed. As MTX increases to the pM range, the binding signal 
varies with respect to concentration from 10
-12
 to 10
-10 
M. Furthermore, in the range above 
nanomolar concentration, all binding responses were similarly low. Each concentration has 
been tested with at least three replicates using a new sensor chip each time. A control test 
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using another receptor, TEM-1-β-lactamase antibody was analyzed in triplicate. It showed that 
the nonspecific interaction of MTX-AuNP with the sensor surface produced a background 
signal that needs to be subtracted from the total response. The competitive binding assay has 
ultimately increased the sensitivity for MTX analysis with the introduction of MTX-labeled 
AuNP to the pM range in comparison to the direct assay which has a working range in µM 
concentrations. It is important to note the high variability in binding response from triplicate 
analysis of the same concentration which corresponds to a coefficient of variation of up to 
30% for low MTX concentrations. This could be caused by variations in preparation of the 
sensor surface or MTX-AuNP from one batch to another. In addition, the response variation 
between the upper and lower concentration limits of the dynamic range is still quite small (0.5 
nm).  
 
Figure 3.9 Sensorgram of 10 fM MTX analysis. First, the sensor chip was conditioned in PBS 
for 5 min. Then, the first increase in SPR signal is due to on-chip immobilization of 0.04 mg / 
mL hDHFR for 15 min injected at time = 300 s followed by 5 min PBS rinsing. A solution of 
10 fM MTX in PBS was then injected at time = 1500 s for 10 min followed by 5 min PBS 
rinsing. Finally 1 nM of MTX-AuNP was injected at time = 2400 s for 15 min with 5 min final 
PBS rinsing.  
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Figure 3.10 Competitive binding curves of varying concentrations of MTX in PBS with 
respect to MTX-AuNP binding response. Control samples represent nonspecific interaction of 
MTX-AuNP with immobilized TEM-1-β-lactamase antibody. 
3.3.5 Investigation of activity of immobilized hDHFR and stability of MTX-
AuNP in PBS 
3.3.5.1 Activity of immobilized hDHFR 
In an attempt to improve the reproducibility of the MTX competitive assay, the activity 
of immobilized hDHFR on different sensor chips was interrogated. The design of the 
experiment consists of immerging the sensor chips directly into a UV-Vis cuvette altogether 
with the enzyme’s substrate, DHF and cofactor, NADPH.  A decrease in absorbance at λ340nm 
confirms substrate and cofactor consumption and thus, enzymatic activity. Both positive and 
negative controls were assayed. The positive control was conducted with free enzyme in 
solution. The negative control was analyzed using 16-MHA-functionalized sensor chips 
without hDHFR attachment. At least triplicate analyses were carried out for each test and 
control conditions. The results confirm the retention of enzyme activity of the enzyme in 
solution since a decrease in absorbance is noticeable (Figure 3.11). However, once the enzyme 
has undergone the surface immobilization reaction, no activity is observed even over a period 
of time of 1h. The results are similar to the negative control test where no hDHFR is present 
on the surface. This series of tests suggests that the majority of the immobilized enzymes are 
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inactive on the surface. The diminution of available enzyme receptors on the surface reduces 
the expected response which leads to lowering sensitivity. The crystallographic structure of 
hDHFR shows that there is a high concentration of lysine residues near the binding pocket of 
the enzyme (Annex 1, figure A1.1). The lysine residues provide amine groups available for 
amide bond formation with 16-MHA functionalized on the surface. By reacting these lysine 
residues with EDC-NHS-activated 16-MHA on the sensor surface, the active site of the 
enzyme is hindered, thus preventing both activity and MTX binding.  
 
Figure 3.11 Activity test of hDHFR in solution in comparison to the assays using surface-
immobilized hDHFR on 16-MHA-coated sensor chip. 
3.3.5.2 Stability of MTX-AuNP in PBS 
The SPR assay for MTX has been conducted in PBS at pH 7.4 in order to stabilize the 
immobilized enzymes. For this reason, MTX-labeled NP in water are centrifuged and 
resuspended in PBS before injecting onto the surface. Therefore, stability of MTX-AuNP in 
PBS is important for interaction to occur. As shown in section 3.3.3, MTX covalently bonded 
to AuNP are stable in water. But once resuspended in PBS, the MTX-AuNP slowly precipitate 
and form flocculate in the vial over the course of the day. This indicates that the number of 
individual MTX-AuNP decreases and randomly sized MTX-AuNP flocculates increase. This 
is suspected to significantly contribute to SPR assay response variability.  
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3.4 Conclusion 
A sensitive assay for detecting MTX has been developed using nanoparticle-enhanced 
SPR. The competitive role of MTX-AuNP in this assay allowed signal amplification for low 
concentration MTX analyses and established a sensing region in the pM range. Although a 
competitive binding curve was elucidated, the sensitivity and replicate reproducibility were 
not optimal. The current preparation method for enzyme immobilization is not suitable for 
hDHFR as its ligand-binding capacity appears to be reduced during the immobilization 
reaction. Furthermore, despite the success of MTX-AuNP synthesis in water, they were not 
stable in PBS over time. 
To circumvent these drawbacks, a new immobilization strategy using copper-derived 
surfaces for chelating histidine-tagged hDHFR is envisaged to ensure structure and orientation 
of the surface-bound enzyme. This will be presented in more detail in chapter 5. To address 
the problem of NP stability, other functionalization methods such as direct ligand adsorption 
will be investigated and discussed in chapter 4.  
 
 
 
 
  
 
Chapter 4 Localized surface plasmon resonance-based 
competitive assay for methotrexate and its application in 
therapeutic drug monitoring 
I was responsible for the majority of the experimental work discussed in this chapter. 
Mathilde Bichelberger has conducted the LSPR sensors calibration curves under my 
supervision. Damien Colin has purified the hDHFR and quantified the specific activity of the 
enzyme. Joelle Pelletier, Jean-François Masson and I have designed the experimental 
approach and edited the paper. Robert Robitaille has provided the results from FPIA and has 
also participated in the edition the paper.  
Abstract 
A solution-based colorimetric competitive binding assay relying on LSPR of folic acid 
functionalized gold nanoparticles (FA-AuNP) and human dihydrofolate reductase enzyme 
(hDHFR) was developed to detect nanomolar to micromolar concentrations of methotrexate 
(MTX). The synthesis of FA-AuNP sensors was first characterized and optimized for 
prolonged stability in buffered conditions. By the nature of the competitive assay for MTX, 
the LSPR shift from specific binding between FA-AuNP and the free enzyme was inversely 
proportional to the concentration of MTX. In addition, the dynamic range for MTX was tuned 
from 10
-11
-10
-6
 M by varying the concentration of hDHFR from 1 to 100 nM. Potential 
interferents such as FA, trimethoprim (TMP) and 4-amino-4-deoxy-N-methylpteroic acid 
(DAMPA) did not conflict with MTX detection in the concentration range of interest. Inter-
day reproducibility and recovery of MTX spiked in PBS were good. Clinical samples of 
human serum from patients undergoing MTX chemotherapy were analyzed following a simple 
solid-phase extraction step to isolate MTX from the serum matrix, with a limit of detection of 
155 nM. Validation of the LSPR method was carried out in comparison to Fluorescence 
Polarization Immunoassay (FPIA), a commonly used method in clinical settings, and LC-
MS/MS, a reference technique. The results of the LSPR competitive assay compared well to 
FPIA and LC-MS/MS, with a slope of 2.4 and 1.1 respectively from the correlation plots.  
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4.1 Introduction  
 
With tunable optical properties and versatile surface chemistry, many gold 
nanoparticles (AuNP) platforms have been developed for biological applications  
72
. More 
specifically, use of AuNP in clinical diagnosis methods has gained increasing attention. 
Bearing specific functionalities on the NP surface allows biomolecular interactions with the 
target analyte. At close proximity to the surface, the analyte induces a change in local 
dielectric environment of NP 
145
 . Very briefly, light interacts with spherical metallic NP of 
diameter << wavelength of the light by inducing a collective oscillation of the free electrons in 
resonance with the electric field of the light. This phenomenon is known as LSPR, which 
gives rise to a local electric field enhancement at the NP surface. Enhanced light extinction by 
the NP is a striking manifestation of the LSPR phenomenon. This results in a SPR band with 
enhanced resonance at the peak maximum 
74
. Processes such as binding events occurring at 
the surface of the metallic NP change the wavelength of the SPR band maximum (λmax). In this 
way, a relationship is established between the shift of λmax with RI changes, which constitutes 
the basis of LSPR sensing.  
Based on studies employing functionalized AuNP for disease biomarker detection, a 
similar approach has been undertaken for therapeutic drug level monitoring. By relying on 
analyte-induced LSPR response change of functionalized AuNP, a novel method is developed 
for determining methotrexate concentrations in patients’ serum. Due to its low mass, MTX is 
unable to induce a significant change in RI near the NP surface for direct detection in LSPR. 
Therefore, a competitor linked to a LSPR probe was introduced to produce a large indirect 
signal for MTX (Figure 4.1). More precisely, folic acid-functionalized gold nanoparticles (FA-
AuNP) are in competition with MTX for a specific number of its targeted enzyme, hDHFR, in 
solution. The FA-AuNP are LSPR sensors which generate the analytical signal of the assay. 
Variations of local dielectric properties associated with RI of the surrounding environment 
induce a displacement of the absorption spectrum of the AuNP. The UV-Vis spectroscopy 
kinetic information derived from the binding of FA-AuNP with hDHFR is inversely 
proportional to the concentration of MTX. Thereby, a simple method based on a competitive 
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binding assay relying on LSPR of functionalized AuNP in solution would be suited for 
quantitative MTX analyses.  
 
 
Figure 4.1 Schematic illustration of the LSPR competitive assay for methotrexate. FA-AuNP 
and MTX enter in competition for hDHFR, which leads to a wavelength shift at low 
concentrations of MTX and a null response for high MTX concentrations. 
 
First, characterization of AuNP is reported in terms of size and bulk sensitivity. Then 
stability of FA-AuNP was compared to covalent MTX-AuNP. Binding interactions between 
FA-AuNP and hDHFR are demonstrated in the absence and presence of MTX.  Thereafter, the 
dynamic range is examined by changing the concentration of the enzyme in solution. 
Furthermore, the assay is tested against potential interferents for selectivity investigation. 
Inter-day calibrations of the system in PBS are conducted followed by an attempt of 
calibration in fetal bovine serum (FBS). As serum matrix hinders the analytical signal, a 
simple solid-phase extraction (SPE) method is chosen for treating serum samples. Finally, 
calibration with a pool of negative human serum samples is undertaken for the analysis of 
MTX contained in human serum retrieved from patients under chemotherapy. The results from 
the established assay are compared with the ones of FPIA and LC-MS/MS.  
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As detailed in the previous chapter, two major challenges limited the applications of 
the MTX assay: loss of enzymatic activity of immobilized hDHFR and NP instability in high 
saline buffer solution. EDC-NHS surface reaction forms amide bonds with lysines near the 
binding pocket of the enzyme that may block the access of MTX into its binding pocket. 
(Annex 1, figure A1.1). In addition, the covalently bound MTX labeled AuNP used as 
amplification elements in the competitive SPR assay flocculate over time, which generated 
highly irreproducible SPR results. 
In this work, a direct ligand adsorption method is investigated. It was previously 
reported that MTX was employed for the study of tumor growth inhibition using MTX 
conjugated AuNP 147. The authors have claimed that MTX can be directly adsorbed onto the 
surface and 100% released from AuNP using isolated radioactive [3H]-MTX adsorbed and 
released from AuNP determined by liquid scintillation counting. In addition, it has also been 
reported that folic acid, a substrate of hDHFR, can also act as a capping agent in a direct 
synthesis of FA-AuNP. It was also supported by Bhattacharya et al. 148 who have claimed that 
FA could be directly adsorbed onto AuNP using noncovalent interactions for cancer cell 
targeting. Therefore, it becomes interesting to explore FA-AuNP as the LSPR sensor because 
an intrinsic competition is favored between MTX and FA for the enzyme. The design aims to 
establish a sensitive system for detecting MTX. By generating a large difference in affinity 
between the competitors, the system sensitivity is augmented. As FA is known to have 4 orders 
of magnitude less affinity than MTX for hDHFR 149, a potential sensitive competitive system 
is generated. In addition, folic acid is a less expensive reagent in comparison to MTX.  
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4.2 Experimental
4
  
4.2.1 Activity of hDHFR 
The hDHFR enzyme was prepared according to Volpato et al. 
121
. The stock enzyme 
solution was quantified as 0.75 mg/mL with a purity of better than 95%. The activity test was 
performed by monitoring the absorbance decrease at λ = 340 nm due to consumption of 100 
μM substrate, DHF and 100 μM co-factor, NADPH with 100 ng/mL of hDHFR. The enzyme 
was stored at – 80°C, thawed on ice to 0°C and diluted to the desired concentration prior to 
analysis.  
4.2.2 Synthesis and characterization of FA-AuNP 
AuNP were synthesized by reducing chloroauric acid to neutral gold by sodium citrate. 
Briefly, 50 mL of 1 mM of gold trichloride trihydrate (Sigma-Aldrich, ≥ 99.9%) dissolved in 
purified water and 2 mL of 2% w/v sodium citrate dihydrate (Fisher Scientific, ≥ 98%) were 
mixed under boiling conditions to form AuNP stabilized with citrate. Different batches of 
stock solutions were quantified according to a previously published method  134 and diluted to 
1 nM for storage at 4°C. The bulk sensitivity of the AuNP has also been characterized using 
UV-Vis by immersing AuNP in different organic solvents of refractive index between 1.33-
1.37. The wavelength maxima of the SPR band (λmax) were recorded and plotted against 
refractive index.  
FA solution was prepared by dissolving a small quantity (Sigma Aldrich, ≥98%) in 0.1 
M Na2HPO4 adjusted with 50 mM NaOH to pH 7. Additional 0.1 M Na2HPO4 was added until 
a clear solution was obtained. The concentration of FA was determined in a 1 cm path length 
quartz cuvette with ε282 nm = 27.0 x 10
3
 M
-1
cm
-1
 in 0.1 M Na2HPO4, pH 7.0 using a Cary 100 
                                                 
4
 Sections 4.2.2 to 4.2.5 were published in Zhao, SS, Bichelberger, M.A., Colin, D.Y., 
Robitaille, R. Pelletier, J.N. and Masson JF. Monitoring methotrexate in clinical samples from 
cancer patients during chemotherapy with a LSPR-based competitive sensor, Analyst, 2012, 
137, 4742 - 4750 - Reproduced by permission of The Royal Society of Chemistry (RSC)         
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Bio UV/Vis spectrophotometer (Varian Canada, Inc., Montréal, QC).  A freshly prepared FA 
stock solution in the range of 1 mM was added dropwise to the AuNP solution to obtain a final 
concentration of 12 μM FA in 5 mL AuNP solution. The mixture was stirred for 20 minutes 
shielded from light and centrifuged at 12 000 g for 20 minutes. The supernatant with excess 
FA was carefully removed and the pellet was resupended and centrifuged twice for rinsing 
with water. The pellet formed by FA functionalized AuNP was finally resuspended in 
phosphate buffered saline (PBS, Cellgro, Mediatech, Inc) before use.  
TEM, UV-Vis, mid-IR and surface enhanced Raman scattering (SERS) analyses were 
carried out to characterize the FA-AuNP. Microscopic appearance of synthesized AuNP has 
been evaluated with Transmission Electron Microscopy (TEM, JEOL-TEM-1200-EX, Tokyo, 
Japan) where a drop of colloidal solution was dried on a copper mesh grip coated with 
amorphous carbon film (Electron microscopy Sciences). Absorption spectra were taken before 
and after AuNP functionalization by a Cary 100 Bio UV/Vis spectrophotometer (Varian 
Canada, Inc., Montréal, QC) for a qualitative test in a 1 cm path length cell. Furthermore, mid-
IR spectra were acquired for confirmation of sequential functionalization of AuNP by using 
FTIR-Reflectance Absorption Spectroscopy (Bruker optics). Samples were prepared by drying 
FA, AuNP and FA-AuNP solutions onto different gold coated coverslips. The FTIR 
measurements were taken at 4 cm-1 resolution with 1048 scans from 600 to 4000 cm-1. Prior to 
Raman measurements, solutions of FA and FA-AuNP have been deposited onto glass 
coverslips and air-dried. The Raman spectrum was measured using a Renishaw InVia Raman 
microscope using 633 nm laser excitation. Spectra were acquired for 10 s at either 1% for the 
AuNP or 100 % of the laser power in μW for pure FA. The Raman shift region covering 800-
1800 cm-1 was monitored for the characteristic Raman peaks of FA.   
4.2.3 Competitive assay for MTX and dynamic modulation 
The enzyme human dihydrofolate reductase (hDHFR) was heterogeously expressed in 
Escherichia coli and purified as previously described for a mutated form of the same enzyme 
145
. 0.25 nM of FA-AuNP were mixed in 1 mL with and without 100 nM hDHFR (2.2 μg/mL) 
and in both cases, in the presence or absence of 100 nM MTX. The analysis was conducted in 
disposable plastic cuvettes of 1 cm path length. The solution containing MTX, FA-AuNP and 
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hDHFR was immediately analyzed for kinetic measurements. The kinetic measurements of the 
binding of FA-AuNP to hDHFR in solution were in the same conditions as described in the 
last section, 4.2.2. Absorbance spectra were recorded using a UV-visible spectrophotometer 
between 500-600 nm every 60 s for 20 or 30 minutes. The λmax at each time point was derived 
using a minimum finding algorithm (Annex 5) and kinetic progression of λmax was monitored. 
For the non-specific interaction study, 14 nM rabbit anti-chicken IgY protein (2.2 μg/mL) was 
used in replacement of hDHFR. Furthermore, a negative control in the absence of hDHFR was 
used to evaluate background response of FA-AuNP (0.25 nM) and MTX (100 nM). To assay 
for MTX binding, 100 nM MTX was added to the mixture of 0.25 nM FA-AuNP and 100 nM 
hDHFR. Methotrexate hydrate (MTX, > 98% HPLC, Sigma-Aldrich) was dissolved in 0.05 M 
KOH and quantified according to Volpato et al. 
121
 with ελ=258 nm = 22.1 x 10
3
 M
-1
 cm
-1
. The 
stock MTX solution was diluted to 100 μM in PBS, aliquoted for single use and stored at -
20°C. Further dilution in PBS was performed at room temperature to reach the desired 
concentration before analysis. Concentrations of MTX ranging from 10 pM to 100 μM were 
added to an analysis solution containing 0.25 nM FA-AuNP and 100 nM hDHFR for the 
investigation of assay dynamic range. The initial λmax of the kinetic curve was subtracted from 
the final point. The binding shift was normalized with respect to the binding signal of the 
highest concentrations of MTX of the series for comparative purposes. Analysis was 
undertaken at least in triplicate for each MTX concentration. 
4.2.4 Influence of interfering species 
Calibration curves were established for various interfering species to assess the 
potential of interference in the quantification of MTX. FA stock solution was prepared as 
mentioned above. A 0.1 mg/mL TMP stock solution was prepared in methanol. Stock solution 
of DAMPA (Alsachim, France) was prepared by dissolving a small quantity in 0.1 N NaOH 
and quantifying according to ε370 nm = 6568 M
-1
 cm
-1 150
. Each stock solution of interfering 
species was diluted in PBS from 10
-10
 to 10
-5
 M prior to use. Similarly to the MTX 
competitive assay, the LSPR wavelength was recorded by measuring spectra between 500-600 
nm every 60 s for 20 minutes. The kinetic measurements of 0.25 nM FA-AuNP and 100 nM 
hDHFR binding in solution in the presence of different concentrations of FA, TMP and 
DAMPA were analyzed. Experimentally, a specific concentration of the interferent, FA-AuNP 
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and enzyme were mixed by pipette in a 1 cm path length plastic cuvette and immediately 
analyzed. The LSPR wavelength at each time point was derived using a maximum-finding 
algorithm and kinetic progression of λmax was monitored with respect to time. The data 
treatment was as described above.  
4.2.5 Analysis of MTX in biofluids 
MTX used for the validation of the analytical system in complex matrix was purchased 
from US Pharmacopeia (Rockville, MD). The appropriate amount of MTX was spiked into 
foetal bovine serum or human serum to make concentrations up to 600 nM. Then, it was 
extracted from serum by adapting a previously published method 
111
. Briefly, solid phase 
extraction (SPE) cartridges (Isolute HAX, 3 mL, 200 mg, Biotage) were conditioned by using 
3 mL of methanol followed by 3 mL of 0.1 M phosphoric acid. The serum sample (0.5 mL) 
was mixed with 2 mL of 0.1 M phosphoric acid for cartridge loading. The cartridge was 
washed with 1 mL of 5% methanol in 0.1 M phosphoric acid and 1.5 mL of Na2HPO4 pH 9, 
followed by 2 mL of PBS. Ultrapure water (2 mL at 18.2 MΩ; Barnstead, Thermo) was used 
for the final elution step. Triplicate aliquots of 0.6 mL of the eluate were transferred directly 
into the cuvettes containing 0.25 nM of FA-AuNP and 100 nM hDHFR for kinetic 
measurements, as described above. The LSPR assay was compared to the FPIA assay 
(Methotrexate II, TDxFLx, Abbott Diagnostics) routinely used at the Hôpital Maisonneuve-
Rosemont (Montréal, Qc, Canada) and to LC-MS/MS (see below) at the Regional Center for 
Mass Spectrometry (Université of Montréal) by assaying clinical samples of patients on MTX 
therapy. A calibration curve in serum was constructed using a pool of ten healthy patients (no 
MTX treatment received). Sixteen positive samples from cancer patients undergoing MTX 
chemotherapy were provided in the concentration range from 0 to 30 μM; one negative (blind) 
sample had been randomly included among the positive ones. Prior to analysis by the LSPR 
and LC-MS/MS assays, samples were stored at -80 ⁰C. Samples were thawed at room 
temperature just before analysis. For the LSPR assay, samples were treated with SPE 
cartridges as described above. Note that dilution of the samples was needed in the case where 
responses were above the linear range of the calibration curve in preliminary studies. The 
Comité d’éthique de la recherche de l’Hôpital Maisonneuve-Rosemont has approved the 
experiments. All experiments were performed in compliance with the relevant laws and 
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institutional guidelines. Since this study was classified as method development, informed 
consent was unnecessary.  
The SPE-treated clinical samples were also analyzed using a LC-MS/MS method 
developed to serve as an alternative reference for our quantification. A Finnigan 
TM
 Surveyor 
TM
 HPLC system (Thermo) was used with a Kinetex
TM
 HILIC 100 Å, 2.6 μm (100 x 4.6 mm) 
column. The mobile phases were: A: 5 mM ammonium formate in 83% acetonitrile (ACN) in 
water and B: 5 mM ammonium formate in water. The flow rate was set to 800 μL/min. The 
treated sera were further diluted 10-fold in 80:20 (ACN: 0.1% formic acid) before sample 
injection. Sample injection volume was set at 5 μL. Analysis was performed on a 
ThermoFinnigan TSQ Quantum Ultra AM (Thermo) triple quadrupole mass spectrometer with 
positive ion Heated Electrospray Ionization (HESI-II) probe in selected reaction monitoring 
(SRM) mode for MTX: precursor m/z 455.2; products m/z 308.2, 175.3 and 134.2. The 
electrospray voltage was set at 3000 V and vaporizer temperature was maintained at 450°C. 
The unit mass resolution for both Q1 and Q3 were 0.70 at full width half maximum. The total 
MS acquisition time was 8 minutes. The initial concentration of the calibration standards and 
samples were calculated by taking account of dilution factors. Data were collected and treated 
using Xcalibur Qual Browser and Quan Browser software. 
4.3. Results and discussion
5
 
4.3.1 Comparative study of direct adsorption and covalent attachment for 
stability in PBS 
Buffered solutions such as PBS are used in bioassays to provide a suitable environment 
for ensuring functions of the biological species. Often the buffered environment with 
appropriate pH and salt concentrations contributes to optimized interaction of a binding pair. 
                                                 
5
 Sections 4.3.2 to 4.3.8 were published in Zhao, SS, Bichelberger, M.A., Colin, D.Y., 
Robitaille, R. Pelletier, J.N. and Masson JF. Monitoring methotrexate in clinical samples from 
cancer patients during chemotherapy with a LSPR-based competitive sensor, Analyst, 2012, 
137, 4742 - 4750 - Reproduced by permission of The Royal Society of Chemistry (RSC)        
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In this case, the enzyme is active in a commercially prepared PBS pH 7.4, showing a specific 
acitivity of at least 3 U/mg. The found values are in concordance with a previous study on 
specific activity of hDHFR 
151
. It was experimentally determined that a requirement of 3 U/mg 
is needed to achieve significant assay sensitivity. Therefore this buffer has been chosen for 
investigation of the enzyme interaction with functionalized gold nanoparticles.  
When MTX-AuNP synthesized in the previous study were rinsed and resuspended in 
PBS pH 7.4, the NP flocculated over time (Annex2, figure A2.1). This is one of the main 
causes of large response variation from analysis replicates of the same concentration of MTX 
tested with the previously established SPR competitive assay. The surface-bound enzymes no 
longer bind to one individual NP but rather associate to clusters of NP of different sizes. The 
proposed explanation behind the observed phenomenon is that although rigorous rinsing took 
place after EDC-NHS assisted covalent formation, residual EDC and NHS molecules may 
have been left in the solution since an excessively high concentration was used. At pH 7.4, 
both EDC and NHS are charged molecules which may interact electrostatically with the NPs. 
In addition to PBS’s high ionic strength environment, residual EDC and NHS molecules may 
promote Van der Waals interactions that associate NP altogether over time.  
As indicated by Chen et al. 
147
, direct adsorption of a specific concentration of MTX 
onto AuNP caused a shift in the LSPR band and the solution remained stable in a phosphate 
buffer solution (10 mM). The NP remained stable and dispersed for a long period of time. In 
this case, addition of a specific concentration of FA into AuNP solution gave similar 
observations, no flocculation was induced. The solution is stable overnight in water and after 
resuspension in PBS, the FA-conjugated NP remained stable for as long as overnight at room 
temperature in the dark (Annex 2, figure A2.1).  This could be explained by the fact that the 
citrate could be replaced by FA. As a ligand with multiple functional groups, FA contributes 
to electrostatic stabilization of AuNP in highly buffered conditions such as PBS since at pH 
7.4, one of the amines on the pteroyl ring is charged. These results are encouraging in a sense 
that the surface chemistry of the LSPR sensors ensures stability in high salt conditions ideal 
for further enzyme interaction.  
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4.3.2 Characterization of FA-AuNP 
The synthesis of FA-AuNP was characterized by several spectroscopic techniques. 
Briefly, the size and shape of the AuNP were confirmed by TEM (Annex 2, figure A2.2). 
TEM confirmed the diameter of the AuNP as 15 ± 3 nm by averaging diameters of 25 NP 
using Image J. Furthermore, the sensitivity of the AuNP of about 13 nm has been found to be 
387 ± 27 nm/RI which corresponds to literature values for spherical small AuNP  77. 
UV-Vis spectroscopy was employed to monitor the functionalization and stability of 
the NP. (Figure 4.2). As explained earlier, the NP is sensitive to localized events at its surface. 
Surface reactions such as ligand functionalization could be monitored. Furthermore, the UV-
Vis spectrum of the NP gives a good indication of the stability of the nanoparticles. For 
instance, as NP flocculate, the close position of the NP allows plasmon coupling which shifts 
the λmax of the NP to longer λ. The sharp peak in the UV-Vis spectrum of the folate-capped 
AuNP is around 527 nm and the absence of a peak or high background signal at high 
wavelengths were confirmatory of AuNP stability by FA even in highly saline buffer 
conditions. The exchange of citrate by folate led to a 2 nm red shift in accordance with FA 
attachment to the AuNP, where the local dielectric environment near the AuNP changes and 
further displaces the plasmon peak towards a longer wavelength.  
 
Figure 4.2 UV-Vis spectra of AuNP and FA-AuNP in water and in PBS. Inset shows the 
displacement of the LSPR band at each step of FA functionalization.  
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Furthermore, mid-IR and SERS analysis of the vibrational bands of the molecules 
present at the surface of the AuNP were confirmatory of the presence of FA on the AuNP. In 
both cases, the mid-IR and SERS spectra agreed with those of pure FA. Vibrational 
spectroscopy revealed that citric acid remains present to some extent on the surface of the FA-
AuNP. The spectrum of FA-AuNP has combined vibrational spectral characteristics of both 
FA and citric acid in the infrared (Figure 4.3). The vibrational bands of folate agree with the 
ones of FA-AuNP with characteristic peaks indicating C=O stretch peak at 1709 cm-1 from 
carboxylic acids, benzene ring vibration mode at 1513 cm-1 and a broad peak at 3384 cm -1, 
representative of presence of N-H stretch in amide and primary amines 152. Then by comparing 
FA-AuNP and AuNP spectra, both peaks at 1411 and 1607 cm-1 have corresponding –OH 
bending and C=O stretch vibrational modes respectively for the presence of carboxylic acids . 
This demonstrates the presence of the reducing agent, citric acid for capping AuNP before and 
after the addition of folic acid. 
 In addition, a complementary SERS study of folic acid adsorption on AuNP also 
confirmed the presence of FA on the AuNP since the presence of NP allows Raman signal 
amplification of the molecule attached to the surface (Figure 4.4). The local electromagnetic 
field is amplified due to resonant oscillation of free electrons found on closely associated NPs. 
The Raman signal of FA attached on the AuNP surface was therefore amplified. The 
confirmation of FA-AuNP was mainly due to the presence of an intense peak around 1610   
cm-1, which is characteristic of the C=O stretch of carboxylic acids 146. Furthermore, the 
second most intense peak around the region of 1250-1380 cm-1 is significant for amines in 
aromatic systems. Thus, all spectroscopic data suggested that folic acid functionalization was 
successful and the stability of FA-AuNP was ensured in PBS. 
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Figure 4.3 FTIR-RAS analysis of evaporated AuNP and FA-AuNP on gold-coated coverslips 
in comparison to FA molecule. 
 
 
Figure 4.4 Raman spectrum of FA in comparison to SERS spectrum of FA-AuNP by using a 
632.8 nm laser where 1% of laser intensity corresponds to 35 μW. Note that the SERS 
spectrum of FA-AuNP was acquired using laser power 100X less than the acquisition of the 
FA spectrum. 
4.3.3 Interaction of FA-AuNP and hDHFR in solution 
UV-Vis spectroscopy served to kinetically monitor the progression of the absorption 
maximum (λmax) due to binding of hDHFR to FA-AuNP, which act as the LSPR sensor. 
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Experimentally, when hDHFR and FA-AuNP were mixed in solution, a red shift of the 
absorption maximum resulted from increasing hDHFR bound to the LSPR sensor surface 
(Figure 4.5). The time-dependant SPR peak shift was the result of the affinity of FA for 
hDHFR as well as the collision frequency between the two 
153
. The equilibrium was slow to 
reach due to the slow diffusion of the sensors in solution, as a result of the bulkiness of FA-
AuNP and hDHFR. The time course was limited to 30 minutes to avoid lengthy analysis time, 
and to remain within the common duration for clinical biochemistry tests.  
The feasibility of a competitive assay where MTX and FA-AuNP compete for binding 
to hDHFR was evaluated for a specific concentration of hDHFR in presence of both MTX and 
FA-AuNP. This experiment mimics the clinically relevant competition between the 
chemotherapy inhibitor and substrate for binding to cellular hDHFR. This competitive assay 
features the controlled binding of hDHFR to FA-AuNP in absence of MTX, which leads to 
high LSPR signal. Increasing concentrations of MTX inhibit the binding of hDHFR to the FA-
AuNP, decreasing the measured LSPR response. The affinity constant (KD) of folate for 
human DHFR was previously estimated at 83 nM 
154
, which is 4-5 orders of magnitude greater 
(weaker binding) than the KI of MTX (34 pM) 
126
. Competitive displacement of the FA-AuNP 
by MTX, on hDHFR, was thus expected to be efficient due to the greater affinity of MTX than 
FA for the enzyme. Consequently, in the absence of MTX, hDHFR was free to bind to FA-
AuNP and generated maximal LSPR signal. As expected, addition of 100 nM MTX led to a 
drastic decrease in the binding shift produced by specific interaction of 100 nM hDHFR and 
0.25 nM FA-AuNP (Figure 4.5, MTX competitive binding). Monitoring a blank and a 
negative control assessed the specificity of the binding interaction. The blank measurement 
consisted of 0.25 nM FA-AuNP and 100 nM MTX (no hDHFR) to verify the stability of the 
FA-AuNP during a kinetic binding assay in the buffered solution. Figure 4.5 shows that the 
blank test resulted in a small binding shift in the absence of the enzyme. The small shift may 
have been induced by the reduction of interparticle distances due to the presence of ionic 
species in the buffered solution 
149
. However, the sensor signal stabilized within 5 minutes.  
Proteins are well known to bind non-specifically on citrate-capped AuNP, and thus are 
a potential interferent in the binding assay for MTX 
155
. FA-AuNP was exposed to rabbit anti-
chicken IgY as a non-specific protein, at a mass/volume concentration equivalent to that of the 
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hDHFR used. The kinetic curve of this negative control showed the level of nonspecific 
interaction between a protein having no affinity for folic acid and the FA-AuNP. As shown in 
Figure 4.5, the nonspecific signal of anti-chicken IgY was significantly weaker than the 
specific signal for hDHFR, providing a dynamic range sufficient for the quantification of 
MTX. The nonspecific signal observed may result from the electrostatic attraction between the 
charged sensor surface and proteins 
156
.  
 
 
Figure  4.5 Real-time kinetic binding of 0.25 nM FA-AuNP with  no hDHFR, 100 nM MTX 
(blank),  100 nM hDHFR (specific binding),  14 nM rabbit anti-chicken IgY (nonspecific 
binding) and   100 nM hDHFR and 100 nM MTX (competitive binding). 
4.3.4 Dynamic range of the competitive assay for MTX in saline solution 
 Several experimental parameters must be optimized to provide operational MTX 
quantification with a competitive assay. The most important regards the concentration of the 
reactants in solution. In a first step, the concentration of hDHFR in the analysis solution was 
optimized to target the clinically relevant concentrations of MTX, which encompass the 
nanomolar to micromolar range for clinical samples 
107
. A limiting factor in this optimisation 
was the concentration of FA-AuNP required for monitoring an intense extinction spectrum 
with sufficient signal to noise. Indeed, low nanomolar concentrations of FA-AuNP are 
required in extinction spectroscopy. The concentration of hDHFR enzyme that will bind to the 
FA-AuNP – perhaps in multiple copies – must be at least equal to the concentration of FA-
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AuNP, otherwise the LSPR signal induced by hDHFR binding to the FA-AuNP would be 
weak, resulting in poor signal to noise. Nonetheless, the resulting concentration of hDHFR 
may be lower than that of MTX in certain samples. This signifies that the concentration of 
MTX required to inhibit hDHFR binding to FA-AuNP will be limited by the stoichiometry of 
the reactants.  
Typically, KDs are measured with the receptor concentration acting as the limiting 
factor in the stoichiometry. In the present competition assay, the hDHFR will not act as a 
limitant and the dynamic range will be dictated by the stoichiometry of the analytical solution, 
which must be optimized. Optimization of the hDHFR concentration was performed to assess 
the dynamic range accessible with increasing concentrations of hDHFR. For a concentration 
of 100 nM hDHFR in solution, the LSPR sensor for MTX was active for concentrations 
between 10 and 100 nM. For MTX concentrations lower than 10 nM and greater than 100 nM, 
the binding signal reached plateaus characteristic of single-site receptor binding where a span 
of approximately 80 fold of target concentration takes place from 10-90% occupancy of the 
available bioreceptors 
157
. The concordance of the saturating concentration of MTX and 
hDHFR proves that stoichiometry drives the competitive assay. In addition, since the 
concentration of MTX was much greater than the KI of the MTX hDHFR binding pair, 
binding between MTX and hDHFR was dominant. A competitive binding curve of MTX for 
hDHFR of reverse sigmoidal shape was thus apparent.  
As expected, decreasing the enzyme concentration by one or two orders of magnitude 
decreased the dynamic range accordingly (Figure 4.6). For example, MTX concentrations as 
low as the higher pM range could be detected at the lower hDHFR concentration (1 nM). One 
drawback of decreasing the concentration of hDHFR resides in the lower binding shifts 
observed. Indeed, a lower concentration of hDHFR leads to fewer binding events on the FA-
AuNP and thus smaller wavelength shifts were observed. Specifically, the differences in 
wavelength shifts for the lowest and highest MTX concentrations are 0.4 nm for 1 nM 
hDHFR, 0.5 nm for 10 nM hDHFR and 0.6 nm for 100 nM hHDFR. On the upside, this shows 
great potential in adapting the assay for the detection of MTX spanning different orders of 
magnitude by modifying the receptor concentration. 
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Figure 4.6 Calibration curve for MTX with 0.25 nM FA-AuNP and varying concentrations of 
hDHFR (1, 10 and 100 nM) in PBS. The binding responses were normalized with respect to 
the response given by the highest concentration of MTX for each binding curve for 
comparative purposes. The error bars represent the standard deviation on three replicate 
measurements. 
4.3.5 Interference from other potential ligands of hDHFR 
The competitive assay based on LSPR was evaluated for its performance in the 
presence of interfering species. FA, DAMPA and TMP, having specific affinity to hDHFR, 
are among the potential interferents to the quantification of MTX due to their possible 
presence in human serum and their structural resemblance. For example, FA occurs at high 
concentration in a patient’s biological fluids due to required supplementary intake during 
MTX therapy for cancer treatment. It could interfere with the binding interaction in the assay, 
since free FA should compete with FA-AuNP or MTX for hDHFR 
158
. DAMPA, as one of the 
major MTX metabolites 
159
 could also be a source of interference due to its similarity in 
chemical structure and demonstrated binding. TMP is an inhibitor for bacterial DHFR, which 
may be present since it is given in concurrence with MTX for renal malfunction treatment in 
certain patients under chemotherapy 
160
 . It has a weaker affinity for human than for bacterial 
DHFR, yet remains a potential competitor.  
The competitive binding curves of MTX, FA, TMP and DAMPA were measured over 
5 orders of magnitude in concentration. This experiment was carried out with 100 nM enzyme 
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for comparison purposes. In reference to the competitive binding curve of MTX, no significant 
change in binding response was induced by any of the three potentially interfering molecules 
in the dynamic range of MTX (Figure 4.7). This absence of response from the potential 
interferents in the dynamic range of MTX could be explained by the lower affinity of the 
enzyme for each interferent in comparison to MTX. The dynamic ranges for all potential 
interferents were shifted to concentrations at least 2 orders of magnitude above the dynamic 
range for MTX. This implies that the interferent molecules could affect the analytical signal 
only if found at concentrations higher than 10
-6
 M for FA and 10
-7 
M for DAMPA in the 
analysis solution. In fact, the MTX-treated human serum employed in this study was analyzed 
by LC-MS in Full Scan mode for the purpose of identifying FA and DAMPA in the samples. 
The results showed no presence of these two molecules.  
The affinity constants measured in solution agreed with the lower affinity observed for 
the interferents in the LSPR assay. For example, the affinity for hDHFR was reported at 34 
pM for MTX, which is significantly lower than 2 nM for DAMPA, 83 nM for FA and 0.5 μM 
for TMP 
161
. Thus, the order of affinity estimated by the competitive LSPR assay was in 
concordance with literature. As explained above, the concentration of analyte and inteferents 
active in the LSPR assay were limited by the receptor concentration, which explains the 
disparity in KD and KI. As expected, TMP had the lowest affinity for human DHFR. It proves 
to be a suitable negative control of the system where the analyte was known to have little 
affinity for hDHFR. In summary, due to lower binding affinity for hDHFR, the other ligands 
have no effect on the response of the MTX dynamic range unless found at excessively high 
concentrations. In other words, the interferents do not compete in the same dynamic range. In 
addition, the assay proves versatile in determining binding affinities of various ligands for 
hDHFR, which could also be beneficial for drug screening.  
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Figure  4.7 Competitive binding curves of 0.25 nM FA-AuNP with 100 nM hDHFR in PBS in 
presence of varying concentrations of MTX, folic acid (FA), trimethoprim (TMP) and 4-
amino-4-deoxy-N-methylpteroic acid (DAMPA). The binding responses were normalized with 
respect to the highest concentration for each binding curve. The error bars represent the 
standard deviation on three replicate measurements. 
4.3.6 Analytical performances of the MTX sensor in phosphate buffered 
saline (PBS) 
The calibration curve was established by measuring the binding shift in the linear 
domain of the competitive assay (Figure 4.8). The chosen nanomolar range for MTX has 
chemotherapeutic significance, such that rapid quantification of MTX in this range allows the 
discrimination of patients requiring urgent leucovorin rescue treatment due to relatively toxic 
concentrations of MTX approaching the end of the treatment 
104
. To achieve sensitivity in the 
nanomolar concentration range and to obtain high signal to noise, an optimal concentration of 
100 nM hDHFR was employed for each analysis. Performing calibration curves on different 
days and by two different analysts ascertained the reproducibility of the measurement.  
The linear regression and sensitivity were reproducible from day to day (Table 4.1). 
The calibration curves were established with good linearity, as demonstrated with R
2
 = 0.975 
to 0.993 on three different days. The absolute sensitivity ranged from -8.0 x 10
-3
 to -8.8 x 10
-3
 
nm/nM. Note that the sensitivity was negative since the response is inversely proportional to 
the concentrations of MTX for a competitive binding assay.  
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To assess the recovery and precision of the method, three samples were prepared by 
spiking a known concentration that centers in the linear concentration range of MTX in PBS 
(50 nM) and treating this known concentration as an unknown in the calibration curve. Each 
sample was analyzed each time the calibration was performed. The accuracy from day to day 
varied between 2 and 18 % for MTX quantification. The precision of the spiked samples 
varied between 18-22%. The seemingly large dispersion of the results is typically expected 
with bioassays, as the bioreceptor activity varies slightly in addition to the usual experimental 
variations. Moreover, a factor of imprecision may be introduced in the initial 
spectrophotometric determination of MTX concentration. Nonetheless, the assay presented 
acceptable accuracy and precision for the quantification of an unknown for three different 
days performed by two different analysts. The acceptable accuracy and precision of the LSPR 
assay were promising for the application of the assay with clinical sample analysis. 
 
Figure 4.8 Calibration curve of MTX using 0.25 nM FA-AuNP and 100 nM hDHFR in PBS of 
day 1. The error bars represent the standard deviation on three replicate measurements. 
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Table 4.1 Inter-day calibration of 0.25 nM sensors and spiked MTX quantification in PBS on 
three different days during a one week period using the same batch of FA-AuNP, performed 
by two different analysts. 
 
 
4.3.7 Challenges of MTX analysis in serum and sample extraction  
Direct analysis of methotrexate in serum is impossible due to the high absorbance in 
the visible region of proteins in serum with diverse prosthetic groups. In the case of fetal 
bovine serum, an intense peak arising around 411 nm is characteristic of the Soret band found 
in heme-containing moieties proteins 
162
. The binding shift induced by interaction between 
FA-AuNP and enzyme is masked by the high background originating from these heme 
proteins shown in Annex 2, figure A2.3.  
A solid phase extraction method for extracting MTX was employed and optimized. The 
extraction method allowed direct analysis of the final elution solution containing MTX, 
eliminating evaporation and resuspension steps which normally take place for sample 
treatment prior to HPLC analysis. Note that with the introduction of sample treatment, the 
optimized elution condition has diluted the initial MTX sample concentrations by 6-fold. To 
take the dilution factor into account when building the calibration curve, the standard solutions 
were spiked in FBS at concentrations 6-fold greater, thus maintaining the same sensitivity as 
analysis in PBS. The efficiency of the extraction method was evaluated with a recovery test by 
comparing the measured concentration with respect to MTX-spiked FBS. The recovery was 
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excellent at 103 ± 5 % using spiked samples in the micromolar concentration range (Annex 2, 
table A2.1).  
Known concentrations of MTX were spiked in FBS as a mimic of human serum 
calibration using SPE extraction. Kinetic analysis of the MTX-treated (0-600 nM) or untreated 
FBS, with extraction, showed significantly different binding shifts. Note that at concentrations 
higher than 480 nM the binding shift saturates which marks the upper limit of the linear range. 
A calibration curve was established with good linearity (R
2
 = 0.954) (Annex 2, figure A2.4). 
4.3.8 Analysis of clinical samples 
The method was validated with clinical samples from cancer patients treated with 
MTX. The quantification using our method was compared to FPIA, the commonly used 
technique in hospital settings as well as LC-MS/MS, a reference technique. The calibration 
curve of the FA-AuNP sensor was constructed using sera from a pool of healthy (untreated) 
patients. MTX was spiked at concentrations up to 540 nM followed by cartridge extraction. 
Direct analysis of the cartridge elution solution was undertaken. The response curve of the 
sensor was shifted to higher concentrations than in figure 4.9 due to the 6-fold dilution of the 
sample prior to analysis, where the concentration of the x-axis refers to the concentration of 
the sample prior to SPE cartridge treatment. Note that each calibration point was obtained by 
averaging the binding signals of triplicate analysis from three different days. The coefficient of 
variation for all calibration points ranges from 5-11% of the absolute signal, which implies the 
reproducibility of the calibration in negative human serum from day to day. The linear portion 
of the resulting calibration curve (155 nM – 360 nM) was used for the quantification of the 
positive samples with a coefficient of correlation of R
2
 = 0.97. The limit of detection was 
calculated as 155 nM, as being 3 times the standard deviation of the blank divided by 
sensitivity. The linear portion of the calibration is therefore comprised between 155 to 360 
nM, which is an adequate dynamic range to make sure MTX concentration drops below the 
200 nM safety level after 72 hours in clinical samples. Samples with micromolar 
concentrations of MTX can be diluted into the dynamic range for analysis. Commercial FPIA 
technology also recommends dilutions for samples with high concentrations of MTX in order 
to accommodate a wide range of analyte concentrations.  
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Figure 4.9 Calibration curve of MTX using 0.25 nM FA-AuNP and 100 nM hDHFR in treated 
human serum after cartridge extraction. Note that the x-axis is scaled with respect to the initial 
spiked concentrations of MTX. Each calibration point is an average of triplicate analysis taken 
on 3 different days. 
 
The results of MTX quantification in a series of clinical samples from patients 
undergoing MTX treatment for cancer are given in figure 4.10. The treatment schedule 
consisted of doses administered sequentially when the previous dose reaches a metabolically-
acceptable (low) concentration of MTX. The metabolic clearance progression was monitored 
at different time points revealing peak and trough concentrations. Specifically, sample series 
1-6, 7-9, 10 (blank), 11-13 and 14-16 were obtained through time, from different patients 
undergoing MTX therapy. Similarly to the FPIA method, the quantification of positive 
samples with MTX concentrations spanning several orders of magnitude is possible with 
sample dilutions, to ensure that responses are included in the linear portion of the calibration 
curve. Calibration curves were performed with 6 standards for both LC-MS/MS and LSPR. 
The LC-MS/MS calibration curve is shown in Annex 2, figure A2.5. The MTX concentrations 
obtained for each sample by FPIA, LC MS/MS and the competitive LSPR sensor were 
comparable and in good general agreement.  
High micromolar concentrations were identified and appropriately diluted to obtain the 
final read-out. On the other hand, samples 4, 5, 6, 9, 10, 13, 15 and 16 showed binding 
responses close to or under the limit of detection of the competitive LSPR sensor before 
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sample dilution (Figure 4.10). Thus, they were identified as samples with concentrations lower 
than the LOD. Sample 10 (blank) was identified as expected below the LOD. In the case for 
LC-MS/MS analysis, it is important to mention that the eluted sample solution from the 
cartridge containing MTX was diluted 10 fold in the elution solvent for LC-MS/MS analysis. 
The sensitivity and limit of detection can thus be improved 10-fold with LC-MS/MS, if the 
final eluted solution from the cartridge was concentrated prior to analysis.  
Lastly, a correlation study was performed to compare the results obtained by our 
method to the reference techniques, FPIA and LC-MS/MS. The correlation was obtained from 
all three techniques using the eight samples (samples 1-3, 6-8, 11, 12, and 14) with 
concentrations above the LOD of the competitive LSPR assay. The LSPR and LC-MS/MS 
compared to FPIA had correlation slopes of 2.4 and 2, respectively, which imply that both 
techniques overestimate  MTX concentration with respect to FPIA by a factor of 2, or that 
FPIA underestimates MTX concentration by a factor of 2 (figure 4.11). Interestingly, the 
correlation factor between LSPR and LCMS/ MS was 1.1, which justifies the performance of 
the developed method in reference to the standard technique. The clinical samples were treated 
with the SPE cartridge and then split in two aliquots for the LC-MS/MS and LSPR analysis 
due to limited sample volume availability. Therefore, it is expected that LC-MS/MS analyses 
correlated well with the LSPR competitive sensor. 
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Figure 4.10 MTX therapeutic level monitoring chart of clinical samples with quantification of 
MTX by using LSPR method in comparison to FPIA and LC-MS/MS. Note that a 
concentration of 1 nM on the logarithmic scale represents a blank with no MTX. 
 
 
Figure 4.11 Correlation studies of MTX quantification by LSPR, FPIA and LC-MS/MS. 
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4.4 Conclusion 
In summary, a rapid analytical technique has been developed by using LSPR sensors 
for the detection and quantification of MTX. A competitive binding curve of MTX was 
established as a proof of concept for the applicability of the novel method. The assay has been 
calibrated in the nanomolar range in both PBS and foetal bovine serum with prior SPE 
cartridge treatment. The assay was then applied to determination of MTX concentrations in the 
serum of patients treated with MTX, and results have been compared to reference techniques: 
FPIA and LC-MS/MS. Quantification of identical samples by LC-MS/MS correlate well with 
the LSPR sensor results. Comparison with FPIA shows overestimation by a factor of 2, mostly 
in the samples with micromolar concentration but offering a reasonable correlation for 
samples with MTX concentrations between 10
-7
-10
-6
 M. 
 This study reports a rare example of analysis of patients’ serum using a LSPR-based 
assay.The current developed analytical tool could not only provide short turn-around time for 
each analysis, but also have potential for downsizing and automation in order to ensure a close 
monitoring of MTX levels in patients. Furthermore, the developed method will serve as a basis 
for the implementation of a direct detection technique of MTX by using SPR spectroscopy by 
functionalizing the enzymes on a surface. In this way, serum samples containing MTX mixed 
with FA-AuNP would be deposited directly on the modified SPR sensitive surface for direct 
readout of MTX concentrations.  
 
  
 
Chapter 5  Direct serum analysis of MTX using SPR 
spectroscopy  
I was responsible for the majority of the experimental work discussed in this chapter. 
Joelle Pelletier, Jean-François Masson and I were responsible for the experimental design. The 
miniaturized SPR system was designed and built by Jean-François Masson and Olivier 
Bolduc. Natalia Bukar has conducted experiments involving RFE enzyme and interrogation of 
the specific activity of hDHFR in different phosphate buffer. The purified hDHFR was 
provided by Lara Michel and Jacynthe Toulouse from Joelle Pelletier’s laboratory. The 
peptide was synthesized by Alexandra Aubé and me. Jean-François Masson and Joelle 
Pelletier were also involved in the edition of the chapter. 
Abstract 
A surface plasmon resonance (SPR) sensor has been developed for the therapeutic drug 
monitoring of methotrexate levels in actual clinical samples. MTX concentrations in patient’s 
serum can be determined by employing folic acid-functionalized gold nanoparticles (FA-
AuNP) in competition with MTX for a specific number of its targeted enzyme, human 
dihydrofolate reductase (hDHFR) immobilized on a SPR sensor surface. A new 
immobilization method based on receptor chelation to the surface was explored. First, receptor 
surface coverage was investigated and direct MTX analysis was attempted. Then the surface 
binding between immobilized hDHFR and 13 nm FA-AuNP has been characterized in the 
presence and absence of MTX. Subsequently, the influence of nanoparticle concentration (0.5, 
1 and 2 nM) and sizes (5, 13, 23 nm) as well as receptors of different affinities (wild-type and 
mutant hDHFR) on the assay were investigated and compared. In addition, the SPR sensor has 
been tested for its selectivity to its metabolite, 7-hydroxy methotrexate (7-OH MTX). 
Calibration of spiked MTX in bovine fetal serum using the sensor platform has been assayed 
as a model to mimic real clinical samples analysis. Preliminary data of calibration using actual 
clinical samples from a local hospital showed linearity in the nM range. Furthermore, initial 
binding rate data analysis demonstrated potential in providing fast sensor response less than 60 
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seconds. Ultimately, this study will focus on integrating the SPR based sensing platform for 
rapid and direct readout of sera MTX levels in patients under chemotherapy. 
5.1 Introduction 
As covered in chapter 1, SPR involves the absorption of reflected p-polarized light by 
the metallic film of the sensor chip when resonance conditions are met. When receptors are 
immobilized on the sensor surface, interaction of analytes with the receptors changes the 
dielectric layer directly above the metallic film. This induces a change in the refractive index 
near the surface which causes a displacement of the recorded reflectance spectrum. In this 
way, the sensor is sensitive to biological events on the surface where binding association and 
dissociation can be monitored in real-time 
22,61
.  
The translated version of the solution-based assay on the SPR platform relies again on 
the competition between MTX and FA-AuNP for immobilized hDHFR. The concept is the 
same as presented in chapter 3. High sensitivity for MTX analysis can be achieved using 
competitive binding assay despite its low molecular weight. The binding of FA-AuNP to 
surface-bound hDHFR induces plasmon coupling between the NP and substrate which 
amplifies the SPR signal. Different concentrations of MTX dictate the extent of FA-AuNP 
binding which in turn generates a SPR response that can be correlated the MTX concentration. 
The metallic film for the SPR assay is prepared in a way that the enzyme is fixed on the film 
using its multi-histidine tail chelating copper (Cu) sites on the metallic film. Several simple 
reactions allow Cu to be attached onto a self-assembled peptide monolayer immobilized on the 
surface. This immobilization method has been chosen over the EDC-NHS on-chip activation 
method discussed in chapter 3 because there is more control over orientation of hDHFR for 
exposing its binding pocket to MTX. In addition, self-assembled peptide monolayers 
especially 3-MPA LHDLHD have shown ultralow fouling properties particularly suited for 
resisting nonspecific adsorption for biomolecules quantification in crude serum 
120
.  
This chapter reports the translation of the LSPR competitive assay for MTX detection 
onto a SPR platform and explores different parameters affecting assay performance. One of 
the biggest challenges of establishing the LSPR sensor assay for small molecule detection in 
complex matrix is the presence of strong optical interference of matrix components from the 
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biological samples (section 4.3.7). In LSPR, the sensing probes are in the same medium as the 
analyzed sample, so the absorption and scattering of matrix component hinder the LSPR signal 
of interest 
76,78,163
. Pre-treatment may be required. In SPR, direct sensing in complex matrices 
is possible because the analyzed sample is not directly in contact with the sensing mechanism. 
Therefore, translating the previous assay onto a SPR platform is attractive in the sense that 
direct analysis of MTX can be undertaken in real biological samples without sample 
preparation.  
 As shown with the previously established LSPR assay in chapter 4, the limit of 
detection was found to be 155 nM and dynamic range of 155-360 nM was used for 
quantification. Samples of higher concentrations were diluted into the range for quantification. 
This current study has the objectives of examining different assay parameters such as NP size 
and concentration as well as the nature of the receptor, high affinity wild-type (WT) or low 
affinity mutant receptors in influencing the limit of detection and dynamic range of the assay. 
Secondly, this study aims to explore direct MTX analysis in clinical samples using the SPR 
platform, eliminating sample pre-treatment.  
 
 
Figure 5.1 Schematic illustration of SPR competitive assay for MTX detection.  
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5.2 Experimental 
5.2.1 Synthesis and functionalization of spherical AuNP of different sizes  
AuNP of 13 nm were synthesized by reducing 50 mL of 1 mM gold (III) chloride 
trihydrate (Sigma Aldrich, ≥ 99.9% trace metals basis) with 2 mL of 2% w/v sodium citrate 
dihydrate (Fischer Scientific) in purified water (18.2 mΩ)  134. 5 nm AuNP were prepared 
based on the protocol from Brown K.R. et al. 
164
. Briefly, 1 mL of 1% HAuCl4 was added to 
90 ml of purified water at room temperature. Then 2 mL of 38.8 mM sodium citrate dihydrate 
was added. A minute later, 1 mL of freshly prepared 0.075% sodium borohydride (Sigma 
Aldrich, ≥ 98.0%) in 38.8 mM citrate solution was added drop by drop. Then the colloidal 
solution was stirred for an additional 5 minutes and stored in a dark bottle at 4°C thereafter. 
Finally, NP of 23 nm were prepared using the seeding growth method 
134
. The seeds were 
made by heating 125 mL of 254 μM of HAuCl4 on a reflux set-up then 12.5 mL of 44.2 mM 
sodium citrate dihydrate was added to the boiling solution. The solution was mixed for an 
additional 15 minutes after colour change. Next, 30 mL of seeds were added to 270 mL of 
purified water with stirring at room temperature. 3 mL of 200 mM aqueous hydroxylamine 
solution (Sigma Aldrich, 99%) was added rapidly to the solution then, 4.5 mL of 25.4 mM 
HAuCl4 was added drop by drop to the mixed solution. The stirring was continued for another 
10 minutes after colour change.  
FA (Sigma Aldrich, ≥ 97%) solutions were prepared as described in a previous study 
165
. Functionalization of the spherical AuNP was done by adding volume of FA making up a 
total concentration of 80 μM in the final 1 nM colloidal solution of 1 mL for 30 minutes. The 
functionalized AuNP were centrifuged for 20 minutes at 11,000 g. The supernatant was 
removed and the pellet was resuspended in appropriate buffer solution before use. 100 mM 
Phosphate Buffer (PB) was prepared by adjusting 100 mM sodium dibasic phosphate 
heptahydrate (Fischer, ≥99%) with 100 mM sodium monobasic phosphate monohydrate 
(Fischer, ACS grade) to pH 8. 10 and 50 mM PB was also prepared in a similar way as 100 
mM PB. Glutamic acid-functionalized AuNP (GA-AuNP) was prepared in the same way as 
FA-AuNP. Functionalization of FA onto AuNP of size 5 and 23 nm was also prepared in a 
similar way. Unless specified otherwise, AuNP concentration was kept at 1 nM during 
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functionalization. Characterization of functionalized NP was carried out as discussed in 
chapter 4. 
5.2.2 Preparation of gold film substrate using 16-mecaptohexadecanoic acid 
(16-MHA) and peptide monolayers  
  The glass coverslips (BK7, 22x22 mm, Fischer) were coated with 1 nm Cr and 45 nm 
Au (ESPI metals) with a Cressington 208HR sputter coater. Then, gold coated glass coverslips 
were immersed into a solution of 5 mM of 16-mercaptohexadecanoic acid (16-MHA, Sigma 
Aldrich, 90%) dissolved in N, N-dimethylformamide (Fisher, ≥ 99.5%) for 16h for organized 
monolayer formation. The monolayer-covered gold coverslips were then rinsed thoroughly 
with ethanol (Fischer, ≥ 99.5%) and ultrapure water. The peptide-based SAM 3-MPA 
LHDLHD-OH were synthesized and attached to gold surfaces as described based on a 
previously established method 
166
. The gold chips were submerged in a peptide solution of 1 
mM in EtOH overnight. The gold chips were then rinsed with EtOH and millipore water. The 
surfaces were activated with 20 mM N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide 
(EDC, Fluka, purity > 97%) and 5 mM N-hydroxysuccinimide (NHS, Sigma Aldrich, purity > 
98%) for 20 minutes followed by the attachment of Nα,Nα-bis(carboxymethyl)-L-lysine 
hydrate (Sigma Aldrich, purity 99%) to the carboxylic acids of the immobilized peptide SAM 
on the surface. Subsequently, the sensor surface was blocked with an aqueous solution of 1 M 
ethanolamine hydrochloride (Sigma Aldrich, ≥ 99.0%) adjusted to pH of 8.5 with 10 M 
sodium hydroxide (Fluka, purity > 98%) to deactivate unreacted linker molecules for 10 min. 
Finally, the gold chips were exposed for 2 h to 100 mM copper (II) sulfate pentahydrate 
(Fischer, ≥ 99.99%) during which Cu2+ binds to the modified peptide layer.  
5.2.3 Wild-type and mutant hDHFR characterization 
The enzyme human dihydrofolate reductase (hDHFR) was heterogeneously expressed 
in Escherichia coli and purified as previously described 
121
. The concentration of each batch of 
enzyme was approximated by the Bradford method 
167
. The purified enzymes were stored at -
80°C. Aliquots of the enzymes were thawed on the day of the analysis. The activity of the 
enzyme was tested by adding a specific concentration of enzyme into a solution containing 
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100 μM β-NADPH and 100 μM DHF in phosphate buffer, 100 mM, pH 8.0, for 10 minutes. β-
NADPH was purchased from Sigma Aldrich (Oakville, On). DHF was synthesized from folic 
acid as described previously 
150
. The activity of the enzyme was measured by following the 
change in absorption intensity at λ = 340 nm using a UV-Vis spectrophotometer (Cary 100 
Bio Varian) due to consumption of the cofactor and substrate.  
5.2.4 Enzyme binding and MTX inhibition in solution  
The binding between enzyme and FA-AuNP was confirmed by using an established 
method relying on the displacement of the absorption spectrum of the functionalized AuNP 
induced by binding interaction of FA-AuNP and hDHFR in solution 
165
. 0.25 nM of FA-AuNP 
was mixed in 1 mL with and without 100 nM hDHFR and in both cases, in the presence or 
absence of 100 nM MTX in 100 mM phosphate buffer pH 8. 0.25 nM of GA-AuNP were also 
mixed in 1 mL with 100 nM hDHFR as a negative control. 1 cm pathlength disposable plastic 
cuvettes were used and the solution was mixed and immediately analysed for kinetic 
measurements. Recording absorbance spectra using UV-visible spectrophotometry between 
500 - 600 nm every 60 s for 20 minutes provided kinetic measurements of the binding of FA-
AuNP or GA-AuNP to hDHFR in solution. The λmax at each time point was derived using a 
maximum wavelength finding algorithm (Annex 5) and kinetic progression of λmax was 
monitored. The analytical signal consisted of the displacement of λmax. To obtain this 
information, the initial λmax of the kinetic curve was subtracted from the final point. Analysis 
was undertaken at least in 6 replicates for each reaction condition.  
5.2.5 Receptor surface density investigation and direct analysis of MTX 
The prepared gold films with Cu sites were placed onto a custom built miniature dove 
prism instrument in the Kretschmann configuration with a single channel for SPR analysis 
118
.  
The real-time monitoring of the SPR signal was accomplished by using an Ocean Optics 
USB4000 fiber optic spectrometer ranging from 550 to 850 nm which was used to acquire the 
spectral information. Custom software was used to process the raw spectral data to obtain SPR 
sensorgrams. A single channel 25 μL Teflon fluidic cell positioned on top of sensor chip was 
used for solution injection. Each sensor chip was used for 4 or 9 analyses depending on the 
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shape of the fluidic cell. The s-polarized reference was acquired in phosphate buffer before 
data acquisition in p-polarization.  
For receptor surface coverage investigation, different concentrations of hDHFR (5, 10, 
15, 20, 35, 40, 50, 60 and 80 μg/mL) were prepared in 100 mM phosphate buffer pH 8. The 
sensor chip was first conditioned in 100 mM phosphate buffer for 5 minutes. Then 200 μL of 
each solution was injected sequentially in an increasing concentration order for 10 minutes 
each. The final rinsing step using 2 mL 100 mM phosphate buffer took 5 minutes. From the 
processed sensorgram, the binding shift was calculated from the subtraction of the initial 50 
points acquired within 50 seconds from the last 50 points acquired for a single injection.  
Methotrexate hydrate (US Pharmacopeia, ≥ 99.9%) was dissolved in 0.05 M KOH and 
quantified according to Volpato et al. with ελ=258 nm = 22.1 x 10
3
 M
-1
 cm
-1 121
. The stock MTX 
solution was diluted to 100 μM in 100 mM phosphate buffer pH 8, aliquoted for single use and 
stored at -20°C. Further dilution in phosphate buffer was performed at room temperature to 
reach the desired concentration before analysis. Direct analysis of MTX was conducted using 
sequential injection of increasing concentrations of MTX (10 nM and 100 nM, 1, 10 and 100 
μM) in 100 mM phosphate buffer pH 8. The sensor chip was first conditioned in buffer for 5 
minutes. Then increasing concentrations of MTX in phosphate buffer were injected for 10 
minutes followed by buffer rinsing for 5 minutes.   
5.2.6 MTX competitive assay calibration  
The instrumental set-up and data acquisition are described above in section 5.2.5. For 
the analysis of different concentrations of MTX (10 pM to 100 M) in competitive format, the 
sensor chips were conditioned in 100 mM phosphate buffer pH 8 for 5 minutes then the buffer 
was replaced with an enzyme solution of 40 μg/mL for 10 minutes for receptor 
immobilization. Then phosphate buffer was used for rinsing excess proteins for 5 minutes. A 
mixed solution containing different concentrations of MTX and a constant concentration of 1 
nM FA-AuNP was injected for 15 minutes followed by a final 5 minute PB rinsing. From the 
processed sensorgram, the binding shift was calculated from the subtraction of the last 50 
points of the enzyme rinsing step from the last 50 points of the final rinsing. The binding shift 
signal given by FA-AuNP was plotted against the logarithm of MTX concentration to derive a 
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competitive binding curve. A competitive binding curve was established for each condition: 
varying concentrations of 13 nm FA-AuNP (0.5, 1 and 2 nM), varying sizes of FA-AuNP (5, 
13 and 23 nm). A competitive binding curve was also established using a concentration of 40 
μg/mL 100% wild-type (WT), 100% mutant (M) and 50 % WT: 50 % M hDHFR with 1 nM of 
13 nm FA-AuNP. Normalization of the competitive binding curve was performed against the 
response of the highest concentrations of MTX.  
5.2.7 Analysis of 7-OH MTX using SPR spectroscopy  
The metabolite of MTX, 7-OH MTX (Santa Cruz Biotech, San Diego, CA) was 
dissolved in 0.05 M KOH and the stock 7-OH MTX solution was diluted to 100 M in 100 
mM phosphate buffer pH 8, aliquoted for single use and stored at -20°C. Further dilution in 
phosphate buffer was performed at room temperature to reach the desired concentration before 
analysis. A mixed solution containing different concentrations of 7-OH MTX and a constant 
concentration of 1 nM 13 nm FA-AuNP was injected for 15 minutes followed by a final 5 
minute phosphate buffer rinsing. From the processed sensorgram, the binding shift was 
calculated from the subtraction of the last 50 points of the enzyme rinsing step from the last 50 
points of the final rinsing. The binding shift signal given by FA-AuNP was plotted against the 
logarithm of 7-OH MTX concentration to derive a competitive binding curve. Normalization 
of the competitive binding curve was done against the response of the highest concentrations 
of 7-OH MTX. 
5.2.8 Initial binding rate data acquisition 
The initial binding rate data analysis was conducted using the processed sensorgrams. 
The slope of the 10 first recorded points at the injection moment of the mixed solution of 
MTX containing sample with FA-AuNP was calculated using Matlab data fitting program. 
The initial binding rate data were plotted against concentrations of MTX for the establishment 
of a competitive binding curve. Normalization of the competitive binding curve was done 
against the response of the highest concentrations of MTX. 
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5.2.9 MTX serum calibration  
The appropriate amount of MTX was spiked into fetal bovine serum (FBS, Sigma 
Aldrich, Sterile-filtered) or human serum. Unidentified human serum samples were received 
from a local hospital (Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada). Six negative 
samples from a pool of healthy patients (no MTX treatment received) were used for the 
construction of the MTX calibration curve in human serum. The instrumental set-up and data 
acquisition are described above. First, the spiked FBS was mixed with different sizes (5, 13 
and 23 nm) of FA-AuNP for the investigation of NP size effect in complex matrix. Then the 
appropriate size of NP was used for human serum MTX analysis. The sensor chip was 
conditioned in phosphate buffer for 5 minutes then the buffer was replaced with an enzyme 
solution of 40 μg/mL for 10 minutes for receptor immobilization. Phosphate buffer was 
afterwards used for rinsing excess proteins for 5 minutes. The spiked FBS or human serum 
sample was mixed with 1 nM of 23 nm NP in phosphate buffer 10 mM and injected onto the 
surface for 15 minutes followed by 5 minutes rinsing with phosphate buffer 10 mM. From the 
processed sensorgram, the binding shift was calculated from the subtraction of the last 50 
points of the enzyme rinsing step from the last 50 points of the final rinsing. The binding shift 
signal given by FA-AuNP was plotted against logarithmic of MTX concentration to derive a 
competitive binding curve. 
Prior to analysis by SPR assay, samples were stored at -80 ⁰C. Samples were thawed at 
room temperature just before analysis. The Comité d’éthique de la recherche de l’Hôpital 
Maisonneuve-Rosemont has approved the experiments. All experiments were performed in 
compliance with the relevant laws and institutional guidelines. Since this study was classified 
as method development, informed consent was unnecessary. 
5.3 Results and discussion 
5.3.1 Free enzyme interaction and inhibition 
Folic acid is a precursor molecule of dihydrofolate which is a substrate of hDHFR. It 
has attracted great interest as a grafting material for gold nanoparticles in imaging and cancer 
cell targeting and therapy 
168
. The single step synthesis of FA functionalized gold 
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nanoparticles has been demonstrated in chapter 4 in generating stable and monodispersed 
population of NP. Folic acid is added to the gold nanoparticles solution to replace citrate 
through ligand exchange. The synthesized FA-AuNP has been characterized previously with 
UV-Vis, FTIR and SERS in section 4.3.2. The functionalized AuNP is employed as a solution-
based LSPR sensor. Through interaction of folic acid grafted onto the AuNP with hDHFR, an 
LSPR shift induces a slight color change. In other words, the gradual shift of the AuNP 
absorption spectrum confirms enzyme binding for FA. As shown in chapter 4, the biological 
system in solution was used to verify enzyme inhibition with MTX. Smaller LSPR 
displacement is expected where MTX inhibits available enzymes for binding.  
When a concentration of 100 nM MTX was mixed with FA-AuNP and hDHFR in 100 
mM phosphate buffer pH 8, the binding shift decreases due to MTX inhibition. A negative 
control in the absence of hDHFR was used to evaluate background response of FA-AuNP 
(0.25 nM) and MTX (100 nM). No significant binding interaction and nonspecific interaction 
without the presence of hDHFR were observed suggesting that the assay background noise is 
low. Glutamic acid is part of the structure of MTX and it is responsible for the 
functionalization of FA onto the AuNP. Therefore, glutamic acid is used to evaluate the 
specificity of the interaction between FA and hDHFR since GA is FA lacking the pteroyl ring 
essential for binding.  No significant LSPR shift was induced when GA-AuNP was mixed with 
100 nM hDHFR. This confirms the importance of pteroyl ring of FA as well as MTX in 
interacting with the active site of the enzyme (Annex 3, figure A3.1).  Note that the 
reproducibility for 6 replicates in each condition is quite good (Annex 3, figure A3.2). Due to 
variability in batches of preparation of hDHFR and FA-AuNP, a first evaluation of binding 
and inhibition interaction of the reagents in buffered solution is desirable.  
5.3.2 Receptor surface density investigation and direct detection of MTX  
It is often difficult to pinpoint a specific receptor concentration to be injected onto the 
SPR sensor surface in order to saturate the sensor surface area. The injected receptor 
concentration cannot be associated with receptor surface coverage. The surface density of 
immobilized receptor is an important factor in SPR sensor design for maximizing assay 
sensitivity. The optimal number of receptors on the surface should be adjusted accordingly 
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since low density coverage potentially induces high nonspecific adsorption whereas high 
surface coverage causes steric hindrance or improper surface immobilization leading to 
reduced interaction with the analyte.  
Usually with SPR spectroscopy, the extent of receptor coverage onto the sensor surface 
follows the Langmuir isotherm and can be monitored in real-time. Using gradually increasing 
concentrations of hDHFR solution injected onto the surface, the level of surface coverage can 
be monitored with respect to the measured SPR signal. The SPR responses were plotted 
against corresponding receptor concentration in figure A3.3 of Annex 3. The graph shows that 
a leveling off of the surface coverage occurs above 40 μg/mL. This implies that with 
concentrations ≥ 40 μg/mL, the surface is approaching saturation and excessively high amount 
of hDHFR are present and need to be washed away from the surface. The optimized 
concentration was then chosen to be in the range of 40 - 50 μg/mL which maintains enough 
receptors for a reasonable assay stoichiometry to generate a highly sensitive analysis in the 
concentration range of interest for MTX.  
Once the surface was coated with hDHFR, direct analysis of the MTX was 
investigated.  In chapter 2, direct analysis of MTX using NHS-MHA immobilized enzyme was 
attempted. Although direct analysis of MTX in the micromolar range was possible, the 
sensitivity and dynamic range are not clinically relevant. In this study, hDHFR possesses a 
histidine-rich tail for chelating Cu sites linked on the Au surface. In this way, this allows better 
preservation of the protein structure and hence activity. Direct analysis of MTX was re-
attempted in this case. Sequential injections of solutions of increasing concentration of MTX 
(10 and 100 nM, 1, 10 and 100 μM) were performed (Annex 3, figure A3.4). The total 
variation in response from 10 nM to 10 μM yielded a shift of 1 nm. The largest shift was 
generated with the injection of 100 μM MTX. However, the SPR signal returns to its initial 
point before the injection of 100 μM MTX during rinsing suggesting that there is presence of 
MTX that are nonspecifically bound to the surface and are washed away. However the signal 
does not return to the baseline with the final rinsing implying specific binding of MTX with 
surface-bound hDHFR. In addition, from the sensorgram, concentrations of MTX under 10 
μM can induce distinctive SPR response. This confirms that the current immobilization 
technique is suitable for enzyme surface attachment demonstrated through the capability of the 
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sensor to detect low concentrations of MTX. Moreover, it shows potential in a more sensitive 
assay using nanoparticle enhancement.    
5.3.3 MTX competitive binding curve in buffer  
5.3.3.1 Characterization of FA-AuNP and surface-bound hDHFR 
The activity of hDHFR immobilized on a SPR sensor surface has been demonstrated 
by Bolduc et al. and Ratel et al. 
166,169
.  An optimal self-assembled monolayer serves as an 
anchor point to the enzyme to maintain proper orientation in exposing its active site 
135,170
 and 
at the same time, possesses anti-fouling properties in preventing nonspecific interaction 
166
. 
The metallic film used in the SPR assay is prepared in a way that the enzymes are fixed on the 
sensor film with their histidine-tags on the enzyme chelating copper sites on the metallic film. 
As mentioned before, proper orientation of the enzyme is ensured for access and binding of 
FA-AuNP and MTX and for preservation of the protein structure for biological function. With 
the confirmation of enzyme interaction with FA-AuNP for detecting MTX in solution, the 
same competitive system was translated onto the SPR platform to verify the activity of the 
immobilized enzymes. 
The SPR biosensor is constructed with a receptor immobilization step first, followed 
by the MTX detection step from FA-AuNP binding signal.  The real-time monitoring of the 
receptor immobilization on the biosensor and MTX analysis is shown on figure 5.2. The 
sensorgram shows that the film is stabilized in a buffer solution at first, the injection of 
receptors causes a red shift then a rinsing step is introduced to wash off unbound receptors. In 
this case, a solution of FA-AuNP or a mixed solution of MTX and FA-AuNP is injected. The 
red shift indicates binding interaction between the receptors on the surface and FA-AuNP 
corresponding to changes of the dielectric layer in contact with the substrate. Then the final 
step is a rinsing step to wash away unbound NP or MTX. The displacement value of the SPR 
signal from the subtraction of the value of the enzyme rinsing step from the final step is 
representative of interaction between surface bound enzyme and NP. The sensorgram in black 
in figure 5.2 left) is a control experiment where no receptor is fixed, only a small shift at the 
detection step indicating nonspecific adsorption of the functionalized AuNP onto the surface. 
This value is considered as background signal and is subtracted from the binding response of 
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the analysis. The binding shift is calculated from the value of the rinsing step after enzyme 
immobilization subtracted from the last rinsing step. 
5.3.3.2 Construction of MTX competitive binding curve  
 Furthermore, overlapping sensorgrams of the detection step with different 
concentrations of MTX is shown in figure 5.2 right). Similarly to the previous LSPR 
colorimetric assay, different MTX concentrations induce varying SPR shifts in buffer.  As 
MTX concentrations increase, SPR shift decreases due to a decreasing number of interacting 
FA-AuNP caused by surface occupancy of MTX for available receptor sites. Each binding 
shift induced by a specific concentration of MTX is generated and then correlated to the 
concentration of MTX for the construction of a competitive binding curve on figure 5.3. The 
reverse sigmoidal curve illustrates the behavior of the system in the presence of different MTX 
concentrations. For further quantification purposes, only the linear portion of the curve was 
considered.  
 
Figure 5.2 Left) Receptor immobilization of SPR biosensor with 0.04 mg/mL enzyme and 1 
nM of FA-AuNP for MTX detection. Right) MTX sensor response with 0.04 mg/mL enzyme 
and 2 nM of FA-AuNP and varying concentrations MTX. 
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Figure 5.3 Competitive binding curve using 0.04 mg/mL hDHFR with 1 nM of FA-AuNP and 
different concentrations of MTX.  
 
5.3.4 Influence of NP concentration 
In immunoassays, the stoichiometry of the reagents influences the shape of the 
calibration curve. In competitive assays, the receptor concentration is optimized in order to 
saturate the substrate surface. The receptor and the competitive labeled entity concentrations 
remain constant throughout all analysis. In this study, the objective was to examine the 
influence of labeled NP concentration on the assay. As the concentration of FA-AuNP 
increases from 0.5 to 2 nM, the competitive binding curve working range shifts towards larger 
concentrations of MTX (Figure 5.4). The displacement of the dynamic range is expected since 
higher concentration of MTX is needed to compete with the increasing labeled population. By 
increasing the probability of FA-AuNP to interact with surface bound enzyme, the maximum 
binding response increases as well.  Increasing NP concentration has an effect on the 
stoichiometry of the system reagents which affects the assay working range 
171
. This could be 
a strategy to modulate the dynamic range in complex matrix analysis but such optimization 
must be considered carefully especially if a low limit of detection is desirable.  
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Figure 5.4 Competitive binding curves using 0.04 mg/mL hDHFR and different concentrations 
of 13 nm FA-AuNP. 
5.3.5 Interference from metabolites 
In order to be clinically adaptable, the degree of interference from metabolites of MTX 
on the assay must be known. In this case, 7-OH MTX is known to demonstrate cross-reactivity 
in other assays. Patients may metabolize MTX to a high concentration of 7-OH MTX after a 
high-dose MTX treatment 
172
. It has been shown that the metabolite is 200 times lower in 
affinity than MTX (KI = 8.9 nM) but may nonetheless interfere with the SPR assay 
173,174
. By 
using the same reagent conditions as MTX, it was found that 7-OH MTX levels below 1 μM 
do not significantly affect the system response due to its decreased affinity for hDHFR relative 
to MTX (Figure 5.5). Note that the samples are diluted 10 times for analysis. Samples 
containing concentrations of 7-OH MTX higher than 1 μM becomes troublesome for the MTX 
assay. Hence, 7-OH MTX could cause cross-reactivity to the system but at excessively high 
concentration in the samples. Again, it is noteworthy to mention that the MTX-treated human 
serum employed in this study was analyzed by LC-MS in Full Scan mode for the purpose of 
examining the potentially abundant presence of 7-OH MTX in the samples. The results 
confirm there was no identification of 7-OH MTX in the samples.   
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Figure 5.5 Normalized competitive binding curve of MTX and 7-OH MTX using 0.04 mg/mL 
hDHFR and 1 nM of 13 nm FA-AuNP. 
 
5.3.6 Influence of NP size on the SPR assay in buffer and in serum 
5.3.6.1 Effect of NP size in buffer 
The study of the effect of Au colloids on SPR enhancement of thin Au film has gained 
popularity in recent years, mainly due to the sensitivity improvement provided by larger sized 
colloidal labels for the detection of small molecules 
130
. Fewer studies reported the effect of 
NP size in plasmonic coupling to Au film for competitive assays. The coupling effect of NP of 
different sizes with the Au film was examined by only adsorbing the NP on the surface 
through polymer layers 
174
. In this work, the effect of size of AuNP on the analytical 
performance of the competitive assay for MTX detection is explored. The chosen sizes for 
examination were 5.2 ± 1.2, 13 ± 3.3 and 23 ± 5.1 nm. TEM images of 5 and 23 nm are shown 
in Annex 3, figure A3.5. NP larger than the 23 nm were not the scope of this study due to the 
fact that large colloidal particles have slower diffusion kinetics and steric hindrance becomes 
unavoidable. The concentrations used for each size are calculated based on the estimated 
number of receptors as well as the volume ratio of the particle.  
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By varying the sizes of the NP, a modulation in the dynamic range of MTX detected is 
possible (Figure 5.6). With NP of 23 nm, it is interesting to note that the MTX detectable 
range has shifted to smaller concentration. This is explained by the fact that kinetically, MTX 
diffuses a lot faster than larger NP to the surface. As the size of NP increases, the diffusion 
coefficient increases. By decreasing the NP diameter by almost 2 times, 13 nm FA-AuNP 
shifts the competitive binding curve towards higher nM range. Using even smaller NP of 5 
nm, the dynamic range is shifted towards even larger concentrations in the μM range. 
Kinetically, NP of 5 nm reach the surface faster than NP of 23 nm. A higher concentration of 
MTX is needed to compete with fast diffusing NP of 5 nm.  
Another factor that contributes to determine the lower limit of the working range is 
nonspecific adsorption. Unlike studies which only focus on the SPR changes induced by the 
coupling effects of adsorbed NP with the surface, nonspecific adsorption must be taking into 
consideration for assays. For instance, nonspecific adsorption on 5 nm NP causes a shortening 
of the linear range in the low concentrations. On the other hand, with larger NP, the dynamic 
range is extended due to the fact that there is less nonspecific adsorption masking lower 
concentration detection. Although the dynamic range is more extensive for larger NP and 
lower detection limit can be attained, it is important to highlight the fact that larger NP diffuse 
more slowly towards the surface and steric hindrance again could play a role in decreasing the 
number of NP approaching the surface. Hence, the SPR response observed due to NP binding 
is smaller than the one induced by smaller size NP during the same time frame. Depending on 
the requirement of dynamic range and detection limit for a specific application, the particle 
size can be optimized to maximize the analytical performance.   
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Figure 5.6 Normalized MTX competitive binding curves using 0.04 mg/mL hDHFR with NP 
of different sizes in 10 mM phosphate buffer at pH 8.   
5.3.6.2 Effect of NP size in serum 
The effect of NP size was further explored in a MTX-spiked FBS competitive assays. 
FBS was used as a mimic for real clinical serum. The MTX-spiked FBS is mixed with NP of 
different sizes. The study intended to interrogate on whether the stability of NP of different 
sizes is maintained when mixed with FBS and to examine the assay sensitivity in complex 
matrix. Experimentally, at the detection step, NP are mixed with FBS spiked with varying 
concentrations of MTX in a 10 to 1 ratio and injected directly onto the SPR surface for 
analysis. Then the binding shifts were plotted against concentration of MTX to obtain a 
competitive binding curve (Annex 3, figure A3.6). Only 4 concentrations (10 and 100 nM, 1 
and 10 μM before dilution) of clinical relevance were examined. It is important to mention 
that before sample injection into the system, mixing of serum with NP did not affect the NP 
stability for all three sizes. This is probably due to the abundance of albumin in serum, which 
has been employed in other studies for the stabilization of colloidal NP in aqueous solution 
175
.  
The dynamic range is similarly modulated by varying NP size in complex matrices as 
shown in figure 6 of Annex 3. For the concentrations of clinical relevance, the use of AuNP of 
23 nm is most appropriate since MTX detection in serum can be achieved in the range of 10 
nM-10 μM since it shows a linear concentration-response relationship. This is explained 
earlier that as the size of NP increases, MTX has the advantage of diffusing faster to the 
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surface in comparison to the larger NP. Again, kinetically, a competition is at play between 
fast diffusing MTX and slow diffusing NP. This was demonstrated from a slow increase in 
SPR shift induced by the NP. Furthermore, since nonspecific adsorption is limited with larger 
NP, the dynamic range is extended to lower concentration in the nanomolar range. Results 
collected confirm the feasibility of the assay in quantifying MTX in a complex matrix. 23 nm 
FA-AuNP were further used for all clinical sample analysis onward.  
5.3.6.3 Surface characterization of FA-AuNP and surface bound hDHFR  
It is interesting to note that at the final rinsing step of an analysis, there is no significant 
dissociation of the NP since there is no decrease in SPR signal (figure 5.2 left)). This implies 
that the FA-AuNP are tightly bound with surface receptors even after rigorous rinsing. 
Consequently, surface characterization can be carried out with an imaging system. The gold 
chips were rinsed thoroughly with water and ethanol and conserved for AFM studies (Annex 
3, figure A3.7). For the purpose of AFM studies, analyses using NP of size ~ 23 nm were 
used. Each sensor chip was scanned on 2 different sensing areas from analysis of the same 
MTX concentration. The images showed monodispersed NP of about 20-30 nm NP bound 
onto the surface. Increasing concentrations of MTX showed decreasing number of bound FA-
AuNP on the surface shown in figure A3.7 of Annex 3. In some cases, bigger agglomerates 
are seen and are also present on the surface. This could contribute to response variation from 
sample replicates. The negative control image where no hDHFR was coated showed some 
nonspecific adsorption of the NP. This correlates with the small shift shown in analysis of 
negative control using SPR (Figure 5.2 right)). All evidence point out that the enzymes are 
active on the surface and interacting with FA-AuNP in dependence of the MTX 
concentrations.  
5.3.7 Binding shift and binding rate data acquisition 
Information retrieved from the binding kinetics is equally important as information 
obtained at binding equilibrium. Springer et al. have shown quantitative analysis using both 
binding shift and initial binding rate parameters  
44
.  So far with the optimization of the system 
in buffer solution, only the binding shift given at reaction equilibrium is used for analysis. The 
initial binding rate information from the first exposure of the FA-AuNP mixed with MTX to 
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surface enzymes was derived using Matlab data fitting program. It is interesting to note that 
the initial binding rate is dependent on the concentration of MTX especially for low 
concentrations. Small molecules such as MTX diffuse more rapidly than FA-AuNP and could 
access the binding pocket more easily as compared to bulky FA-AuNP. NP of size 5 nm were 
employed since diffusion to the surface receptors is faster in comparison to NP of bigger size 
thus allowing a rapid response of the system.  
From both sets of data in figure 5.7, the responses of the binding shift and rate 
generated by using 5 nm for MTX analysis are normalized for comparison. It should be 
highlighted that the curve using binding rate spans in the same range of concentration and 
even extends into low concentrations of MTX. This is explained by the fact that the results are 
not acquired at thermodynamic equilibrium. The thermodynamic model is used when all the 
binding sites are saturated. The SPR shift is taken when the system is at equilibrium. At the 
injection of FA-AuNP and MTX to the surface, the binding sites are not saturated so kinetics 
dominate in a way the initial binding rate can be correlated to concentration of analyte on the 
surface. This becomes an interesting aspect where results from two different parameters of the 
same data can be used for cross validation. In addition, the limit of detection is lower using 
binding rate data acquisition.  Such data treatment allows rapid readout of the response under 
60 seconds which is welcome for a point-of-care device.  
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Figure 5.7 Normalized MTX competitive binding curves using 0.04 mg/mL hDHFR with 1 
nM NP of 5 nm in 100 mM phosphate buffer pH 8.   
5.3.8 Dynamic range modulation using mutant hDHFR 
As 23 nm NP offer a lower limit of detection and extended dynamic range to the assay, 
the stability of the NP must be ensured during the analysis. It was observed that the 23 nm NP 
become less stable in 50 mM phosphate buffer, pH 8 with respect to time. This is explained by 
the high ionic strength environment of the solution. With higher concentration of salt, 
electrostatic interactions between individual NP are disrupted inducing flocculation of the NP. 
So the buffer solution was changed to a lower salt composition buffer, 10 mM phosphate 
buffer to accommodate NP stability. As the buffer conditions change to accommodate NP 
stability, the binding interactions between folic acid and enzyme were also affected. This is 
shown from the narrowing of the working range of MTX using 50 mM phosphate buffer, pH 
8. Previously, it was observed that increased ionic strength benefited the activity of the 
enzyme shown in Annex 3, figure A3.8. As the dynamic range is dependent on size of the NP, 
the NP stability poses a serious limitation to assay reproducibility. If NP form random-sized 
aggregation, it generates large variability in SPR signal amplification which deviates from 
MTX concentration dependence.   
In regard to this problem, the effect of the nature of the receptor was explored for 
dynamic range modulation and expansion. Volpato et al. have investigated a combination of 
active site mutations in hDHFR for increasing MTX resistance 
121,133,176
. Basically, different 
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amino acids inside the active site of the enzyme are modified by protein engineering in order 
to vary the enzyme’s affinity for MTX.  RFE hDHFR (Arginine, Phenylalanine and Glutamic 
acid) is different from the wild-type hDHFR (FFQ) with phenylalanine, phenylalanine and 
glutamine residues at positions 31, 34 and 35 of the primary structure of the enzyme 
respectively responsible for MTX binding. RFE hDHFR is a 2 point mutation enzyme which 
has 4 orders of magnitude lower in affinity for MTX. It has a KI 
MTX
 of 21 nM 
176
 in 
comparison to wild type hDHFR (≤ 0.034 nM). It is interesting to highlight that the active site 
mutations do not influence protein folding of RFE so similar surface coverage is expected 
when coated on the gold film. First, sensor chips coated exclusively with RFE or WT hDHFR 
enzyme are compared using identical conditions with 1 nM 13 nm FA-AuNP in 100 mM 
phosphate buffer. The competitive binding curve in buffer was shifted towards higher 
concentrations of MTX (1-30 μM) as shown in figure 5.8. This makes sense because, as the 
receptor affinity for MTX decreases, the MTX concentration needs to increase to induce the 
same signal achieved with low concentrations for higher affinity receptors.  
Once the behavior of RFE for detecting MTX had been studied, a mixed surface 
coverage of WT and RFE was studied to elucidate their effects on MTX binding. NP of 13 nm 
are employed and mixed with different concentrations of MTX in a 10 to 1 ratio. The solution 
is directly injected onto the surface populated with 50% WT and 50% mutant enzymes. Figure 
A3.9 of Annex 3 shows that in 100 mM phosphate buffer, as the % of mutant enzyme 
increases, the dynamic range shifts towards higher MTX concentrations. Only with 50:50 
volume ratio of WT and mutant enzyme surface population, the variation of response occurs 
inclusively between concentrations from 10 nM to 1 μM before dilution whereas using 100% 
WT, their dynamic range was between 1 -100 nM. On the other hand, when 100% mutant 
enzyme was coated on the surface, no significant induction in SPR signal was noticeable in the 
lower range of concentration. This is a perfect example of how the enzymes differing in 
affinity could be used to modulate and extend the dynamic range at ease. 
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Figure 5.8 Normalized MTX competitive binding curves using 0.04 mg/mL WT and RFE 
mutant hDHFR with 1nM NP of 13 nm in 100 mM phosphate buffer pH 8.   
5.3.9 Assay calibration in human serum 
The SPR competitive assay was further validated by using negative clinical samples 
provided by Hôpital Maisonneuve-Rosemont. Sera from six different individuals were taken 
for the construction of calibration curve. The samples were spiked with MTX and mixed with 
23 nm FA-AuNP in a 1:10 ratio. Only WT hDHFR was used in this case. The calibration 
curve shown in figure 5.9 in human serum is shifted in comparison to the one in buffer (Figure 
5.6). The system using 23 nm in buffer was sensitive below 1 nM in saline solution whereas in 
complex matrix, no significant signal variation is induced in concentrations lower than 1 nM. 
The sensitivity has been lowered in comparison to the sensitivity in buffer. This is expected 
due to matrix effects introduced from the clinical samples. The reproducibility of the results 
for each concentration is quite large in some cases with coefficient of variation ranging up to 
31%. This is expected due to the great variability of serum components from one individual to 
another inducing large discrepancy in results. Nonetheless, Figure 5.9 right) shows high 
linearity of the system in the nM range.  
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Figure 5.9 Left) Calibration curve constructed using MTX-spiked serum from 6 different 
individuals using 1 nM 23 nm FA-AuNP in PB pH 8. Right) Zoom of the calibration points in 
the nM range. Note that the concentration of the sample has been diluted 10 times in the 
process of analysis. 
5.4 Conclusion 
In summary, the previous LSPR competitive assay has been successfully translated 
onto the SPR platform. NP concentrations and sizes as well as high and low affinity hDHFR 
can influence the sensitivity and limit of detection of the SPR assay. The metabolite, 7-OH 
methotrexate does not affect the performance of the assay unless found at above 1 μM before 
dilution of the sample. It was shown that NP of 23 nm were stable in FBS and an extended 
dynamic range between 10 nM-1 μM can be achieved in MTX FBS analysis. Finally the SPR 
human serum calibration was undertaken using sera from different individuals. The dynamic 
range shifted to higher concentrations and sensitivity drastically decreased. Reproducibility of 
replicate for each concentration is also not ideal. Considering the analysis is done with a single 
channel SPR system, a new prototype multi-channel system with a reference channel would 
assist in eliminating the nonspecific adsorption portion from the analytical signal. As 
mentioned above, the variability of the human sera causes large discrepancies of results. For 
clinical applications, presence of a reference channel could alleviate this problem, as the 
specific binding would be standardized regardless of differences in serum matrix. Furthermore 
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a multi-channel system would improve the precision of the analysis. The following chapter 
will discuss the use of a fully integrated multi-channel system in tackling the problems. 
 
 
 
  
 
Chapter 6  Performance and clinical application of a 
prototype multi-channel SPR system in methotrexate 
chemotherapeutic monitoring 
I was responsible for the majority of the experimental work discussed in this chapter. 
Jean-François and I were responsible for the experimental design. The fully integrated 
miniaturized SPR system was designed and built by Daniel Pelechasz and Jean-François 
Masson. The purified hDHFR was provided by Jacynthe Toulouse from Joelle Pelletier’s 
laboratory. The peptide was synthesized by me. In addition, Jean-François Masson and Joelle 
Pelletier were involved in the edition of the chapter. 
Abstract 
A multi-channel fully integrated SPR system has been built for the analysis of MTX as 
a potential point-of-care device. First, the analytical performance of the system was evaluated. 
The sensitivity of the gold-coated prism is comparable to the one of a conventional gold 
sensor chip with 2736 ± 328 nm / RIU. The resolution of the system is equivalent to existing 
commercial portable SPR with 10
-6 
RIU. The reproducibility of sensing channels is acceptable, 
as shown by coefficients of variation (CV) of 7-18%. The MTX competitive assay was 
adapted to the novel system and assay calibration was conducted in buffer as well as in human 
serum. The dynamic range of 28-500 nM was evaluated for human serum calibration. 
Thereafter, analysis of actual clinical samples using the multi-channel SPR system was 
demonstrated and compared to existing techniques: FPIA and LC-MS/MS. Furthermore, the 
prototype system applicability was validated in a hospital setting at the biochemistry 
laboratory of Hôpital Maisonneuve-Rosemont. The analytical performance and assay 
calibration at the clinical setting were examined and compared to analysis conducted at a 
controlled environment research laboratory. Lastly, the newly engineered system was 
compared to K-MAC SPR micro, a commercially available miniature SPR system, and the 
TDx from Abbott Laboratories, the current workhorse for MTX quantification, in order to gain 
insights on specific needs of a clinical laboratory for such system.  
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6.1 Introduction 
There is a growing demand in clinical settings for point-of-care devices in assisting 
medical practitioners for making critical decisions. The ideal device should be portable and 
easy to use but provide highly accurate results in a short period of time. As mentioned in 
section 1.3, there are no reported studies of SPR systems used in the clinical setting. Currently, 
commercially available SPR systems are not adaptable or have not yet shown adaptability in 
the clinical environment. The bulkiness, the cost of the instrumentation and materials as well 
as sensitivity and matrix interference issues are all challenges posed with existing SPR 
systems
 19,61,68
. 
MTX chemotherapy is the most common treatment given to patients with cancer 
102
. 
The monitoring of MTX levels in patients is crucial in ensuring the efficacy and safety of the 
drug dose. Currently, once the samples are collected, they are sent to the clinical laboratory to 
be pre-treated and analyzed using a laboratory-based instrument. Then, the results of MTX 
quantification in patients’ samples are back after at least a few hours to days, which sometimes 
delays proper patient care. A point-of-care device in this case would provide a rapid response 
on-site where the results are generated within the time frame of the treatment.  In addition, 
such a point-of-care (POC) device for MTX quantification would be beneficial for 
personalized care of patients living in remote areas where frequent accessibility to a clinical 
setting is not possible. The patient would be able to assess his/her own condition based on the 
doctor’s indications on the response of the POC device and engage in remedial action in the 
case of toxicity, for instance. 
Previously, the miniaturization of a custom built single-channel SPR 
37
 could achieve 
up to 9 analyses per sensor chip. The single-channel system is based on the Krestchmann 
configuration with wavelength interrogation. Fewer mechanical/optical parts are needed in 
comparison to angulo-interrogation SPR system.  All optical components are integrated in an 
aluminum block of size comparable to a credit card (Figure 6.1). Its resolution of 10
-6
-10
-7
 
RIU is comparable to the ones of commercially available systems.  No optical alignment is 
required as miniaturization brought the optics closer together in a single optical axis 
alignment. However, only one analysis is conducted at a time and there is no referencing for 
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temperature fluctuations. In addition, from the human serum calibration attempted and 
discussed in section 5.3.9, there is clearly a need for a reference to eliminate nonspecific 
adsorption signal that varies from serum of one individual to another. Furthermore, analysis 
with replicates is highly desirable for precision and throughput considerations. 
A new prototype fully integrated SPR reader has been engineered and developed for 
overcoming the challenges encountered using the single-channel SPR system. The system is 
multi-channel composed with 4 light beams in parallel. It employs a double injection port for 
solution delivery into 4 different sensing areas.  One injection port delivers solution into 3 
sensing regions in parallel and the other delivers solution into a single sensing region. This 
allows triplicate sample analysis with a reference or control reading concurrently. The 
applicability of the sensing system is validated by the adaptation of the MTX competitive 
assay. Calibration in human serum is demonstrated and compared to previous results using the 
single-channel system. Analysis of actual clinical samples is conducted and compared to 
results from two reference techniques, FPIA and LC-MS/MS.  Then, the optical reader 
performance for MTX analysis is verified at the clinical laboratory of Hôpital Maisonneuve-
Rosemont. The inter-day assay calibration in buffer is assessed. The user dependence of 
sample delivery is evaluated amongst five users. Finally, the prototype system is compared to 
another commercially available miniature system, the SPR micro from K-MAC as well as 
Abbott Laboratories’ TDx instrument currently employed by the hospital for MTX 
quantification.  
 
 
Figure 6.1 Picture of single-channel miniature SPR system.  
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6.2 Materials 
6.2.1 Multi-channel SPR system 
The prototype is a small and portable reflectance-based spectrophotometer with the 
integration of a light emitting diode (LED), fiber-optic coupled excitation and collection of 
light, a small USB spectrophotometer, microfluidics and electronics (Figure 6.2). A gold-
coated prism was deposited into an assigned cavity of the system and then pressed against a 
PDMS disposable fluidic cell secured with a clip. The glass prisms (BK7, 20 X 12.4 X 3 mm, 
Vy Optics, China) are dove shaped with an edge cut of 45° and a total internal reflection angle 
of 72.8°. The prisms were directly coated with 1 nm Cr and 45 nm Au (ESPI metals) using a 
Cressington 208R sputter coater, protecting the prism sides with Scotch tape. A PDMS fluidic 
cell with parallel double flow delivery channels was designed and used. One of the flow 
channels is S-shaped with a total volume of 16 μL. It covers 3 sensing areas in parallel on the 
prism. The other flow channel only covers one sensing area with a volume of 5 μL. The first 
channel serves usually for standards or sample analysis in triplicate. The second channel 
serves for reference or control analysis.  
Data acquisition was controlled by a custom Labview software where the SPR signal 
was integrated at each time point using a mathematical algorithm. Sensorgram derived from 
the SPR raw data was shown in real time. This was accomplished by using an Ocean Optics 
USB4000 fiber optic spectrophotometer ranging from 467 to 727 nm for spectral information 
acquisition. The data acquisition for each channel was acquired sequentially with a speed of 
10 integrations per channel per second with 90 milliseconds integration time.  
 115 
 
Figure  6.2 (Left) Picture of the inside of the prototype system.  Its dimensions: 181(L) x 166 
(w) x 55 (H) mm. Its weight: 1.3kg. (Middle) Picture of gold-film coated disposable prism and 
disposable PDMS fluidic cell next to a dime. (Right) Graphical depiction of the casing of the 
SPR system. 
6.2.2 Preparation of gold coated prisms with peptide SAM 
The 3-MPA LHDLHD peptide SAM was immobilized on gold-coated prisms in a 
similar way to the SPR substrates described in section 5.2.2. Briefly, the gold-coated prisms 
were immersed in a peptide solution in EtOH overnight. Then several reaction steps were 
conducted to generate peptide-linked copper on the surface ready for histidine-tagged protein 
fixation. 
6.2.3 System performance investigation 
For the investigation of sensitivity of the gold film-coated prisms, three different 
prisms from different batches of gold deposition were used. Solutions of different glucose 
concentrations of refractive index between 1.33 and 1.39 RIU were injected sequentially into 
all four channels for the establishment of the calibration curve of SPR signal in relation to 
refractive index. The sensing precision was evaluated during MTX control analysis (sample 
containing no MTX) performed on three different prisms of different batches. The rundown of 
the analysis is described in the next section, 6.2.4. The generated SPR values from bulk 
solution measurement, enzyme immobilization and MTX detection indirectly via FA-AuNP 
were compiled and compared.  
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The resolution was evaluated from the sensitivity of the prism and the noise level from 
sensorgrams of four different sensing areas of three different prisms. The resolution was 
calculated using equation: 
 
12)                   σRI = 3  
   
 ⁄  
                                                        
Where σ RI is the resolution of an SPR sensor, σ So is the standard deviation of the noise of the 
sensor output and S is the sensitivity of the SPR sensor to a change in refractive index 
54
. 
6.2.4 MTX assay calibration and analysis of clinical samples using prototype 
SPR system 
A gold-coated prism with suitable surface chemistry was inserted into the SPR system 
cavity. A PDMS fluidic cell was pressed on top of the prism and secured with a clip. Both 
flow channels were injected with ultrapure water for s-polarization reference acquisition 
followed by data acquisition in p-polarization. All four sensing surfaces were conditioned in 
buffer at first for 5 minutes. Thereafter for the analysis channel, the buffer was replaced with a 
200 μL enzyme solution of 40 μg / mL for 10 minutes for receptor immobilization. Buffer was 
then used to rinse away excess proteins for 5 minutes. Subsequently, a 200 μL mixed solution 
of MTX-containing standard or sample solution and 1 nM of 23 nm FA-AuNP was injected to 
the sensing areas for 15 minutes followed by a final 5 minutes buffer rinsing. Note that for 
control experiments, samples containing no MTX with FA-AuNP were analyzed. For the 
reference channel, the enzyme immobilization step was omitted.  
The binding shift data was calculated from the sensorgram. The binding shift value of 
the rinsing step after enzyme immobilization was subtracted from the value of the final rinsing 
step. The binding shift difference was then correlated with logarithmic concentration of MTX 
for the construction of the competitive binding curve. The initial binding rate data analysis 
was conducted using the derived sensorgrams as well. The slope of the 10 first recorded points 
at the injection moment of the mixed solution of MTX contained sample with FA-AuNP was 
calculated using Matlab data fitting program. The binding rate data were plotted against 
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logarithmic concentrations of MTX for the establishment of the competitive binding curve. 
Normalization of the competitive binding curves was done against the response of the highest 
concentrations of MTX. 
Methotrexate hydrate (US Pharmacopeia, ≥ 99.9%) was dissolved in 0.05 M KOH and 
quantified according to Volpato et al. 
121
 with ελ=258 nm = 22.1 x 10
3
 M
-1
 cm
-1
. The stock MTX 
solution was diluted to 100 μM in PBS pH 7.4, aliquoted for single use and stored at -20°C. 
Further dilution in PB was performed at room temperature to reach the desired concentration 
before analysis. Standards with concentrations of MTX ranging from 10 pM to 100 M in 
buffer were prepared before mixing with FA-AuNP for analysis.  
Unidentified human serum samples were received from a local hospital (Hôpital 
Maisonneuve-Rosemont, Montreal, QC, Canada) for MTX quantification with the multi-
channel SPR. Six negative samples from a pool of healthy patients (no MTX treatment 
received) were provided for the construction of the calibration curve in human serum. The 
appropriate amount of MTX was spiked into different human serum samples. For the analysis, 
the spiked serum samples were mixed with 1 nM of 23 nm NP in PB 10 mM a ratio of 10:1. 
Prior to analysis by SPR assay, samples were stored at -80 ⁰C. Samples were thawed at room 
temperature just before analysis. The Comité d’éthique de la recherche de l’Hôpital 
Maisonneuve-Rosemont has approved the experiments. All experiments were performed in 
compliance with the relevant laws and institutional guidelines. Since this study was classified 
as method development, informed consent was unnecessary. The results of SPR analysis of the 
clinical samples were compared to the ones of FPIA and LC-MS/MS results. The FPIA results 
were provided from the hospital laboratory. The LC-MS/MS results were acquired as 
described in section 4.2.5. 
6.2.5 MTX analysis with K-MAC SPR system and FPIA  
The commercially available K-MAC SPR micro instrument is based on angle 
interrogation with high resolution of 10
-6
-10
-7
 RIU. It has dual flow delivery microfluidics 
covering two defined sensing areas. The analysis of MTX described in section 6.2.3. has been 
attempted using this particular commercial system.  Triplicate analysis of a control and a 
sample containing 100 nM MTX in PB was conducted and compared to the prototype system.  
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Four samples (two samples of 150 nM and one of 500 nM and 1 µM) were prepared by 
spiking known concentrations of MTX in buffer solution. These samples are treated as 
unknown samples and analyzed using the TDx platform for accuracy and precision evaluation.  
100 µL of 3 different controls (50, 400 and 800 nM) and 100 µL of all 4 unknown samples 
were aliquoted in different cuvettes in a carousel. Then the carousel was locked inside the 
instrument. The reagent case was placed in a designated area inside the instrument before the 
start of the analysis. The results report was printed at the end of the analysis. 
6.3. Results and discussion   
6.3.1 Multi-channel system features  
6.3.1.1. Sensitivity 
For commercially available SPR systems, a gold-coated sensor chip is typically placed 
on top of a prism. Optical oil is often used for refractive index coupling and adhesion of the 
sensor chip onto the prism. The use of optical oil is delicate in a clinical context and increases 
the duration of the analysis since the stabilization of the sensor chip on an oily surface takes 
time. Gold film deposited directly onto prisms eliminates the use of optical oil leading to 
decreased assay time and simplified analysis. First the sensitivity of the gold film-coated prism 
was investigated by using solutions of varying refractive index. The sensitivity is defined as 
the slope of the calibration curve of SPR signal in relation to the refractive index. The average 
sensitivity amongst four sensing areas of all three prisms of different depositions is 2736 ± 
328  nm / RIU with a coefficient of variation (CV) of 12 % (Annex 4, figure A4.1). The 
sensitivity is comparable to gold film-coated glass chips of 2970 nm / RIU 
177
. The small CV 
value implies that the batch-to-batch Au deposition on prisms is highly reproducible. Note that 
the prisms are reusable as the gold film can be dissolved in aqua regia solution and re-coated 
with a new gold deposition. 
6.3.1.2. Reproducibility 
The sensing area-to-area response reproducibility is an important parameter to assess 
the precision of the system. The control analysis of the MTX assay where no MTX is present 
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was repeated on three different prism surfaces. The SPR shifts of the bulk measurements of 
refractive index change, enzyme immobilization and MTX analysis via FA-AuNP interaction 
were compiled and compared amongst three sensing areas of each prism with the fourth 
sensing area serving as reference. Amongst all nine different sensing areas, a coefficient of 
variation of about 10% was found for bulk solution measurements, less than 7% for enzyme 
immobilization and not more than 18% for interaction of FA-AuNP with surface bound 
enzyme (Annex 4. figure A4.2). An example sensorgram of the control analysis is shown in 
figure A4.3 of Annex 4.  
The larger discrepancy at the MTX detection step using FA-AuNP might be induced 
by the sensitivity difference of the sensing areas on the same surface of the gold film. The 
sensors are prepared by a sputtering process that may lead to some heterogeneities on the 
prism surface. Polycrystalline gold substrates have been characterized by numerous STM 
studies 
136
. Microscopically, they have been presented with varying surface topography of 
numerous irregularities. The heterogeneous surface then impacts the thickness of deposited 
gold from area to area which results in surface sensitivity differences. The presence of 
irregularities further causes SAM defects. Due to peptide SAM defects, the enzyme 
immobilization in each sensing area differs; some may be less active or less accessible for 
interaction. In this way MTX and FA-Au NP interaction with surface-bound receptor results in 
varying NP-surface plasmonic coupling effects depending on the position and activity of 
enzyme 
38,178
. Lastly, presence of larger NP assembly amongst monodispersed NP can also 
cause deviations in the measured SPR response from different sensing areas.  
6.3.1.3. Resolution 
One of the most important parameters in assessing SPR sensor performance is the 
resolution. The resolution is defined as the smallest change in the refractive index that 
produces a detectable change in the sensor output 
54
. The resolution is dependent on the 
sensitivity, the generated spectral bandwidth and noise of the instrument. The noise level was 
measured from the four sensing regions of three different prisms. The standard deviation of 
the background noise does not exceed on average more than 0.025 nm. The resolution was 
approximated to be 10
-6
 RIU. By increasing the number of spectra integrated and using 
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denoising algorithms, the resolution can be easily improved to 10
-7
 RIU 
118
. This is 
comparable with commercially available and research-grade SPR sensor systems 
54
. It is 
important to note that the resolution of the instrument affects the limit of detection of the 
analysis. Improving resolution will contribute to improve the limit of detection of the analysis 
if needed. 
6.3.1.4. MTX competitive assay assessment 
After sensor performance evaluation, the MTX competitive assay was validated using 
the multi-channel system with measurements of two MTX concentrations (1 nM and 1µM) in 
buffer. There are no modifications in reagent preparation and analysis from the single-channel 
system MTX analysis. The real-time sensorgrams from all four sensing regions are shown in 
Figure 6.3. The sensorgrams demonstrated successful enzyme immobilization followed by 
indirect MTX analysis with FA-AuNP. The analysis showed that the system was sensitive to 
changes in MTX concentrations, 1 nM and 1µM, as evidenced from the reduced binding shift 
for higher MTX concentration.  Nonspecific adsorption signal from the reference channel was 
subtracted from the test channel results.  
 
Figure 6.3 MTX analysis sensorgrams in PB pH 6 generated from the multi-channel system. 
(Colored) Sensorgrams from the test channels. (Black) sensorgram from the reference channel. 
left) [MTX] = 1 nM and right) [MTX] = 1 μM. The first increase in binding shift in the test 
channels is due to immobilization of the His-tagged enzyme onto the surface. The second 
large increase is due to the interaction of NP with surface-bound enzyme. No enzyme was 
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injected in the reference channel, therefore, the sample injection step did not show any 
increase in signal.  
6.3.2. MTX calibration in human serum and clinical sample analysis  
The prototype sensor system was employed for the calibration of MTX concentrations 
in human serum. Similarly to calibration performed using the single-channel system, sera from 
six different untreated individuals were spiked with MTX of varying concentrations. Each 
concentration was analyzed at least three times in triplicate. All human serum calibration 
standards and samples from MTX treated patients were diluted 10-fold with the mixing with 
FA-AuNP before injection onto the sensor surface. 
In comparing the calibration curve established with the single-channel and the one with 
the multi-channel system, the sensitivity and linearity have been improved in the case of 
multi-channel system. The dynamic range has extended from 10-100 nM previously to about 
50 nM-500 nM (Figure 6.4 Right)). The coefficient of variation was quite large using single-
channel (up to 31%) in comparison to current analysis using multi-channel system yielding 
CV of 5-26%. All evidences point out to the improvement of the analysis using the multi-
channel system. The variability in matrix components poses a challenge for calibration using 
human serum, leading to large standard deviation in response. Furthermore, the response of 
nonspecific adsorption signal of different sera masks the signal induction from small 
concentrations of MTX. The standardization of nonspecific adsorption of serum matrix 
components from different individual using the reference channel helps in eliminating the 
variability factor and in isolating the specific binding signal for each sample of serum. This 
shows the importance of referencing for complex matrix analysis. It is interesting to note that 
the high concentrations of MTX such as at 1 μM still induces a response of 4 ± 1.8 nm. 
Theoretically, a zero response is expected since high concentration of MTX saturates all 
receptor sites so no binding of FA-AuNP is possible. The residual background response may 
be explained by nonspecific adsorption of individual or clusters of FA-AuNP via electrostatic 
interactions with the enzyme on the surface even at high concentrations of MTX.  
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Figure 6.4 Comparison of the MTX assay calibration in human sera of six different individuals 
using 1 nM of 23 nm FA-AuNP mixed in a 1 to 10 ratio in 10 mM PB at pH 6 using the 
single-channel SPR miniature system and the four-channel fully integrated system. 
 
The linear portion of the calibration curve was used to analyze a few clinical samples 
in different concentration ranges. The dilution factor needs to be taken into account before the 
samples are diluted 10-fold before the analysis. The dynamic range was estimated to be 
between 28 – 500 nM with a limit of detection of 28 nM defined as being 3 times the standard 
deviation of the blank divided by sensitivity.  Samples were further diluted in the case where 
the first analysis fell out of the calibration range. The results compared to FPIA show that 3 
out of 4 micromolar samples were identified correctly. The samples with concentrations in the 
nM range were identified at the first attempt. However, the order of magnitude cannot always 
be correlated. The blank was identified as a nM range sample. In general, the LC-MS/MS 
results correlated better with the ones from FPIA (Table 6.1). The linearity of the calibration 
curve established with the SPR system should be defined better with more data points 
especially in the low concentration range. Lack of calibration points may misevaluate the 
sensitivity of the assay which in turn affects sample quantification. 
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Table 6.1 Comparison of the analysis of MTX-containing clinical samples using 3 different 
techniques.  
 
 
6.3.3 Field test at Hôpital Maisonneuve-Rosemont  
The miniature SPR system is suitable for a clinical laboratory with limited bench space 
(Figure 6.5). These laboratories are often crowded with instruments, each specific for a 
particular test. The multi-channel SPR system was set in the clinical laboratory of the hospital 
biochemistry department for 2 days. The objective of the exercise was to assess the 
performance of the system in a clinical setting in terms of day-to-day reproducibility of MTX 
assay calibration in buffer and sensor resolution. Furthermore, user dependence of sample 
delivery into the SPR system was examined amongst five users.  
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Figure 6.5 Picture of the multi-channel SPR system in a clinical laboratory. 
6.3.3.1. Calibration of the MTX assay using binding shift and initial binding rate data  
The multi-channel system was used for the buffer calibration of the MTX assay in the 
μM range. The calibration was conducted at the research laboratory before deployment (in-
laboratory). Then, calibration was repeated at the clinical laboratory on both days by two 
different operators (Figure 6.6). There are less potential instrumental noise perturbations at the 
research laboratory because there are no other instruments running at the same time and the 
temperature is better controlled in the research laboratory setting. The calibration conducted at 
the research laboratory and the ones done at the clinical laboratory demonstrated linearity 
from 1-100 µM. The sensitivity was similar for the calibration conducted before deployment 
and the one conducted at day 1. On day 2, the calibration sensitivity has reduced by half in 
comparison to the ones conducted on the other days.  It has also been observed previously that 
the day-to-day reproducibility of the calibration curve sometimes varies which is not due to a 
change of operators. It has been previously investigated that the response of a particular 
concentration of MTX induced different responses from day-to-day with the same operator. 
The cause of sensitivity difference is believed to be more dependent on the variability of the 
reagents used daily. It is important to note that each calibration is performed with a different 
aliquot of enzyme. The transportation of the enzyme aliquot to the hospital laboratory may 
cause non-uniform thawing of the enzyme which affects its activity.  
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Figure 6.6 Calibrations of MTX assay using the multi-channel SPR system using binding shift 
response. Red) operator 1, in-laboratory, y = -0.054 x + 9.3; R
2
 = 0.985 (black) operator 1, day 
1 of field test, y = -0.064x + 10.4; R
2
 = 0.962 (blue) operator 2, day 2 of field test, y = -0.031x 
+ 7.05; R
2
=0.972. 
 
 Using initial binding rate as response illustrates the enormous potential of the multi-
channel system in generating rapid direct readout of MTX concentrations (Figure 6.7). The 
initial binding rate response was acquired within 60 seconds of the sample injection whereas 
the binding shift is recorded after 15 minutes of sample injection at thermodynamic 
equilibrium. Both types of response, binding shift and binding rate are used for MTX assay 
calibration for comparison. It is interesting to note that all calibrations (pre-deployment, 
deployment day 1 and 2) using initial binding rate as response showed a shortening of the 
dynamic range in higher µM concentrations. The system demonstrated sensitivity towards low 
µM concentration. This is expected due to the fact that the response is acquired before the 
biological system reaches thermodynamic equilibrium. Lower concentrations can be better 
correlated to initial response where the surface receptors have not been fully saturated. Higher 
concentrations show no significant difference in response due to immediate saturation of 
surface receptors. The limit of detection can be improved using binding rate as response. This 
is in concordance to previous findings as section 5.3.7.   
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Figure 6.7 Calibrations of MTX assay using the 4 channels SPR system using binding rate 
response. Red), operator 1, in-laboratory (black) operator 1,  day 1 of field test and (right) 
operator 2, day 2 of field test. 
6.3.3.2. System noise level and resolution in the clinical setting 
It is interesting to note that the SPR system was placed in a crowded clinical laboratory 
next to a few running instruments. On day 2, the air conditioning in the laboratory was 
operating due to increased humidity in the air. With these known potential perturbations, the 
noise level (± 0.02 nm) on day 1 and 2 are comparable to the noise level of the system placed 
in an instrument-free and temperature controlled laboratory (Annex 4, Figure A4.4). The 
resolution of the system is also in the 10
-6
 RIU range. In addition, the system can achieve a 
resolution of 10
-7
 RIU if the number of integration increases. The deployment of the system in 
a clinical setting helps to evaluate its performance in the context it will be used. With the field 
test, the system has shown robustness and portability from its deployment to a clinical 
laboratory.     
6.3.3.3. Investigation of system user dependence 
With the alpha version of the prototype system, manual injection has been performed 
for solution injection. Three easy steps for instrumental set-up were required before the 
analysis: insertion of prisms, microfluidic cell installation and finally, manual injection of 
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solution into the microfluidics. Manual injection can vary among different operators. This 
experiment addresses the extent of system user-friendliness if it were to be placed as a point-
of-care device with users having no expertise on operating SPR systems. Three new users 
were invited to repeat the same analysis as two experienced users. The new users were 
instructed to produce a drop per second at the exit of the microfluidic channel while injecting 
200 μL of the sample solution. First, two samples of the same concentrations of MTX was 
repeated by user one. The results from three different sensing areas of both analyses were 
reproducible. The same analysis was conducted by a second user and reproducibility was quite 
good. Note that user two and five are experienced users whereas user one, three and four are 
new users. The coefficients of variation were comparable independently of experienced or 
new users (Annex 4, figure A4.5). It was demonstrated that on the same day, 2 different users, 
one new and one experienced achieved CV of 9-23% for analysis of the control test (0 MTX) 
and 6-16% for MTX concentration of 50 μM. It can be concluded that the system can be 
potentially operated by inexperienced user without extensive training. 
6.3.4. Comparison to SPR micro 
K-MAC SPR micro is one of the few existing miniature SPR devices on the market. It 
was compared with the prototype system in terms of sensor performance, user friendliness and 
validation in MTX analysis. The K-MAC system employs double flow channel microfluidics 
in a Kretschmann configuration with angle scanning (Figure 6.8). One flow channel serves for 
the analysis and the other serves as a reference for the purpose of eliminating background 
signal. The size of the K-MAC is equivalent to the prototype. The resolution of the system has 
been evaluated to be in the range of 10
-6
-10
-7
 RIU. Sensor chips coated with gold film can be 
purchased from the manufacturing company of K-MAC SPR micro. First, optical oil is applied 
on the prism. Then the sensor chip is placed on top of the prism and pressed with a Teflon 
microfluidic cell composed of two distinct chambers. The SPR micro has features that are 
good references for comparison of the prototype system.   
The K-MAC system offers high resolution and an easy-to-use program in addition to 
providing real-time monitoring of the SPR signal. Its high resolution and low noise level are 
desirable for analyses demanding low limit of detection. The program offers automatic 
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subtraction of the reference from the test results. The spectral bandwidth of the SPR signal 
from both sensing areas is small and reproducible with interchanging sensor chips. The two 
major downsides of the K-MAC system are the use of optical oil for optical coupling of the 
sensor chip with the prism and its microfluidics. The use of optical oil is finicky. Depending 
on the sensor chip surface to be adhered to the prism, the appropriate amount of oil is needed 
for sensor chip stabilization on the prism with the pressing of the microfluidic cell to ensure a 
stable baseline. Ideally, the sensor chip should be easily secured on the system and ready for 
analysis. Furthermore, a questionable design of the microfluidic cell in terms of its inability to 
deliver consistent flow caused significant leaks during the analysis. From a clinical point of 
view, leakage of clinical samples into the system is regarded as an instrumental weakness. 
Leakage may cause serious contaminations and becomes troublesome for clean-up. In 
addition, the clinical samples are considered as biohazards since the presence of pathogens in 
the samples is unknown. Breathing or improper contact of the sample especially in an aerosol 
form exposes the operator to a health danger. Manual injection may cause significant pressure 
built-up into the system which causes the flow rate to vary. However, this problem with the 
KMAC system could be alleviated with a pump system which has better flow control.  
The adaptability of the KMAC system was also validated using the MTX competitive 
assay without any modifications. Two conditions of MTX were used: control (sample with no 
MTX) and 100 nM MTX mixed with 1nM 13 nm FA-AuNP. Triplicate analysis was 
undertaken for each condition. The sensorgrams shown are from the subtraction of the 
reference from the test channel results (Annex 4, figure A4.6). For the control experiment, the 
enzyme immobilization SPR shift values are similar. But the SPR shift due to indirect MTX 
detection of FA-AuNP interactions varied significantly with a CV of 41%. Similarly with a 
sample of 100 nM MTX, the reproducibility of all 3 tests is poor (CV of 116%). Although the 
average value of 100 nM MTX-induced SPR response is less than the response with no MTX, 
a calibration would not be possible due to the large overlap of standard deviation. Again, 
during the analysis, leaks occurred and air bubbles caused frequent loss of SPR signal. The 
poor reproducibility is associated with the poor design of microfluidics for solution delivery. 
The MTX competitive assay is more adaptable onto the prototype system than with the K-
MAC instrument using manual injection. 
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Figure 6.8 Picture of left) the KMAC SPR micro system. Dimensions: 45(w) x 140(L) x 
130(H) mm and right) sensor chip deposition before microfluidic cell mounting on KMAC 
SPR micro. 
6.3.5. FPIA analysis of MTX and comparison with multi-channel system 
The TDx instrument from Abbott Labs is the mainstream technique for MTX 
quantification in clinical settings (Figure 6.9) 
179
. The instrument relies on the principle of 
Fluorescence Polarization Immunoassay (FPIA) for evaluating MTX concentration in clinical 
samples. The technology is a competitive assay where MTX in the sample and MTX labeled 
with fluorescein compete for a specific number of antibody molecules that are specific for the 
binding of methotrexate.  Labeled MTX rotates freely in solution and cause depolarization of 
the polarized light. Antibody-bound, labeled MTX rotates slowly and so the incident polarized 
light remains polarized. The higher the level of the polarization of the light detected, the more 
labeled MTX are bound and consequently the less MTX there is in the samples. On the other 
hand, the more MTX there is in the sample, the more depolarization occurs.  
There are only few sample preparation and instrument set-up steps before the analysis 
with TDx. First, the sample was loaded onto a cartridge on a carousel. The minimum sample 
volume required is 100 μL. Then, the reagents case was inserted into the instrument all at once 
to a designated place. Note that dilution of the samples with expected concentrations above 1 
μM is executed automatically. The sample and reagents were mixed together automatically in 
a glass cuvette placed on a carousel parallel to the sample loading cartridge. The 
measurements are taken in transmission from the glass cuvette. Similarly, the calibration 
standards and controls are prepared in the same way for analysis 
180
. The calibrators are 
provided and controls are available commercially. Recalibration is not necessary each time 
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before sample analysis. It is only required when the values of the control are offset from the 
expected values or when a new batch of reagents is used. Only controls of low, medium and 
high (10, 50, 500 nM) concentrations are analyzed before the sample evaluation 
180
.   
The TDx is an integrated system composed of automated dilution mechanical parts and 
a report printer altogether with the MTX detection platform. It requires minimal user input and 
supervision. It is sensitive in complex biological matrix with a limit of detection of 0.02 μM 
and dynamic range of 0.02-1μM. The calibration linearity is excellent with R2 = 0.996. The 
system offers relatively high throughput analysis. Usually, at least 10 samples can be analyzed 
together with 3 controls within 30 minutes. The user collects a report at the end of analysis 
with MTX concentration results. Despite its high performance and fast turn-around time, the 
cost of analysis is high due to expensive reagents. Furthermore, as mentioned in chapter 1, 
Abbott Laboratories has announced the discontinuation of the TDx and related products with 
no upcoming replacement 
181
. Lastly, TDx is an intended laboratory-based instrument not 
suitable for point-of-care due to its bulkiness. 
For validation of the accuracy of TDx, four ‘unknown’ samples were prepared for 
analysis (two replicates of 100 nM, 500 nM and 1 µM). All four samples were correctly 
identified as shown from the printed report (Annex 4, figure A4.7). The sample at 1 µM was 
identified as HI since the highest point of the calibration curve is 1 µM. In that case, dilution 
should be undertaken. Two samples with concentration 100 nM were analyzed and the results 
showed high precision. The large deviation of the response of the lowest concentration (100 
nM) from the expected value is probably due to the fact that the expected value, 100 nM was 
quantified using a different calibration.  
In comparison to TDx, the multi-channel prototype system is designed for potential 
point-of-care applications. It is sufficiently small in size and portable to be placed near the 
patient for personalized care. One of the biggest advantages of the prototype is the low cost of 
materials and reagents as well as the miniaturized prototype system itself. So far, there is some 
user input and supervision needed for the alpha version of the prototype. However, 
programmable syringe pump can be integrated in a future version to minimize user input. In 
comparison to TDx for the quantification of MTX, a single sample analysis in triplicate with 
background subtraction or a single sample analysis in triplicate in parallel with a control 
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analysis can be achieved within 30 minutes. For the same duration of time, at least 10 samples 
can be analyzed using TDx. The time of analysis of the prototype could be reduced by 
deriving initial binding rate as response where only acquisition in the first 60 seconds suffice 
to produce a relevant response corresponding to concentrations of MTX. Moreover, the 
enzyme immobilization can be prepared beforehand. In this way, once the enzyme 
immobilized sensor prism is inserted into the system, response can be collected instantaneous 
within the first 60 seconds of the sample injection. Up to now, the alpha version of the SPR 
prototype demonstrated less sensitivity in complex matrix for MTX quantification as 
compared to TDx. As shown earlier in section 6.3.2., with the dilution factor, the dynamic 
range spans from 28 nM-500 nM with a limit of detection of 28 nM.  The linearity of R
2 
= 
0.96 needs to be improved for more accurate quantification. The MTX analysis results using 
the prototype could be partially correlated to the results from TDx and LC-MS∕MS. The assay 
calibration can be further optimized using the prototype system to improve sensitivity and 
linearity. Both instruments do not require large sample volume as only 100 μL and 200 μL are 
needed for TDx and prototype system respectively. Finally, both instruments can be easily 
operated and no laborious sample preparation is needed.  
 
 
Figure 6.9 Picture of TDx for MTX analysis in the biochemistry department laboratory at 
Hôpital Maisonneuve-Rosemont. 
 132 
6.4. Conclusion 
A highly sensitive prototype multi-channel system with high resolution and reasonable 
reproducibility was built. Its applicability was demonstrated through the adaptation of the 
MTX competitive assay. Its sensor performance and ability to be employed in the clinical 
laboratory proves its potential application in its designated context. The system performance is 
no different under deployment. The calibration conducted in the research laboratory was 
reproduced in the clinical setting. Finally, the system is not user dependent since new and 
experienced users generated results with similar coefficient of variation.  
It is suspected that the sensitivity difference between day 1 and 2 is led by a difference 
in the quality of reagents used from day-to-day. More tests are needed to assess the extent of 
daily preparation of enzyme solutions and FA-AuNP on inter-day assay reproducibility. A 
referencing method to standardize inter-day results might be needed. In addition, at this point, 
it is important to evaluate each reagent’s shelf life to ensure their quality before assay use. 
Although manual injection is reproducible amongst different users, it is more desirable to 
employ a syringe pump for sample injection. As observed during the field test, one 
technologist is responsible for a few analytical instruments running at the same time for 
maximized sample analysis turnaround. A programmable syringe pump for controlling 
solution injection into the system at different time and volume would enormously facilitate the 
user’s contribution. With optimized human serum calibration conditions, more accurate 
analysis of actual samples using the prototype system is soon to be achieved. Currently, the 
multi-channel system is being employed in developing other assays for biomarker analysis and 
quantification. In addition, the system is capable of multiplex analysis by coating sensing 
areas with different receptors. 
 The SPR system has shown potential as a clinical laboratory-based instrument. High 
throughput and better sensitivity in complex media for MTX analysis are needed in order to be 
comparable to TDx. The next milestone would be to prove the point-of-care ability of the 
prototype system at the bedside of the patients. With current encouraging results, the objective 
of the prototype system served as a point-of-care device may soon be attained.  
  
 
Chapter 7  Conclusion and future perspectives 
The studies conducted for this thesis reported the development and application of SPR 
biosensors for methotrexate chemotherapeutic monitoring. At first, different aspects of SPR 
sensor development such as surface chemistry, integration of amplification elements 
specifically AuNP as well as colloidal LSPR sensor surface chemistry and stability were 
investigated. Subsequently, two sensing platforms based on localized SPR and SPR were 
developed for the detection of MTX in complex matrix. LSPR sensors were subject to matrix 
interference. A simple pre-treatment was required before the analysis but nonetheless, the 
results of clinical samples from patients under MTX chemotherapy were comparable to the 
results of FPIA and LC-MS/MS. The MTX assay was further translated onto the SPR platform 
in view to eliminate sample treatment. The SPR MTX assay analytical performance was 
investigated and optimized for generating an extended dynamic range and reasonable limit of 
detection for MTX direct detection in human serum. The evolution and adaptability of the 
MTX assay into a potential point-of-care device was demonstrated through a prototype multi-
channel miniature SPR system. The availability of three test channels and one reference 
channel on the prototype system allowed the standardization of human serum standards and 
samples variability. The deployment of the miniature SPR system to the hospital laboratory 
further confirmed the analytical potential of the system in a clinical setting as a rapid and 
reliable tool for MTX TDM.  
Chapter 2 is a short report on the preparation of the SPR sensor surface in hope to 
realize direct detection of methotrexate. Proper surface chemistry is crucial for the success of 
SPR biosensors. First, the presence of coated SAM molecules serving as receptor anchors on 
the sensor surface was confirmed using FTIR, contact angle and SPR. It is important to stress 
that any chemical reaction used for linking a receptor to the surface should be examined and 
optimized to ensure high receptor surface coverage. Usually, direct detection of small 
molecules of molecular weight under 1000 Daltons is challenging for SPR. Smaller molecules 
do not induce a large change in refractive index near the SPR sensor which consequently does 
not generate significant SPR response. However the custom-built high resolution SPR system 
allowed the direct analysis of MTX in the high micromolar concentrations. Although direct 
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detection of MTX was achieved, the assay sensitivity and dynamic range needed improvement 
to accommodate TDM application. TDM of MTX typically requires desirably a linear 
concentration-response dependence from the low nM to high μM concentration. 
In chapter 3, a SPR competitive binding assay with labeled gold nanoparticle 
enhancement was established in an effort to increase sensitivity and to extend the dynamic 
range to the nM range. First, the surface chemistry for covalent attachment of MTX onto 
AuNP was investigated. The SAM surface modification of metallic nanoparticles generated 
great instability of the colloidal system which led to flocculation. The pH, ionic strength and 
initial ligand concentrations of the reaction were examined and optimized. Subsequently, the 
success of synthesis of MTX-coated AuNP was confirmed with UV-Vis and FTIR. The MTX-
AuNP were then used in a replacement competitive assay in determining MTX concentration 
indirectly. Unfortunately, despite the fact that the established SPR assay is responsive to 
varying concentrations of MTX in the picomolar range, the replicates’ response 
reproducibility resulted in high standard deviation. The assay accuracy and precision were 
under scrutiny. Both the surface bound receptors and MTX-AuNP were re-examined. It was 
found that the enzyme immobilization method needed to be refined to ensure the activity of 
the enzyme bound to the surface and the stability of the labeled AuNP needed improvement in 
buffer conditions. 
In an attempt to preserve the biological structure of hDHFR, a solution-based 
colorimetric LSPR competitive assay was developed and discussed in chapter 4. The labeled 
AuNP can be employed as solution-based sensors that can transduce refractive index changes 
near the NP surface due to binding events. By doing so, the receptors are kept free in solution 
in their most active form. In order to maintain colloidal stability in buffer conditions, the 
labeled entity was then modified in terms of the nature of the ligand and the method employed 
for ligand attachment. The synthesis of stable FA-AuNP further endorsed the development of 
a simple colorimetric competitive assay based on colloidal FA-AuNP competing with MTX in 
samples for available enzyme in solution. The assay dynamic range was easily controlled with 
concentrations of hDHFR. Presence of potential interfering species such as DAMPA and FA 
only becomes relevant in the high μM concentration. Furthermore, the assay calibration in 
buffer was undertaken in the low nM range (10-100 nM) with good linearity and inter-day 
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reproducibility. Despite the attained sensitivity for MTX analysis in buffer, serum MTX 
analysis is hindered by the optical interference induced by the complexity of the matrix. With 
the addition of a simple solid phase extraction pre-treatment step, the analysis of MTX in 
actual clinical samples provided by hôspital Maisonneuve-Rosemont was possible using a 
calibration curve established between 155-360 nM using human serum from healthy 
individual spiked with MTX. The LSPR MTX quantification results correlated better with LC-
MS/MS than with FPIA. More samples needed to be tested using all three techniques for a 
more extensive comparative study and assay validation.  Furthermore, the LSPR assay is 
rendered more laborious with an extra sample pre-treatment step. The narrow dynamic range 
requires multiple dilutions of high MTX concentration samples which also becomes time-
consuming.   
 The developed LSPR competitive assay for MTX analysis is a good example of a 
simple colorimetric assay that can be conducted using low cost instrumentation such as UV-
Vis spectrophotometer or plate reader. To this point, up to four samples were analyzed in 
triplicate in parallel by employing the conventional spectrophotometer for a period of 20 
minutes. The developed solution-based assay can be adapted to UV-Vis plate reader for 
increased throughput using 96-well plates. However a 96-well plate solid phase extraction 
cartridge is required for treating the samples beforehand. Another advantage worth mentioning 
is the reduction of user input since programmable robotic pipettors can be integrated to a plate 
reader for solution handling.  
Furthermore, in order to bypass serum sample treatment to eliminate optical 
interference from matrix components, nanoparticles with LSPR band in the longer wavelength 
characteristics of gold nanorods are interesting alternatives for LSPR sensing in complex 
matrix. The nanorods possess a sensitive longitudinal band in the near IR region. The 
decoupling of the absorption peak of serum components near 450-500 nm and the LSPR band 
in NIR region for sensing may allow direct analysis of MTX in complex serum 
91. 
However, 
the stability of gold nanorods is an important issue: surface modification must ensure that 
monodisperse gold nanorods are available for interacting with the receptors in solution. 
Moreover, the reproducibility of synthesized gold nanorods from batch to batch needs careful 
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considerations as change in the shape and size of the nanorods cause differences in sensitivity 
that may require standardization.   
Chapter 5 discussed the establishment of a MTX competitive assay using stable FA-
AuNP translated into a SPR platform in hope to improve the limit of detection and dynamic 
range as well as bypass complex matrix sample pre-treatment. Various parameters such as 
concentration and size of the labeled gold nanoparticles as well as the nature of the receptor, 
wild type or mutant with 4 order of magnitude difference in receptor affinity, were 
interrogated for the modulation and improvement of dynamic range and limit of detection. 
Although the studies have given insights on the influence of different parameters on sensitivity 
and dynamic range, direct analysis of MTX in human serum was limited instrumentally. The 
single-channel miniature SPR system was not able to conquer response variability from serum 
of different individuals. Large response standard deviation of calibration standards showed the 
necessity of a multi-channel SPR system with an internal referencing channel.  
The recent development based on nanostructured Au film offers incredible SPR 
enhancement. In order to directly measure MTX in complex matrix, these nanostructured Au 
films can be explored for signal and sensitivity enhancement. It has been demonstrated 
previously that Anti-IgG and IgG immunodetection had a few folds of magnitude increase in 
sensitivity with an improved detection limit 
39,177,182
. In particular, nanohole and microhole 
arrays exhibit interesting optical properties beneficial for the construction of SPR bio-
analytical assays. These nanostructures exhibit increased sensitivity toward binding events 
occurring close to the surface compared to conventional SPR. In addition, further signal 
amplification can be assayed via plasmonic coupling of the AuNP with the patterned arrays to 
obtain desirable limit of detection. 
The analytical performance of a sensitive multi-channel portable SPR sensing platform 
developed for patient MTX level monitoring was detailed in chapter 6. First, the sensitivity, 
resolution, reproducibility and adaptability of the MTX competitive assay on the novel system 
have been evaluated. The versatility of the miniature system in adapting the MTX assay 
contributed to improving MTX analysis in complex matrix. The dynamic range and sensitivity 
were improved in comparison to single-channel SPR system. The feasibility of MTX assay 
using multi-channel system was validated with an exclusive quantitative analytical test with 
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clinical samples provided by a local hospital. Subsequently, the deployment of the prototype 
system to the hospital laboratory proved its portability and robustness in the intended 
environment. The performance of the novel system was also compared to SPR micro, a 
commercially available miniature SPR system and TDx, the current workhorse in clinical 
setting for MTX analysis. The results showed that the prototype system is clearly more 
adaptable for MTX TDM than SPR micro because of better microfluidics design and it is 
competitive to TDx in terms of low cost, ease of use, small sample volume and potential high 
throughput. However, improvement of the prototype can be made in areas targeting MTX 
assay sensitivity in complex matrix in serum and user input minimization. While the prototype 
has demonstrated applicability in methotrexate chemotherapeutic monitoring, there is current 
development of rapid quantification assay for important biomarkers such as prostate-specific 
antigen indicative of medical conditions. Finally, the first deployment of the prototype system 
assessed its potential in serving as a clinical laboratory-based tool. The next breakthrough will 
concentrate on establishing the point-of-care ability of the prototype system. 
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II 
Annex 1 - Supporting information: SPR competitive 
binding assay using free methotrexate and methotrexate-
functionalized gold nanoparticles (Chapter 3) 
 
Figure A1.1. Crystallographic structure of hDHFR complexed with NADPH and trimethoprim 
(TMP). Image courtesy of Damien Colin from Joelle Pelletier’s laboratory.  
  
III 
Annex 2 - Supporting information: Localized Surface 
Plasmon Resonance-based competitive assay for 
methotrexate and its application in Chemotherapy Drug 
Monitoring (Chapter 4) 
 
Figure A2.1 Comparison of NP stability in PBS during the course of 8h. (Left) MTX 
functionalized NP using EDC-NHS chemistry. (Right) FA conjugated NP with direct 
adsorption. 
 
Figure A2.2 TEM image of synthesized citrate reduced AuNP of spherical shape with 
diameter of 15 nm. 
 
  
IV 
 
 
Figure A2.3 Overlapping UV-Vis spectra of 0.25 nM FA-AuNP in PBS and diluted FBS in 
PBS.  
 
 
Figure A2.4 Calibration curve of MTX using FA-AuNP and 100 nM hDHFR in direct treated 
FBS after cartridge extraction. Note that the x-axis is scaled with respect to the initial spiked 
concentrations of MTX. Linear regression  y = -0.0018x + 2.43 R
2
 = 0.95. 
  
V 
 
Figure A2.5 LC-MS/MS calibration curve of MTX spiked in human serum followed by 
cartridge treatment. Note that the x-axis is scaled with respect to the initial spiked 
concentrations of MTX. Linear regression:  y = 27x - 2130 R
2
 = 0.97. 
 
Table A2.1 Recovery test conducted by spiking a specific concentration of MTX into FBS 
followed by treatment by cartridge. The concentrations of MTX have been quantified before 
spiking into FBS and after elution from cartridge treatment by UV-Vis spectroscopy using 
ε258nm = 22.1 mM
-1
cm
-1.
 
 
 
 
  
VI 
Annex 3 - Supporting information: Direct serum analysis 
of MTX using SPR spectroscopy (Chapter 5) 
 
Figure A3.1 Real-time kinetic binding of 0.25 nM FANP with  100 nM hDHFR,  100 nM 
hDHFR and 100 nM MTX,  no hDHFR, 100 nM MTX (blank) and   0.25 nM GA-AuNP 
with 100 nM hDHFR in 100 mM phosphate buffer pH 8.  
 
Figure A3.2 Comparison of the LSPR binding shifts of 0.25 nM FA-AuNP binding with 100 
nM hDHFR, 100 nM hDHFR and 100 nM MTX, no hDHFR, 100 nM MTX and 0.25 nM FA-
AuNP with 100 nM hDHFR. 
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Figure A3.3 Plot of SPR shift vs. injected hDHFR concentration. Solutions of different 
concentrations of hDHFR (5, 10, 15, 20, 35, 40, 50, 60 and 80 μg/mL) were injected 
sequentially onto the SPR surface followed by buffer rinsing.  
 
Figure A3.4 Direct analysis of increasing concentrations of MTX. Concentrations of 10 nM, 
100 nM, 1 μM, 10 μM and 100 μM MTX in PB 100 mM pH 8 were injected sequentially 
followed by buffer rinsing. 
  
VIII 
 
Figure A3.5 TEM images of synthesized AuNP of left) 5.2 ± 1.2 nm and right) 23 ± 5.2 nm. 
  
 
Figure A3.6 Overlapping calibration curve of MTX competitive binding curve using NP of 
varying sizes in FBS. The concentrations used for each size (1 nM 13 nm, 0.5 nM 23 nm and 
20 nM 5 nm) are based on the volume ratio of the nanoparticle and the signal to noise ratio of 
the SPR signals in FBS.  
 
  
IX 
 
  
X 
Figure A3.7 AFM images of SPR surfaces after analysis of A) and B) no MTX, C) and D) 10 
nM, E) and F), 100 nM, G) and H) 1 µM and I) 0 MTX with no surface bound hDHFR. J) An 
image of plain gold film without any surface treatment. AFM images were obtained in tapping 
mode with a Multimode microscope and a Nanoscope III controller (Digital Instruments) 
using the Nanoscope V5.30 software, operated under ambient atmosphere. The tips (Arrows 
NC model; spring constant 42 N/m, oscillation frequency 285 kHz, tip radius <10 nm) were 
obtained from Nanoworld (Neuchâtel. Switzerland). Images were provided courtesy of Zhu 
Hu.  
 
 
Figure A3.8 Specific activity of 100 ng/mL hDHFR with saturating concentrations of DHF 
and NADPH (100 μM) in different buffers. Figure courtesy of Natalia Bukar.  
 
  
XI 
 
Figure A3.9 Calibration curves using 0.04 mg/mL 100% wild type hDHFR, 50% wild 
type and 50% RFE mutant hDHFR and 100% RFE mutant hDHFR with 1 nM of 13 nm FA-
AuNP in PB pH 8. 
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Annex 4 - Supporting Information: Performance and 
clinical application of a prototype multi-channel SPR 
system in methotrexate chemotherapeutic monitoring 
(Chapter 6) 
 
 
Figure A4.1 Comparison of sensitivity of four sensing areas from three different prisms. 
  
XIII 
 
Figure A4.2 Comparison of reproducibility from three sensing areas of three different prisms 
for MTX control analysis. A) bulk solution refractive index measurement B) enzyme 
immobilization and C) FA-AuNP binding.  
 
 
  
XIV 
 
 
Figure A4.3 Sensorgrams of three test-sensing areas and a reference sensing area of the MTX 
control test acquired at the clinical laboratory. The first increase in binding shift in the test 
channels is due to immobilization of the His-tagged enzyme onto the surface. The second 
large increase is due to the interaction of NP with surface bound enzymes. The enzyme was 
not injected into the reference channel, therefore, the sample injection step did not show any 
significant increase in signal.  
  
XV 
 
Figure A4.4 Enlargement of sensorgrams for noise level inspection. Comparison of noise level 
at A) university research laboratory, B) clinical laboratory day 1 and C) clinical laboratory day 
2.  
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Figure A4.5 Reproducibility tests of binding shift results from 2 different users for the analysis 
of A) 10 μM MTX on day 1. CV varied from 4-8% B) 0 μM MTX on day 2.The CV varied 
from 6-16% and C) 50 μM MTX on day 2. The CV varied from 9-23%. 
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Figure A4.6 Subtracted sensorgrams of K-MAC SPR micro analysis of 0 and 100 nM MTX in 
triplicate. The first increase corresponds to enzyme immobilization followed by MTX 
detection via binding of FA-AuNP.  
  
XVIII 
 
Figure A4.7 Analysis report of MTX ‘unknown’ samples from TDx. Quality control reagents 
with concentrations of 0.07, 0.4 and 0.8 μM were aliquoted into cuvettes LOC 1, 2 and 3 
respectively. 1, 0.5 and replicates of 0.1 μM prepared ‘unknown’ samples were aliquoted in 
cuvettes LOC 4, 5, 6 and 7 respectively for MTX analysis.  
 
  
XIX 
Annex 5 - Minimum finding mathematical algorithm used 
for SPR data analysis 
 
In chapters 2, 3, 4 and 5, a SPR spectrum minimum finding algorithm for Matlab was used to 
treat the acquired raw data in order to elucidate a single SPR wavelength minimum in 
nanometer that varied over time. This algorithm was written by Karl Booksh from University 
of Delaware and modified by Jean-François Masson. 
 
%[mins,pixs,Y]=minpixhuntlr(A); 
%A is the matrix of ratioed spectra 
%mins is the wavelength minima of each spectrum 
%pixs is the pixel minima of each spectrum 
%Y is the section parabola from which the minima is determined 
 
function [mins,pixs,Y]=minpixhuntlr(A,lamda); 
%wavel=([1:1:1024].*0.3676+551.57)'; 
wavel = lamda(1:3648,:); 
[m,n]=size(A); 
count=1; 
pixel=[1:1:3648]'; 
countr=1; 
mins=[]; 
for i=1:1:n 
   [mn,indx]=min(A(:,i)); 
   %[startp,endp]=fpnts(A(:,i),mn,indx); 
   startp = 400; 
   endp = 1200; 
   dip=A(startp:endp,i); 
   wavdip=pixel(startp:endp); 
  
XX 
   p=polyfit(wavdip,dip,2); 
   pp=polyder(p); 
   min1=roots(pp); 
   mins=[mins,min1]; 
 end; 
pixs=round(mins); 
[m,n]=size(A); 
Y=[]; 
for j=1:1:n 
   [mn,indx]=min(A(:,j)); 
   %[stp,enp]=fpnts(A(:,j),mn,pixs(j)); 
   stp = 400; 
   enp = 1200; 
   dip=A(stp:enp,j); 
   wavdip=wavel(stp:enp); 
   p=polyfit(wavdip,dip,2); 
   ppv=polyval(p,wavdip); 
   pp=polyder(p);  
   Y=[Y;ppv]; 
   mins(:,j)=roots(pp); 
   countr=countr+1; 
end; 
 
function [sp,ep]=fpnts(M,mn1,indx1) 
p=mn1; 
ep=indx1; 
sp=indx1; 
while p<1.05.*mn1 
    p=M(ep); 
    ep=ep+1; 
  
XXI 
end; 
 
 p=mn1; 
while p<1.05.*mn1 
    p=M(sp); 
    sp=sp-1; 
end; 
 
 
 
 
 
 
 
 
